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Chapter 1 
2 
A) GENERAL PRESENTATION OF IVERMECTIN. 
 
The discovery of avermectins, and to a lesser extent milbemycins, has 
revolutionised antiparasitic treatment in animal health and crop protection. These 
compounds are at least 25 times more potent than the preceding generation of 
anthelmintics (for example, oxfendazole: 5 mg/kg; ivermectin: 200 µg/kg), and 
present a broad spectrum of activity against nematode and arthropod parasites of 
domestic animals. It is this unique combined killing of endo- and ectoparasites 
which gave rise to the embracing name of “endectocides”, under which they are 
now classified. 
Discovered by Merck Sharp & Dohme laboratories, ivermectin was the first 
avermectin to be introduced onto the international animal health market in 1981. 
Within a period of 5 years, this drug had captured 16% of the worldwide sales for 
antiparasitic compounds in animal health (Bloomfield, 1988). Since then, several 
other endectocides (moxidectin, doramectin, eprinomectin, selamectin) have been 
commercialised, but ivermectin still remains the most widely used endectocide 
across animal species worldwide, with millions of cattle treated per year. 
Ivermectin is also currently used in human medicine to treat and control various 
parasitic conditions. It is the first-line treatment for onchocerciasis (river 
blindness), a severe public disease in Africa and tropical America, and has been 
approved for treatment of lymphatic filariasis, intestinal strongyloidiasis and 
scabies. More than 18 million people are estimated treated with this drug every 
year (Burkhart, 2000).  
 
1) Chemistry. 
Avermectins are closely related 16-membered macrocyclic lactones derived 
from the fermentation products of the actinomycete Streptomyces avermitilis (Burg 
and Stapley, 1989; Fisher and Mrozik, 1989). Although they share structural 
features with the macrolide antibiotics and antifungal macrocyclic polyenes, they 
are virtually devoid of any antibacterial or antifungal activity (Burg and Stapley, 
1989). The milbemycins are structurally related to the avermectin group, but are 
lacking the disaccharide substituent at C-13 (see Fig. 1) (Fisher and Mrozik, 1989; 
Shoop et al., 1995a). Ivermectin is the generic name given to a mixture of 22,23-
dihydroavermectin B1a (H2B1a; >80%) and 22,23-dihydroavermectin B1b (H2B1b; 
<20%), which are two equipotent semisynthetic derivatives of the avermectin 
family (Fig. 1) (Campbell, 1985; Fisher and Mrozik, 1989). Ivermectin is a large 
(874 MW) and neutral molecule, which is poorly soluble in water, dissolves in 
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most organic solvents and is highly soluble in lipids (Lo et al., 1985; Fisher and 
Mrozik, 1989). Its fluorescence properties are particularly useful for analytic 
determination by thin-layer chromatography (TLC) or high-performance liquid 
chromatography (HPLC) (Alvinerie et al., 1987; Fisher and Mrozik, 1989). 
 
Figure 1.  a) Chemical structure of ivermectin. R = CH2CH3 : 22,23-dihydroavermectin B1a 
(>80%). R = CH3 : 22,23-dihydroavermectin B1b (<20%).  b) Chemical structure of the 
milbemycin moxidectin. 
 
O
O
O
OH
H
OO
OH H
CH3H
H
N
H3CO
13 
O O
O
O-CH3
CH3
CH3
O-CH3
OH
O
O
O
O
R
H
OH
H
OO
OH H
CH3H
H
13 
22 
23 
a) 
b) 
Chapter 1 
4 
2) Existing pharmaceutical formulations. 
Ivermectin is formulated for subcutaneous, oral or topical administration, 
depending on the species. A summary of the existing formulations (reviewed by 
McKellar and Benchaoui, 1996) is presented in Table 1. Most original formulations 
for cattle have been the intraruminal sustained-release device (SR-bolus) and the 
topical (pour-on) formulation. The SR-bolus formulation consists of a mini-
osmotic pump, which is retained in the rumen after ingestion and releases the drug 
over 120 days at a constant rate of 40 µg/kg/day (Pope et al., 1985). It provides the 
advantage over other conventional formulations of long duration of activity and 
less frequent administration. The pour-on formulation is a high concentrated 
solution of drug, which is poured along the dorsal midline of the animal in a 
narrow strip extending from the withers to the tailhead. This application technique 
is very convenient, since the owner can apply the treatment himself with minimal 
risk of injury and little animal distress (Hennessy, 1997). The pour-on formulation 
has now largely displaced the conventional and less practical injectable formulation 
in farming practice. 
 
3) Spectrum of activity and mode of action. 
As for other avermectins and milbemycins, ivermectin has no useful activity 
against trematodes or cestodes (Shoop et al., 1995b) but is highly effective against 
the adult, developing and hypobiotic larvae of most gastrointestinal nematodes and 
lungworms (listed in Table 2) (Benz et al., 1989; McKellar and Benchaoui, 1996). 
It also presents a good systemic activity against several arthropod external parasites 
of domestic animals (Table 2) (Benz et al., 1989; McKellar and Benchaoui, 1996). 
It is noteworthy though that ivermectin is not equally active against all nematode 
species or all stages of a given species (Campbell, 1985; McKellar and Benchaoui, 
1996). In cattle for instance, the dose-limiting gastrointestinal parasite species for 
ivermectin are Cooperia spp. and Nematodirus spp. (Shoop et al., 1995a; McKellar 
and Benchaoui, 1996). In addition, ivermectin was discovered to have excellent 
activity against the microfilariae of Onchocerca volvulus in man (Greene et al., 
1989; Goa et al., 1991), Onchocerca cervicalis in horses (Campbell et al., 1989a), 
and Dirofilaria immitis in dogs (Campbell, 1989b). 
It is difficult to assign a single mechanism of action for ivermectin in all 
parasite species. The main antiparasitic efficacy of ivermectin is now attributed to a 
high-affinity binding to glutamate-gated chloride ion channels in invertebrate nerve 
and muscle cells (Duce and Scott, 1985; Cully et al., 1994; Arena et al., 1995; 
Cheeseman et al., 2001). The opening of these channels results in a slow and 
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irreversible increase in membrane conductance, leading to the paralysis of the 
somatic musculature and particularly of the pharyngeal pump (Geary et al., 1993). 
An interaction with gamma-aminobutyric acid (GABA) -gated chloride channels 
has also been reported at higher drug concentrations (Turner and Schaeffer, 1989; 
McKellar and Benchaoui, 1996). 
 
4) Pharmacokinetic properties. 
Studies performed in humans (Fink and Porras, 1989) and in dogs (Daurio et al., 
1992) suggest that the pharmacokinetics of ivermectin is dose-independent. The 
plasma disposition of ivermectin is characterised by a long persistence in the body 
due to a low plasma clearance and to an extensive distribution into fat consistent 
Table 1. Formulations and dosages of ivermectin in current commercial use. 
Formulation   Species Administration 
route 
Dose rate 
(µg/kg b.wt.) 
Oral tablets 
 
Human 
Human 
Dog 
p.o. 
p.o. 
p.o. 
150 
200 
6 
Oral chewable 
 
Dog 
Cat 
p.o. 
p.o. 
200 
200 
Oral drench 
 
Cattle 
Sheep, goat 
Horse 
p.o. 
p.o. 
p.o. 
200 
200 
200 
Oral paste 
 
Cattle 
Horse 
p.o. 
p.o. 
200 
200 
Feed premix  Pig p.o. 100 µg/kg/day* 
Sustained release bolus 
Osmotic pump 
Cattle Intraruminal 
 
40 µg/kg/day  
for 120 days 
Injectable 
 
Cattle, sheep 
Pig 
s.c. 
s.c. 
200 
300 
Pour-on  Cattle topical 500 
* recommended daily dosage for 7 days of treatment. 
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with the lipophilicity of the drug. The plasma elimination half-life after i.v. 
administration appears to be longer for polygastric species (2.8 days in cattle, 2.7 
days in sheep) than for monogastric species (estimated to be 0.5 day and 1.8 days 
in pigs and dogs, respectively) (Lo et al., 1985; Wilkinson et al., 1985; Fink and 
Porras, 1989). Ivermectin total clearance appears to be low in most species. In 
cattle and sheep, the total clearance of ivermectin is 0.79 L/day/kg (Wilkinson et 
al., 1985) and 0.56 L/day/kg (Prichard et al., 1985), respectively, which 
corresponds to a body coefficient of extraction of <1% in both cases. Several 
Table 2. Label efficacy claims for ivermectin in the different species. 
Cattle Sheep 
Gastrointestinal nematodes 
Haemonchus placei 
Ostertagia spp. 
Trichostrongylus spp. 
Cooperia spp. 
Nematodirus spp. 
Strongyloides papillosus 
Oesophagostomum  
radiatum 
Bunostomum phlebotomum 
Other nematodes 
Dictyocaulus viviparus 
Parafilaria bovicola 
Thelazia spp. 
Gastrointestinal nematodes 
Haemonchus contortus, H. placei 
Ostertagia spp. 
Trichostrongylus spp. 
Cooperia spp. 
Nematodirus spp. 
Strongyloides papillosus 
Oesophagostomum spp. 
Chabertia ovina 
Trichuris ovis 
Gaigeria pachyscelis 
Lung nematodes 
Dictyocaulus filaria 
Protostrongylus rufescens 
Warbles (Hypoderma spp. …) 
Sucking lice  
Mites  (Psoroptes spp.  
Sarcoptes spp.) 
Nasal bots 
Oestrus ovis  
Mites 
Psoroptes ovis 
Psorergates ovis 
Aids in the control of 
Biting lice (Damalinia bovis) 
Mite (Chorioptes spp.) 
Horn flies (Haematobia irritans)  
Ticks (Boophilus spp.) 
(Campbell, 1985; McKellar and Benchaoui, 1996). 
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Table 2. continued. 
Goat Pig Horse 
Gastrointestinal nematodes 
Haemonchus contortus 
Ostertagia circumcincta 
Trichostrongylus  
colubriformis 
Nematodirus spathiger 
Strongyloides papillosus 
Oesophagostomum  
columbianum 
Chabertia ovina 
Gastrointestinal nematodes 
Ascaris suum 
Hyostrongylus rubidus 
Oesophagostomum spp. 
Strongyloides ransomi 
Lung nematodes 
Dictyocaulus filaria 
Lung nematodes 
Metastrongylus spp. 
 
 
Gastrointestinal nematodes 
Trichostrongylus axei 
Habronema muscae 
Strongyloides westeri 
Strongylus vulgaris 
Strongylus edentatus 
Strongylus equinus 
Cyathostomum spp. 
Oxyuris equi 
Parascaris equorum 
Triodontophorus spp. 
Cylicocyclus spp 
Cylicostephanus spp.  
Cylicodontophorus spp. 
Gyalocephalus sp. 
 Lung nematodes 
Dictyocaulus arnfieldi 
Microfilaria 
Onchocerca sp. 
 
Kidney worms 
Stephanurus dentatus 
Lice 
Haematopinus suis 
Mites 
Sarcoptes scabiei 
Gastric bots 
Gastrophilus spp. 
 
 
studies suggest that the plasma clearance of ivermectin is greater in goats > sheep > 
cattle (Lo et al., 1985; Scott et al., 1990). Given an extensive distribution in fat 
tissues, high volumes of distribution were observed in all species (4.6 L/kg in 
sheep, 1.9-2.2 L/kg in cattle, and 2.4 L/kg in dogs; Lo et al., 1985; Wilkinson et al., 
1985; Fink and Porras, 1989). Binding studies in humans and dogs showed that 
ivermectin bound extensively to plasma proteins (93%; Okonkwo et al., 1993), 
including albumin and lipoproteins (HDL) (Rohrer and Evans, 1990). 
  
Table 3. Ivermectin plasma pharmacokinetic parameters obtained for the commercial formulations in the different species. 
Species Dose (mg/kg) - route N Cmax (ng/mL) Tmax (h) AUC (ng.h/mL) F(%) Reference 
Man 0.15 -p.o. 9 38.2 4.7 1545 
 Okonkwo et al. (1993) 
Cattle 0.2-s.c. 
 
0.5-topical 
SR bolus 
20 
5 
12 
6 
31.7 
54.6 
12.2 
28.5 
95.5 
34.8 
81.6 
364.8 
8664 
10790 
2772 
59424 
 
 
15 
 
Toutain et al. (1997)  
Toutain et al. (1988) 
Gayrard et al. (1999) 
Alvinerie et al. (1998) 
Sheep 0.2-s.c. 
 
0.2-p.o. 
0.2-i.r. 
6 
5 
5 
4 
11.9 
30.8 
22.0 
17.6 
40.8 
60.0 
16.4 
23.5 
1536 
5718 
2039 
2260 
 
 
36 
25* 
Cerkvenik et al. (2002) 
Marriner et al. (1987) 
Marriner at al. (1987) 
Prichard et al. (1985) 
Goat 0.2-s.c. 
0.2-p.o. 
0.5-topical 
5 
6 
6 
6.1 
16.0 
4.0 
68.4 
< 24.0 
48.0 
1440 
516 
317 
 
 
 
Alvinerie et al. (1993) 
Scott et al. (1990) 
Scott et al. (1990) 
Pig 0.3-s.c. 5 28.4 27.2 1714 
 Scott & McKellar (1992) 
Horse 0.2-p.o. 
 
0.2-s.c. 
6 
3 
3 
16.4 
82.3 
60.7 
15.0 
3.3 
80.0 
 
4822 
13209 
 
37 
 
Asquith et al. (1987) 
Marriner et al. (1987) 
Marriner et al. (1987) 
Dog 0.006-p.o. 
0.1-p.o. 
16 
16 
2.97 
44.3 
5.3 
4.2 
107 
1035 
 
 
Daurio et al. (1992) 
Daurio et al. (1992) 
N, number of animals involved in the study; Cmax, maximum plasma concentration; Tmax, time to reach Cmax; AUC, area under the plasma concentration-
time curve; F, bioavailability of ivermectin compared to the subcutaneous route (* to the intravenous route when available);  SR bolus, sustained release 
bolus (40 µg/kg/day over 120 days). 
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The route of administration and the nature of the formulation influence 
markedly the systemic availability of ivermectin and its persistence in plasma at 
therapeutic concentrations (Table 3) (for review, see McKellar and Benchaoui, 
1996). Studies from Lo et al. (1985) in cattle showed major differences in the 
pharmacokinetics of ivermectin after subcutaneous administration, whether the 
drug was injected as an aqueous micelle or non-aqueous solution. The use of the 
aqueous based-formulation resulted in a higher bioavailability of ivermectin, but in 
a shorter plasma elimination half-life similar to that obtained after i.v. 
administration. The longer plasma elimination half-life observed after 
administration of the non-aqueous solution (the commercialised formulation) has 
been attributed to a very slow absorption process (probably due to the precipitation 
of ivermectin at the injection site) which limits the decrease in plasma 
concentrations (so called flip-flop effect) (Lo et al., 1985). This prolonged 
persistence in plasma correlates with the sustained efficacy of the subcutaneous 
formulation against endo- and ectoparasites, which may last for up to 3-4 weeks for 
some nematode species (Campbell, 1985; Fink and Porras, 1989; Barth et al., 
1997). No "flip-flop" effect has been reported for ivermectin oral formulations in 
sheep and cattle (Marriner et al., 1987; Steel, 1993; McKellar and Benchaoui, 
1996). 
Since ivermectin is barely administered by the i.v. route, the absolute 
bioavailability of ivermectin after oral or topical administration has not yet been 
determined. However, bioavailabilities relative to the subcutaneous route have 
been calculated. They indicate a low (15%) and erratic systemic availability for the 
topical formulation in cattle (Gayrard et al., 1999). Ivermectin bioavailability after 
oral or intraruminal dosing is also lower than for the subcutaneous route in many 
species. This has been shown in cattle (Pope et al., 1985; Chiu et al., 1990), sheep 
(Marriner et al., 1987; Bogan and McKellar, 1988), horses (Marriner et al., 1987) 
and pigs (Fink and Porras, 1989). Together with a lower persistence in plasma, a 
poor oral bioavailability explains why oral treatment is less effective than 
subcutaneous treatment against ectoparasites (mange mites, ticks, lice) (Campbell, 
1985; McKellar and Benchaoui, 1996). In the case of the tablet formulations 
(humans), a low dissolution rate of tablets has been identified as a limiting factor of 
oral absorption (Fink and Porras, 1989). In ruminant species, the low oral 
bioavailability of ivermectin has been attributed to an extensive binding of the drug 
to the particulate phase of rumen digesta (>95% in sheep and cattle; Steel, 1993; 
Ali and Hennessy, 1996). The large binding of ivermectin to digesta would explain 
why in sheep the absolute bioavailability of ivermectin given intraruminally is 
25%, while that after intra-abomasal administration is almost 100% (Prichard et al., 
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1985). Changes in ivermectin pharmacokinetics with the diet (Taylor et al., 1992) 
and the level of feed intake (Ali and Hennessy, 1996) suggest that this ivermectin-
digesta complex greatly influences the systemic availability of ivermectin after oral 
administration as well as the profile of faecal excretion (Steel, 1993). 
Large interindividual variations in drug exposure have been observed following 
parenteral administration to cattle (Lo et al., 1985; Toutain et al., 1997), pigs (Scott 
and McKellar, 1992), sheep (Cerkvenik et al., 2002) and goats (Scott et al., 1990) 
taken under the same experimental conditions. These have been attributed to 
differences in body condition (fat content) and/or differences in absorption, 
metabolism and elimination of the parent drug in relation to the age, sex and 
physiological status of animals (Lo et al., 1985; Bogan and McKellar, 1988; Scott 
et al., 1990; Scott and McKellar, 1992; McKellar and Benchaoui, 1996; Toutain et 
al., 1997). 
Metabolism and drug residue studies have been carried out in laboratory 
animals (rats) and target animal species (cattle, sheep) using radiolabelled 
ivermectin. Drug residues were higher in liver and fat than in other edible tissues, 
but were low in muscle (Chiu and Lu, 1989; Chiu et al., 1990). In sheep, cattle and 
rats, the major liver metabolites are the 24-hydroxymethyl-H2B1a and -H2B1b and 
the monosaccharide of 24-hydroxymethyl-H2B1a (Miwa et al., 1982; Chiu and Lu, 
1989). In contrast, the main liver metabolites in pigs are the 3-O-desmethyl-H2B1a 
and -H2B1b (Chiu et al., 1984; Chiu and Lu, 1989). The formation of a 3-O-
desmethyl metabolite has also been characterised in goats (Alvinerie et al., 1994). 
No glucuronide conjugates of metabolites have been identified so far. Metabolites 
that are less polar than the parent drug have been found in fat tissues from sheep 
and cattle (but not pig) (Chiu and Lu, 1989). It has been suggested that the polar 
metabolites produced in the liver are esterified as fatty acid esters and deposited in 
the fat as non-polar entities (Chiu and Lu, 1989). Finally, in vitro studies using 
liver microsomes have identified cytochrome P450 (CYP) 3A4 as the major 
enzyme for the metabolism of ivermectin in humans (CYP3A and CYP1A1 in rats) 
(Zeng et al., 1996, 1998). 
Ivermectin is extensively eliminated into faeces, regardless of the species and 
administration route (Campbell, 1985), with less than 2% of the administered dose 
excreted in the urine (Chiu and Lu, 1989; Chiu et al, 1990). After subcutaneous 
administration to cattle, the parent drug accounts for approximately 40% of the 
drug faecal residues, the remainder consisting of metabolites (Halley et al., 1989). 
Because concentrations of ivermectin in bile are substantially higher than those in 
plasma (Bogan and McKellar, 1988; Chiu et al., 1990; Lifschiftz et al., 2000), it is 
currently believed that biliary secretion is the main elimination pathway of the 
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parent drug. Ivermectin is also excreted in milk in humans, dairy cows, ewes, goats 
and camels, which is consistent with its high lipid solubility (Bogan and McKellar, 
1988; Toutain et al., 1988; Scott et al., 1990; Alvinerie et al., 1993; Ogbuokiri et 
al., 1994; Oukessou et al., 1999; Cerkvenik et al., 2002). Excretion in milk 
accounts for less than 1% of the dose in goats (Alvinerie et al., 1993) and sheep 
(Cerkvenik et al., 2002), and for approximately 5.5% of the dose in cattle (Toutain 
et al., 1988). It has been shown that lambs suckling ivermectin-treated ewes receive 
around 4% of a normal therapeutic dose via the milk (Bogan and McKellar, 1988). 
 
5) Ivermectin toxicity. 
The large-scale use of ivermectin in man and target animal species for 20 years 
has provided evidence for the safety of this drug at the applied dose rates 
(Burkhart, 2000). At very high doses however, neurointoxication may develop with 
symptoms such as ataxia, tremors, depression and death (Lankas and Gordon, 
1989). This neurotoxicity is presumed to involve ivermectin binding to GABA-
gated chloride channels, which are confined to the central nervous system in 
mammals (Turner and Schaeffer, 1989; Huang and Casida, 1997; Burkhart, 2000). 
No glutamate-gated chloride channels have been identified in mammals so far. It 
has been shown that ivermectin distributes poorly into the brain at the normal doses 
(Chiu and Lu, 1989; Chiu et al., 1990). The reason for this poor distribution has 
been attributed to the presence of a drug transporter at the blood-brain barrier 
called P-glycoprotein (described below), which pumps ivermectin back into blood 
(Schinkel et al., 1994; Didier and Loor, 1995; Lankas et al., 1997; Kwei et al., 
1999; Nobmann et al., 2001). A deficiency in P-glycoprotein at the blood-brain 
barrier has been demonstrated in CF-1 mice (Lankas et al., 1997) and some breeds 
of Collie dogs (Mealey et al., 2001), which are unusually sensitive to the toxic 
effects of ivermectin at normal dosage (Pullian and Preston, 1989; Lankas et al., 
1997). Furthermore, neonates have been shown to be more susceptible than adult 
rats to the neurotoxicity of ivermectin, probably due to an immature blood-brain 
barrier and a lack of functional P-glycoprotein (Lankas and Gordon, 1989; 
Burkhart, 2000). Finally, acute and chronic toxicity studies showed that ivermectin 
was not carcinogenic and was not selectively toxic to the developing embryo 
(Lankas and Gordon, 1989). 
 
6) Environmental safety. 
Fear has been expressed that the large-scale use of ivermectin in grazing cattle 
could have an overall negative impact onto the environment. Indeed, faecal 
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ivermectin remains biologically active long after its excretion by treated cattle and 
has been shown to be toxic to many non-target dung-breeding and dung-degrading 
insects (Wall and Strong; 1987; Sommer et al., 1993; Strong et al., 1996; McKellar, 
1997). A few studies even suggested that the parent drug could affect the processes 
of dung colonisation and slow down the subsequent degradation of dung on the 
pasture (Wall and Strong, 1987; Strong et al., 1996). The ecotoxicity of ivermectin 
has been debated over 20 years, but it now seems that the risk of an overall 
environmental impact is low (for review, see McKellar, 1997). However, a possible 
local environmental effect of ivermectin cannot be excluded, depending on the 
local farm practices (number of animals treated in the herd, period and frequency 
of treatments) (McKellar, 1997).  
It is noteworthy though that all formulations of ivermectin are not equivalent in 
terms of environmental exposure (Steel, 1993; Herd et al., 1996). The use of the 
pour-on formulation results in higher faecal ivermectin concentrations compared to 
the injectable formulation, which is quite surprising given the lower ivermectin 
plasma concentrations (Herd et al., 1996). An explanation for this apparent 
discrepancy has not yet been identified. The greatest ecological risk, however, has 
been associated with the use of SR bolus formulation in cattle. Because of a low 
oral bioavailability (40%, Pope et al., 1985), the constant delivery of drug in the 
rumen leads indeed to high and particularly persistent concentrations of parent 
ivermectin in the dung (Herd et al., 1996; Alvinerie et al., 1998). 
 
7) Development of drug resistance. 
Ivermectin was introduced at a time when benzimidazole and levamisole 
resistance in sheep was widespread. A similar situation is now emerging for 
ivermectin in sheep and goat, resistance involving Haemonchus contortus, 
Ostertagia spp. and Trichostrongylus spp. (McKellar and Benchaoui, 1996). Signs 
of resistance have been reported in cattle for Cooperia spp. (Coles et al., 1998).  
The actual mechanisms of ivermectin resistance in nematodes are poorly 
understood (McKellar and Benchaoui, 1996; Gill and Lacey, 1998). Parasites 
resistant to avermectins, including ivermectin, are generally also resistant to 
milbemycins, and it has been suggested that the drug transporting P-glycoprotein 
could be one of the mechanisms involved in this cross-resistance (see below; 
Blackhall et al., 1998a; Xu et al., 1998; Molento and Prichard, 1999). Parasite 
resistance may also be associated with mutations of the gene encoding the α-
subunit of glutamate-gated chloride channels (Blackhall et al., 1998b). The relative 
significance of these mechanisms is still under debate (Kwa et al., 1998). Animal 
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husbandry practices that contribute to the selection for resistance are frequent 
dosing and, to a lesser extent, underdosing depending on the frequency in the allele 
carrying resistance in the population (Smith et al., 1999). 
 
B) P-GLYCOPROTEIN AND DRUG TRANSPORT. 
 
P-glycoprotein (P-gp) is a drug efflux transporter associated with the plasma 
membrane (Fig. 2). This 170-kDa protein consists of two similar halves, each 
containing six putative transmembrane segments and an intracellular ATP binding 
site (Chen et al., 1986; Gottesman et al., 1996; Borst and Elferink, 2002). The well-
conserved ATP binding regions and the presence of multiple transmembrane 
segments define P-gp as a member of the ATP-binding cassette (ABC) superfamily 
of transporters (Higgins, 1992). ABC transporters have been identified in 
organisms ranging from archebacteria, bacteria, yeast, plants, and insects to 
mammals (Higgins, 1992; Gottesman et al., 1996; Borst and Elferink, 2002). Up to 
48 human ABC transporters have been identified to date, which are localised 
within intracellular membranes (endoplasmic reticulum, peroxisomes) or in the 
plasma membrane, depending on their physiological function (Borst and Elferink, 
2002). 
 
 
 
Figure 2. Representation of P-glycoprotein with its transmembrane segments and its two 
intracellular nucleotide (ATP) -binding sites. 
 
Cell membrane 
Cytoplasm 
ADP ATP ATP ADP 
substrate 
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Table 4. Non-exhaustive list of compounds that are well-established P-gp substrates.  
Class of compounds  Molecules  
Anticancer drugs Vinca alkaloids (vinblastine, vincristine …) 
Anthracyclines (daunorubicin, doxorubicin …) 
Epipodophyllotoxins (etoposide, teniposide) 
Tubulin polymerising drugs (paclitaxel, docetaxel, 
colchicine) 
Immunosuppressive agents Cyclosporin A, FK506 
Cardiac drugs Digoxin, quinidine  
Calcium channel blockers Verapamil, diltiazem, nicardipine 
HIV protease inhibitors Indinavir, nelfinavir, ritonavir, saquinavir  
Steroids Aldosterone, cortisol, corticosterone,  
dexamethasone, 
Antimicrobial agents Sparfloxacin, grepafloxacin, erythromycin 
Antihistamines Terfenadine  
Dopamine antagonists Domperidone 
β-adrenergic antagonists Talinolol 
Lipid lowering agents Lovastatin 
Opioids Morphine, fentanyl 
Antiemetics Ondansetron, domperidone 
Antidiarrheal agents Loperamide 
Anthelmintic agents Ivermectin 
Antimalarial agents Quinine, chloroquine 
Antituberculous agents Rifampicin 
Cytokines Interleukins IL-2, IL-4, and gamma interferon (INF-γ) 
Fluorescent dyes Rhodamine 123, Fluo-3 AM (Acetoxymethy), 
calcein-AM, Hoechst 33342/33258 
(Shapiro and Ling, 1998; Litman et al., 2001; Matheny et al., 2001) 
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P-gp was discovered in the mid 1970’s through its ability to confer multidrug 
resistance (MDR) in mammalian tumour cells (Juliano and Ling, 1976). This 
observation has led to the finding that P-gp is an ATP-dependent efflux pump that 
expels a wide range of functionally and structurally unrelated compounds out of the 
cell, including anticancer agents (Germann, 1996; Gottesman et al., 1996; Shapiro 
and Ling, 1998; Litman et al., 2001; Borst and Elferink, 2002). In tumour cells, P-
gp lowers the effective concentrations of drugs inside the cell, resulting thereby in 
therapeutics failure. The development of strategies that will successfully reverse 
multidrug resistance in cancer is now a major issue in chemotherapy. 
An increasing number of compounds have been discovered to be substrates of 
P-gp, including clinically-important drugs such as immunosuppressive agents, HIV 
protease inhibitors, cardiovascular drugs, steroids, antimicrobial and antiparasitic 
agents (Shapiro and Ling, 1998; Litman et al., 2001; Matheny et al., 2001). An 
indicative list of P-gp substrates is presented in Table 4. Experiments performed 
with the National Cancer Institute drug screen suggest that this list could be 
extended by several hundreds (Litman et al., 2001). How P-gp recognises its 
substrates (mostly neutral or cationic lipophilic compounds) and transport them out 
of the cell is still not known in details. The most recent models for P-gp transport 
mechanisms are reviewed by Litman et al. (2001) and Borst and Elferink (2002). 
 
1) Key role of P-gp in drug disposition. 
The significance of P-gp extends far beyond resistance to chemotherapeutic 
agents. In addition to tumour cells, P-gp has been found to be physiologically 
expressed in various tissues, including the major organs of drug absorption, 
distribution and elimination. P-gp is present at high levels in the apical (lumenal) 
membrane of intestinal epithelial cells and kidney proximal tubule cells, in the 
biliary canalicular membrane of hepatocytes, the lumenal membrane of capillary 
endothelial cells at the blood-brain, blood-testis and blood-inner ear barriers, and in 
the apical membrane of placental trophoblasts (Thiebaut et al., 1987; Sugawara et 
al., 1988; Cordon-Cardo et al., 1989, 1990). As a result of this tissue distribution, 
P-gp has been shown to reduce the uptake of its substrates from the gastrointestinal 
tract (Van Asperen et al., 1998; Schellens et al., 2000; Benet and Cummins, 2001), 
to limit their penetration into critical tissues such as the brain, testis or foetus 
(Schinkel et al., 1994, 1995, 1996; Lankas et al., 1997, 1998; Smit et al., 1999), 
and enhance their elimination by biliary, intestinal or renal secretion (Schinkel et 
al., 1994, 1995, 1997; Hunter and Hirst, 1997; Smit et al., 1998; Van Asperen et 
al., 1998).  
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There are now accumulating in vitro and in vivo evidence that P-gp contributes 
significantly to the disposition of many drugs by mediating their elimination into 
the intestinal lumen, bile or urine (Schinkel et al., 1994, 1995, 1997; Hunter and 
Hirst; 1997; Smit et al., 1998; Van Asperen et al., 1998; Tanigawara, 2000; 
Matheny et al., 2001). Furthermore, preclinical and clinical studies have shown that 
intestinal P-gps could effectively limit the absorption of orally-administered drugs 
such as paclitaxel and docetaxel (Van Asperen et al., 1998; Aungst, 1999; 
Schellens et al., 2000; Matheny et al., 2001). There is a striking, albeit not 
complete, overlap between substrates of P-gp and those of the human cytochrome 
P450 3A4 (CYP3A4) (Wacher et al., 1995; Benet and Cummins, 2001). Thus, it 
has been suggested that the intestinal P-gps could act in combination with intestinal 
cytochrome P450 to reduce even more the systemic availability of orally-
administered compounds (Wacher et al., 1995; Benet and Cummins, 2001). 
Briefly, the drug molecules that escape intestinal metabolism in the enterocyte 
would be pumped back into the intestinal lumen by P-gp, allowing thereby their re-
exposure to intestinal metabolic enzymes following reabsorption. The P-gps 
located at the blood-brain barrier have been shown to limit access of xenobiotics to 
the central nervous system (CNS) and thus to serve a protective role against the 
neurotoxicity of several drugs such as ivermectin (described below) (Schinkel et 
al., 1994, 1995, 1996; Matheny et al., 2001). However, these P-gps can also limit 
the efficacy of drugs targeted to the CNS (Matheny et al., 2001; Borst and Elferink, 
2002). In HIV therapy for instance, the CNS has been shown to serve as a reservoir 
for HIV infection due to the poor ability of HIV protease inhibitor to cross the 
blood brain barrier (Matheny et al., 2001). 
P-gp expression is likely to vary among individuals, which significantly 
complicates prediction of drug disposition in vivo. Indeed, some natural 
polymorphisms in P-gp have been reported in humans (Borst and Elferink, 2002). 
Besides, P-gp can be induced in vivo by several drugs and food components 
(rifampicin, St John’s wort, grapefruit juice) (Matheny et al., 2001; Borst and 
Elferink, 2002). Finally, as for cytochrome P450 isoenzymes, P-gp can play an 
important role in clinically-relevant drug-drug interactions (Dale, 1999; Matheny et 
al., 2001). 
It is worthwhile to mention that other ABC transporters may play a role in drug 
disposition. A second major ABC transporter called MRP (multidrug resistance-
associated protein, now MRP1) was identified by Cole et al. in 1992. Since then, 
eight homologues of MRP1 have been discovered, including MRP2 originally 
identified as the canalicular multispecific organic anion transporter cMOAT (for 
review, see Borst and Elferink, 2002). Like P-gp, MRP2 is located on the apical 
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membrane of epithelial cells (whereas MRP1 is basolateral) and is expressed in the 
liver, the intestines and the kidneys (König et al., 1999; Litman et al., 2001; Borst 
and Elferink, 2002). MRP2 has generally greater affinity for unconjugated 
amphiphilic anions or anionic conjugates of lipophilic compounds, whereas P-gp 
interacts predominantly with uncharged and cationic substances (König et al., 
1999; Borst and Elferink, 2002). There is, however, some overlap in their substrate 
specificities with respect to neutral compounds (König et al., 1999; Litman et al., 
2001; Borst and Elferink, 2002). MRP2 has been shown to play a major role in the 
transport of bilirubin glucuronide into bile, but mediates also the biliary, intestinal 
and renal secretion of several compounds (König et al., 1999; Gotoh et al., 2000; 
Suzuki and Sugiyama et al., 2000; Borst and Elferink, 2002).  
 
2) Physiological role of P-gp. 
One major physiological role of P-gp is certainly the detoxification of the 
organism and its protection against the potentially toxic compounds arising from 
the environment. P-gp is encoded by one gene in humans (MDR1) and two genes 
in rodents, mdr1a (or mdr3) and mdr1b (or mdr1), which probably fulfil the same 
function as the single human MDR1 gene (Borst and Elferink, 2002). It is 
noteworthy though that Mdr1a P-gp is the only expressed in the brain and in the 
intestines in mice (Borst and Elferink, 2002). Another MDR gene has been 
identified in humans (called MDR2 or MDR3) and in rodents (mdr2), which codes 
for a phospholipid transporter important in normal hepatobiliary function (Smit et 
al., 1993). It is generally considered that the MDR3 gene product is not involved in 
drug transport. However, a recent study showed that this protein was capable of 
transporting several drugs, including ivermectin (Smith et al., 2000).  
The existence of additional physiological functions of the drug transporting P-
gp is still under debate (reviewed by Borst and Elferink, 2002). This protein could 
play a possible role in the transport of lipids and peptides, and in the secretion of 
cytokines (interleukins 2 and 4, and gamma interferon) by certain subsets of 
lymphocytes expressing P-gp. Furthermore, P-gp is highly expressed in the human 
adrenal cortex (Sugawara et al., 1988), which has raised a possible role in cortical 
hormone transport (Ueda et al., 1992; Tanigawara, 2000). Interestingly, mdr1a/b 
double knockout mice are healthy and fertile in a protected environment and 
display no clear physiologic abnormalities or decreased lifespan (Schinkel et al., 
1997). However, it is possible that other membrane pumps compensate the vital 
functions of these proteins in their absence. 
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3) Ivermectin, a P-gp substrate and inhibitor. 
Studies using P-gp-transfected or overexpressing cell lines showed that 
ivermectin could be a P-gp substrate and a potent P-gp inhibitor (Schinkel et al., 
1995; Didier and Loor, 1996; Pouliot et al., 1997; Smith et al., 2000; Eneroth et al., 
2001). The implication of P-gp in the disposition of ivermectin was demonstrated 
in vivo with the use of P-gp-deficient mice (knockout or naturally deficient with 
mdr1a) or by co-administration of P-gp modulators in rat or mouse (Schinkel et al., 
1994; Didier and Loor, 1995; Lankas et al., 1997, 1998; Alvinerie et al., 1999; 
Kwei et al., 1999). These studies have identified P-gp as a major barrier against the 
penetration of ivermectin into the brain and the foetus (Schinkel et al., 1994; Didier 
and Loor, 1995; Lankas et al., 1997, 1998; Kwei et al., 1999; Nobmann et al., 
2001). Indeed, P-gp-deficient mice were shown to accumulate 30- to 90-fold more 
ivermectin in their brain than wild-type mice, and were also 100 times more 
sensitive to the neurotoxicity of ivermectin (Schinkel et al., 1994; Lankas et al., 
1997; Kwei et al., 1999). Similarly, the absence of P-gp in the placenta resulted in 
an increased exposure and sensitivity of the fœtus to the ivermectin derivative 
abamectin (Lankas et al., 1998). However, the exact contribution of P-gp to the 
overall disposition of ivermectin is still not fully understood. 
Little information is available regarding the involvement of P-gp in the 
disposition of other endectocides. It has been suggested that abamectin and 
moxidectin could be P-gp substrates as well (Lankas et al., 1997, 1998; Dupuy et 
al., 2001; Lifschitz et al., 2002). 
Finally, homologues of P-gp have been identified in nematodes (Haemonchus 
contortus) (Xu et al., 1998), and it has been suggested that these P-gps could play a 
role in the cross-resistance of parasites to ivermectin and moxidectin (Blackhall et 
al., 1998a; Xu et al., 1998; Molento and Prichard, 1999). An overexpression of P-
gp was indeed observed in resistant strains of nematodes compared with 
susceptible strains (Xu et al., 1998). Furthermore, resistant strains were more 
sensitive to ivermectin in the presence of P-gp inhibitors (Xu et al., 1998; Molento 
and Prichard, 1999). Recently, two putative P-gp genes have been identified in 
Onchocerca volvulus  (Kwa et al., 1998; Huang and Prichard; 1999), which were 
expressed at low levels in ivermectin sensitive larval stages and at high levels in 
ivermectin tolerant adult worms (Huang and Prichard; 1999). The relevance of P-
gp as a mechanism for drug resistance, however, is still under debate (Kwa et al., 
1998). 
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C) SCOPE OF THE THESIS. 
 
To understand and optimise the clinical efficacy of ivermectin, it has to be taken 
into account that many parasites do not feed on plasma. Thus, the compartmental 
distribution of ivermectin in secondary compartments such as bile and intestinal 
fluids needs to be documented. Ivermectin is extensively eliminated from blood 
into the digestive tract lumen as parent drug (40% of total faecal residues in cattle; 
Halley et al., 1989) and as less active metabolites. However, the routes by which 
unchanged ivermectin reaches the gut are not fully understood. As for other 
endectocides (Hennessy et al., 2000), biliary secretion has been assumed to be the 
major route of elimination of the parent drug. On the other hand, the possibility of 
a direct secretion of ivermectin through the gut wall has been raised (Bogan and 
McKellar, 1988). For some drugs such as ciprofloxacin, roxithromycin, and 
vinblastine, intestinal secretion is even more important than biliary secretion in the 
overall elimination process (Arimori et al., 1998; Dautrey et al., 1999; Van 
Asperen et al., 2000). Since ivermectin has been shown to be a P-gp substrate 
(Schinkel et al., 1994, 1995), intestinal P-gps could provide the mechanistic 
support for the secretion of parent ivermectin from blood into the intestinal lumen.  
 
The existence of an intestinal secretion of ivermectin is examined in the first 
part of the thesis, using two validated in vitro and in situ models. The possible 
extrapolation of the results to the target animal species is further discussed, on the 
basis of the existence of functional P-gps in those species. The following issues 
were addressed: 
- Investigation of an intestinal secretion of ivermectin by human epithelial 
Caco-2 cell monolayers, and examination of the role of P-gp and MRP2 in 
the secretion process (chapter 2). 
- Comparative evaluation of the intestinal and biliary secretions of parent 
ivermectin in anaesthetised rats, using the intestinal closed-loop model. 
Ivermectin intestinal and biliary clearances were evaluated in situ, while 
ivermectin total (plasma) clearance was assessed from a parallel in vivo 
experiment. P-gp involvement in both intestinal and biliary secretions was 
investigated (chapter 3). 
- Comparative evaluation of P-gp activity in sheep, cattle, horses, goats, pigs 
and rats, using a lymphocyte-based ex vivo model. The expression of P-gp in 
the intestines (jejunum) was also investigated (chapter 4). 
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Ivermectin elimination from blood, however, cannot always account for the 
total excretion of parent drug in faeces after parenteral administration. In cattle, 
higher faecal concentrations of ivermectin have been reported following topical 
administration than following subcutaneous administration, which is inconsistent 
with the lower plasma concentrations (Herd et al., 1996). One reason for this 
discrepancy could be that cattle are licking themselves, ingesting thereby a part of 
the topical dose. This hypothesis was examined in the second part of the thesis, as 
follows: 
- Evaluation of the influence of animal licking behaviour on the absolute 
bioavailability, plasma disposition and faecal disposition of topical 
ivermectin in cattle, using 6 pairs of monozygotic twin cattle separated into 
two groups of licking and non-licking cattle (chapter 5). 
- Quantification of the actual contribution of animal licking to the plasma and 
faecal disposition of topical ivermectin in cattle, by pharmacokinetic 
modeling of the i.v. and pour-on (plasma and faecal) data obtained in each 
pair of twins (chapter 6). 
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Abstract 
 
In a recent study using rat intestinal loops, we suggested that intestinal secretion 
could be a major route for the elimination of parent ivermectin from blood. In order 
to confirm an intestinal secretion process and delineate its underlying mechanisms, 
we examined the bilateral transport of [3H]ivermectin across human intestinal 
epithelial Caco-2 cell monolayers. Directional transport of [3H]ivermectin in the 
secretory direction was demonstrated, with a basolateral-to-apical flux exceeding 
up to 10 times that in the opposite direction, depending on the donor concentration. 
The net secretion of [3H]ivermectin was totally abolished at 4°C and in the 
presence of the P-gp inhibitor cyclosporin A (50 µM). Furthermore, basolateral-to-
apical transport was partly inhibited by the P-gp modulators verapamil (100 µM), 
testosterone (100 µM) but not digoxin (100 µM). Altogether, these results suggest 
that P-glycoprotein plays an important role in the intestinal secretion of ivermectin. 
The organic anion p-aminohippurate (100 µM) and LTC4 (0.5 µM), a modulator of 
MRP2 (multidrug resistance associated-protein 2), had no significant effect on 
[3H]ivermectin transport. However, MK571 (100 µM), another MRP2 modulator, 
significantly reduced [3H]ivermectin secretory flux, suggesting the involvement of 
MRP2 in the secretion process. Expression of P-glycoprotein and MRP2 in Caco-2 
cells was confirmed by Western immunoblotting. In conclusion, our results provide 
further evidence for an active secretion of ivermectin from blood into the intestinal 
lumen, which is of clinical significance since many gastrointestinal parasites do not 
feed on plasma. The relevance of ivermectin secretory transport is discussed in 
terms of oral bioavailability.  
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Introduction 
 
Ivermectin is an extremely potent antiparasitic drug with a broad spectrum of 
activity against ecto- and endoparasites and a wide margin of safety. It is currently 
used for control and treatment of various parasitic conditions in human and 
veterinary medicine, and has become the first-line treatment for human 
onchocerciasis, a major public disease (Burkhart, 2000). 
Ivermectin is almost exclusively excreted into faeces, irrespective of the species 
and administration route, with less than 2% of the dose excreted in the urine (Chiu 
et al., 1990; McKellar and Benchaoui 1996). A large amount of ivermectin is 
eliminated unchanged from blood (40% of a i.v. dose in cattle; Laffont et al., 
2001), but the routes by which parent ivermectin reaches the digestive tract are not 
fully understood. Since high concentrations of ivermectin have been reported in 
bile (Chiu et al., 1990), it is currently believed that biliary secretion is the main 
elimination pathway of the parent drug. However, in a recent study using rat 
intestinal loops, we showed that ivermectin could be secreted from blood through 
the gut wall (Laffont et al., 2002). All segments of the rat small intestine excreted 
the parent drug after systemic administration, and ivermectin small intestinal 
clearance was approximately 5-fold higher than ivermectin biliary clearance. 
The purpose of the present study was to confirm the existence of an intestinal 
secretion process using the human colonic adenocarcinoma cell line Caco-2. This 
cell line is a well-established in vitro model of the intestinal epithelium and is 
widely used for prediction of intestinal absorption or secretion of drug molecules. 
Caco-2 cells form monolayers of well-differentiated cells, which display many 
morphological and functional characteristics of the normal enterocytes (reviewed 
by Boulenc, 1997). They express many transporters normally found in the small 
intestine, including the drug transporting P-glycoprotein (P-gp) and multidrug 
resistance-associated protein MRP2 (Hosoya et al., 1996; Boulenc, 1997; Hunter 
and Hirst, 1997; Hirohashi et al., 2000; Walgren et al., 2000). P-gp and MRP2 are 
two drug efflux pumps localised at the apical membrane and have been shown to 
mediate the intestinal secretion of many compounds (Hunter and Hirst, 1997; Van 
Asperen et al., 1998; König et al., 1999; Walgren et al., 2000). Since ivermectin 
has been shown to be a substrate of P-gp (Schinkel et al., 1994, 1995; Pouliot et al., 
1997), the implication of P-gp in the secretion process was examined. The possible 
involvement of MRP2 was also investigated, as MRP2 has the capacity to transport 
neutral compounds (König et al., 1999). 
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Materials and Methods 
 
Chemicals 
Ivermectin, cyclosporin A, verapamil hydrochloride, testosterone, digoxin, p-
aminohippurate, leukotriene C4 (LTC4) were purchased from Sigma (St. Louis, 
MO, USA). MK571 was from Alexis Biochemicals (Grünberg, Germany). LTC4 
was commercially available as a solution in 70% (v/v) ethanol. For ivermectin and 
other compounds, which were poorly soluble in transport medium, stock solutions 
were prepared in dimethyl sulfoxide (DMSO). [3H]ivermectin was kindly provided 
by Merial (NJ, USA). Cell culture media and reagents were from Gibco BRL 
(Breda, the Netherlands). P-gp and MRP2 monoclonal antibodies, C219 and M2III-
6, were purchased from Fujirebio Diagnostics, Inc. (Malvern, PA, USA) and 
Monosan (Uden, the Netherlands), respectively. Biotinylated goat anti-mouse IgG 
and streptavidin-AP conjugate were from Zymed (CA, USA) and Boehringer 
(Mannheim, Germany), respectively. 
 
Cell culture 
Caco-2 cells were obtained from the American Type Culture Collection 
(ATCC). Cells were routinely cultured at 37°C in a humidified 5% CO2 
atmosphere, using Dulbecco’s modified Eagle's medium (DMEM) supplied with 
phenol red and 4.5 g/L glucose, and supplemented with 10% heat inactive foetal 
calf serum (FCS), 1% non-essential amino acids, 2 mM glutamine, and antibiotics 
(100 µg/mL streptomycin and 100 IU/mL penicillin). Cells were grown in 75-cm2 
tissue culture flasks and subcultured every week by trypsinisation, replacing 
medium every two or three days. For transport experiments, cells were harvested 
with trypsin-EDTA and seeded onto inserts (Falcon, 0.4 µm pore size, 0.3 cm2, 
high density PEPT) at 100,000 cells/cm2 in 24-well culture plates. The cells used 
for transport studies were between passage 89 and 96, after which cell culture was 
restarted from the original frozen stock. Cells were grown as epithelial monolayers 
for 19 days, refreshing medium 3 times per week for two weeks and daily 
thereafter. 
 
Transepithelial transport studies 
The MTT test was used to assess the potential cytotoxicity of ivermectin and of 
P-gp or MRP2 modulators at the applied concentrations. The MTT test, which 
measures the reduction of dimethylthiazol diphenyl tetrazolium bromide (MTT) to 
formazan by the mitochondrial enzyme succinate dehydrogenase was based on 
Denizot and Lang (1986). No detectable cytotoxicity was observed in Caco-2 cells 
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after 3 h of exposure (data not shown). Although previous in vitro transport studies 
on ivermectin did not address the problem, ivermectin was found to bind very 
significantly to glassware and plastics of cell culture material (at 0.1-1 µM, the 
recovery of radiolabelled drug in cells plus compartments did not exceed 30%). 
Aspecific binding could be prevented during preparation of loading solutions of 
ivermectin by sonication, but could not be avoided during transport experiments 
and thus had to be taken into account. As aspecific binding was saturated at high 
concentrations (25 µM), quantitative investigations were limited. 
Transport experiments were performed at 37°C or 4°C using phenol red-free, 
serum-free (to avoid ivermectin binding to serum) DMEM as transport medium. 
Loading solutions of [3H]ivermectin (0.1-25 µM; 0.15 µCi/mL) were prepared in 
transport medium, and lucifer yellow was added at the final concentration of 20 
µg/mL. Aliquots (200 µL) were taken from the loading solution of [3H]ivermectin, 
after and before addition of lucifer yellow, to evaluate quenching. The linearity of 
[3H]ivermectin transport over time was checked at various donor concentration 
levels (1, 5, 10, 25 µM) in both absorptive and secretory directions. Caco-2 cells 
were washed with phosphate buffered saline and were pre-equilibrated in transport 
medium for 1 h at 37°C in a humidified 5% CO2 atmosphere. Apical medium was 
removed, and the inserts were transferred to a fresh 24-well plate. [3H]ivermectin 
loading solution was added to the apical (apical-to-basolateral transport, AP > BL) 
or basolateral (basolateral-to-apical transport, BL > AP) side of the inserts, with the 
corresponding volume of transport medium added on the opposite side. After 
incubation for 30 min, 1, 2 or 3 h at 37°C in a humidified 5% CO2 atmosphere, 
aliquots of 200 µL were sampled from the receiver compartment and when 
possible from the donor compartment. Three inserts per time point were used in BL 
> AP experiments, while in AP > BL experiments, inserts (n=3) were moved at 
intermediate times to other wells containing fresh transport medium. The amounts 
of ivermectin recovered in the samples were evaluated by liquid scintillation 
counting taking into account quenching. 
Once the linearity of [3H]ivermectin transport was checked over 3 h, only one 
time point (t = 3h) was investigated. Bilateral transport of [3H]ivermectin was then 
examined over a broader range of concentrations (0.1, 0.5, 1, 2, 5, 10, 25 µM). This 
was done in a single experiment to avoid possible changes in P-gp expression 
(Anderle et al., 1998). After a 3-h incubation at 37°C in a humidified 5% CO2 
atmosphere, aliquots of 200 µL were sampled from the receiver and donor 
compartments, and radioactivity was measured. Three inserts per condition were 
used. Bilateral transport of [3H]ivermectin was also investigated at 4°C at the donor 
concentration of 1 µM. 
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Inhibition studies 
The P-gp substrates and/or inhibitors verapamil (100 µM), cyclosporin A (50 
µM), testosterone (100 µM) and digoxin (100 µM) were applied to block the P-gp 
function (Ford and Hait, 1990; Dale, 1999). MK571 (100 µM), leukotriene LTC4 
(0.5 µM), and the organic anion p-aminohippurate (100 µM) were used as MRP2 
modulators (König et al., 1999; Litman et al., 2001). Transport studies were 
performed as described above, with a single time-point after 3 h of incubation at 
37°C. P-gp or MRP2 modulators were added to both sides of the inserts, and the 
bilateral transport of [3H]ivermectin was measured at the donor concentration of 1 
µM. The final concentration of DMSO or ethanol (in the case of LTC4) were 0.65% 
(v/v) and 0.4% (v/v), respectively. Control wells consisting of 0.65% DMSO or 
0.4% ethanol were thus included in each experiment. The time course of transport 
of [3H]ivermectin (1 µM) in the presence of cyclosporin A (50 µM) was 
additionally measured over 3 h. 
 
Monolayer integrity 
The integrity of the cell monolayers was routinely checked by measuring the 
transepithelial electrical resistance (TEER) and the permeability to lucifer yellow, a 
marker for the paracellular route. The TEER was measured at the start and at the 
end of the transport experiments using the Millicell® -ERS voltohmmeter, and 
monolayers with a TEER below 200 ohm.cm2 were discarded. The paracellular 
flow was monitored by the appearance of lucifer yellow on the receiver side for up 
to 3 h. The concentrations of lucifer yellow were measured by fluorometry 
(Cytofluor 2300 Fluorescence Measurement System, Millipore, Corp. Bedford, 
MA, USA) at the emission and excitation wavelengths of 409 nm and 525 nm, 
respectively.  
 
Analysis of P-gp and MRP2 expression by Western blotting 
Caco-2 cells grown on inserts for 19 days and used for transport studies were 
scraped in 200 µL of PBS and the samples were homogenised. Brush-border-
enriched proteins were also prepared from Caco-2 cells cultured in tissue culture 
flasks by a previously described method (Pinto et al., 1983). Primary cultures of rat 
hepatocytes were used as a positive control for P-gp: after one day of culture on 
10-cm dishes, hepatocytes were washed twice and scraped in PBS. After 
centrifugation, the cells were resuspended in 500 µL of PBS and the samples were 
homogenised. Protein concentrations were determined using the Pierce BCA 
protein assay reagent (Pierce, Rockford, IL, USA), using bovine serum albumin 
(BSA) as a standard. Seven µg of protein were loaded in each lane and 
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electrophoresed on SDS-polyacrylamide gels (4% stacking and 8% running gel) in 
a Mini-Protean III Cell (Biorad, Veenendaal, The Netherlands), as described by 
Laemmli (1970). Electroblotting was performed onto a polyvinylidene difluoride 
membrane according to the method of Towbin et al. (1979). For the detection of P-
gp (170 kDa), the monoclonal antibody C219 specific for P-glycoprotein was used 
in a dilution of 1:200 in TBS (Tris-buffered saline) containing 0.3% (v/v) Tween 
20 and 1% (w/v) BSA. MRP2 (190 kDa) was detected with the monoclonal 
antibody M2III-6 diluted 1:20 in TBS-Tween-BSA. Biotinylated goat anti-mouse 
IgG and streptavidin-AP conjugate were used for detection of the primary 
antibody. 
 
Data analysis  
Data analysis was carried out using the SYSTAT® 8.0 software (SPSS Inc., 
Chicago, IL). Secretion-to-absorption ratios were calculated by dividing the rate of 
[3H]ivermectin transport in the BL > AP direction by that in the AP > BL direction. 
Transport rates were estimated by linear regression analysis on the time course plot 
of the amount of [3H]ivermectin transported (in kinetics studies) or were obtained 
as the total amount of [3H]ivermectin transported to the receiver side over 3 h 
divided by the time of incubation. Data are presented as means ± SD. Statistical 
analysis was performed using the Student’s t-test. A p < 0.05 was regarded as 
significant. 
 
Results 
 
The linearity of transport of [3H]ivermectin was confirmed over 3 h at different 
concentration levels, in both AP > BL and BL > AP directions. The results of the 
kinetic studies are presented in Fig. 1. Transport in the BL > AP direction was 
greater than that in the AP > BL direction at each sampling point, indicating a net 
secretion of [3H]ivermectin from basolateral to apical surfaces of the Caco-2 cell 
monolayers. The bilateral transport of [3H]ivermectin was measured for a broader 
range of donor concentrations (0.1, 0.5, 1, 2, 5, 10 and 25 µM) after a 3-h 
incubation period. Under the same experimental conditions, the secretion-to-
absorption ratio of [3H]ivermectin decreased from 10 to 2 with donor 
concentrations increasing from 0.1 µM to 25 µM. 
The net secretion of [3H]ivermectin (1 µM) was abolished at 4°C, with no 
significant difference between absorptive (0.48 ± 0.11 pmol/3h) and secretory 
fluxes (0.66 ± 0.07 pmol/3h), supporting the involvement of energy-dependent 
active transport mechanisms. By comparison, the secretion-to-absorption ratio for 1 
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Figure 1. Vectorial transport of [3H]ivermectin across Caco-2 cell monolayers. The
monolayers were incubated at 37°C with 1 µM (a), 5 µM (b), 10 µM (c) or 25 µM (d)
[3H]ivermectin added to either the basolateral side ()) or apical (h) side of the inserts.
The radioactivity on the opposite side was measured at indicated time points. Each point is
the mean ± SD of three monolayers. 
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µM [3H]ivermectin at 37°C was 4.2 - 4.6. 
Inhibition studies showed a significant reduction of the secretory flux of 
[3H]ivermectin in the presence of all P-gp modulators except digoxin. BL > AP 
transport of [3H]ivermectin was inhibited by 71%, 40% and 35% by cyclosporin A, 
verapamil and testosterone, respectively (see Fig. 2A). Cyclosporin A was the most 
effective modulator, producing a complete inhibition of the net secretion of 
[3H]ivermectin in all individual experiments (4 independent experiments performed  
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Figure 2. Secretory flux (open columns) or absorptive flux (filled columns) of
[3H]ivermectin across Caco-2 cell monolayers in the presence or absence of inhibitors.  
A) Digoxin (Dgx, 100 µM), testosterone (Tst, 100 µM), verapamil (Vrp, 100 µM) and
cyclosporin A (CsA, 50 µM) were applied as P-gp modulators. B) P-aminohippurate (PAH,
100 µM), LTC4 (0.5 µM) and MK571 (100 µM) were applied as MRP2 modulators.
[3H]ivermectin (1 µM) was added either to the basolateral or apical compartment, with or
without inhibitors added to both sides of the inserts. After a 3-h incubation at 37°C, the
radioactivity on the receiver side was measured. Each column represents the mean ± SD of
3 to 9 monolayers. *, p < 0.05; **, p < 0.01; ***, p < 0.001. 
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Figure 3. Vectorial transport of [3H]ivermectin across Caco-2 cell monolayers in the
absence (filled symbols) or presence (open symbols) of cyclosporin A (50 µM).
[3H]ivermectin (1 µM) was added to either the basolateral ( , )) or apical (f, h) side of
the inserts. The radioactivity on the opposite side was measured at indicated time points.
Each point is the mean ± SD of three monolayers. 
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Figure 4. Western immunoblots of MRP2 (A) and P-gp (B) expression in Caco-2 cells.
Lines 1-4: cell lysate of 19-day old Caco-2 cells grown on inserts (4 different monolayers);
line 5: brush-border enriched preparation from Caco-2 cells grown in tissue culture flasks;
line 6: cell lysate of primary rat hepatocytes as a positive control for P-gp and negative
control for MRP2. 
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in triplicate) (see Figs. 2A and 3). P-aminohippurate and LTC4 had no significant 
effect on the bilateral transport of [3H]ivermectin at the applied concentrations  
(Fig. 2B). In contrast, MK571 significantly reduced the secretory flux of 
[3H]ivermectin by approximately 51% (Fig. 2B shows the mean ± SD of 3 
independent experiments performed in triplicate). A significant increase in AP > 
BL transport was observed in the presence of cyclosporin A (+26%) and MK571 
(+57%). The expression of P-gp and MRP2 in Caco-2 cells was confirmed under 
our experimental conditions by Western immunoblotting (Fig. 4). 
 
Discussion 
 
The present study provides convincing evidence for a polarised transport of 
ivermectin across Caco-2 cell monolayers in the secretory direction. These findings 
are in agreement with our previous study in the rat (Laffont et al., 2002) and 
reinforce the hypothesis of an intestinal elimination pathway for ivermectin from 
blood into the intestinal lumen. 
In the presented experiments, only radioactivity was measured. However, it can 
be assumed that no substantial amounts of metabolites were produced during the 3-
h experiments and that radioactivity was indicative for the amount of parent 
compound. In general, no appreciable levels of cytochrome P450 3A4 (CYP3A4) 
activity are found in Caco-2 cells (Boulenc, 1997; Schmiedlin-Ren et al., 1997). 
This was confirmed under our experimental conditions by measuring the rate of 
testosterone 6ß-hydroxylation (data not shown). CYP3A4 has been shown to be 
responsible for the metabolism of ivermectin by human liver microsomes, and no 
ivermectin metabolites could be detected in its absence (Zeng et al., 1998).  
As has been previously reported (Andrew and Halley, 1996), we found that 
ivermectin could bind to plastic material and glassware. The problem of aspecific 
binding did not impair the use of the Caco-2 cell model for bilateral transport 
studies or mechanistic insights. However, no permeability coefficients could be 
calculated. Furthermore, as aspecific binding was saturated at high concentrations 
(25 µM), no conclusions could be made on the apparent saturation of BL > AP 
transport with increased donor concentrations. These considerations question the 
relevance of previous quantitative studies on ivermectin transport by P-gp, which 
did not address this problem and nevertheless calculated transport and binding 
parameters. 
The net secretion of ivermectin was totally abolished at 4°C, which is consistent 
with the involvement of active transport mechanisms. Furthermore, BL > AP 
transport was significantly reduced by the P-gp inhibitors cyclosporin A, verapamil 
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and testosterone, indicating that P-gp played a role in the secretion process. The 
lack of effect of digoxin might be explained by different binding sites on P-gp or 
by a lower affinity of digoxin for P-gp compared to that of ivermectin which is 
high (Pouliot et al., 1997). It is noteworthy that the directional transport of 
ivermectin across Caco-2 cells is less efficient than for other P-gp substrates. By 
comparison, under the same experimental conditions, we measured a secretion-to-
absorption ratio of 23 for rhodamine 123, a prototypic P-gp substrate (data not 
shown). A less efficient transport of ivermectin is probably due to a higher affinity 
of ivermectin for P-gp and hence a lower dissociation rate constant (Pouliot et al., 
1997), and is consistent with the low plasma clearance of ivermectin encountered 
in vivo (Fink and Porras, 1989; McKellar and Benchaoui 1996). 
Our findings are in agreement with our previous study in the rat showing a 50% 
inhibition of the jejunal secretion of ivermectin after co-administration of 
verapamil (Laffont et al., 2002). It is noteworthy though that verapamil had no 
significant effect on ivermectin secretion by the duodenum and ileum in the same 
animals. Although the use of verapamil in vivo is not exclusive in demonstrating a 
P-gp-mediated process, these results pointed towards the existence of other 
transport mechanisms. In the present study, the MRP modulator LTC4 and the 
organic anion p-aminohippurate failed to inhibit ivermectin BL > AP transport, 
which is in line with the results of previous studies using kidney proximal tubules 
of killifish or porcine brain endothelial capillaries (Fricker et al., 1999; Nobmann et 
al., 2001). However, addition of the MRP-selective inhibitor MK571 resulted in a 
significant inhibition (51%) of the BL > AP flux of ivermectin, suggesting that 
MRP2 could be involved as well in the secretion process. It can seem surprising 
then, that cyclosporin A, known as a potent inhibitor of P-gp, totally abolished the 
net secretion of ivermectin across Caco-2 cells. However, cyclosporin A has been 
reported to also inhibit MRP2 at high concentrations (Legrand et al., 1998; König 
et al., 1999). This is the first time an interaction of ivermectin with MRP2 is 
reported. Such an interaction remains to be confirmed in vitro by using MRP2-
transfected vesicles as well as in vivo. It has been shown that MRP2 is highly 
expressed  in the proximal small intestine, with a gradual decrease in expression 
from jejunum to distal ileum (Mottino et al., 2000). Therefore, it could significantly 
contribute to the overall intestinal elimination process.  
We identified P-gp as an important mechanism for the intestinal secretion of 
ivermectin, which is in agreement with the literature. Previous in vitro studies 
using P-gp transfected or overexpressing tumour cell lines demonstrated indeed 
that ivermectin could be a P-gp substrate (Schinkel et al., 1995; Pouliot et al., 
1997). In vivo, P-gp is expressed in various tissues other than the intestines, 
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including the liver, the kidneys, the blood-brain and blood testis barriers and the 
placenta (Thiebaut et al., 1987; Cordon-Cardo et al., 1989). P-gp has been shown to 
play a major role in the protection of the brain against the neurotoxicity of 
ivermectin by restricting its entry in this organ (Schinkel et al., 1994; Kwei et al., 
1999). However, its contribution to the elimination of ivermectin had never been 
clearly investigated. A possible role of P-gp in ivermectin biliary secretion remains 
to be demonstrated. 
From the present in vitro studies, it can be expected that the secretory transport 
of ivermectin by Caco-2 cells could antagonise the absorption of orally-
administered ivermectin. In vivo however, despite a low oral bioavailability of 
ivermectin in many target species (cattle, sheep, pig, horse; McKellar and 
Benchaoui, 1996), this secretory transport may not be of significant relevance. In 
sheep, ivermectin is 25% bioavailable after intraruminal administration but is 
100% bioavailable after intra-abomasal administration (Prichard et al., 1985). It 
appears that in ruminant species, the major factor limiting oral bioavailability is an 
extensive binding of the drug to the particulate phase of the rumen digesta (>95% 
in cattle and sheep; Ali and Hennessy, 1996). A good intestinal absorption of 
ivermectin could be explained by the saturation of counter-active transport at the 
local concentrations, high rates of passive diffusion, or the existence of 
gastrointestinal sites with a lower expression of efflux transporters where drugs can 
be easily absorbed (Aungst, 1999; Doppenschmit et al., 1999). Furthermore, it must 
be noted that all these species have a low ivermectin plasma clearance, 
corresponding to a body extraction ratio of <1%. Even considering the possibility 
of a synergistic action of intestinal CYP3A isoenzymes and P-gp in reducing even 
more systemic availability (Benet and Cummins, 2001), it is unlikely that such a 
low extraction ratio (transport and metabolic processes) could significantly affect 
the oral bioavailability of this drug. The hypothesis that P-gp could act as a barrier 
against oral absorption arised in fact from the observation that P-gp-deficient mice 
showed 3-times higher ivermectin plasma concentrations than wild-type mice after 
oral administration (Schinkel et al., 1994; Kwei et al., 1999). Ivermectin, however, 
is relatively well absorbed in mice following oral administration (over 60% of the 
dose; Kwei et al., 1999), and an improved oral bioavailability cannot explain such 
an increase in plasma concentrations. Thus, a reduced elimination of ivermectin 
has to be considered as well. 
Finally, our study suggests that ivermectin could interact at the intestinal level 
with other drugs that are also P-gp substrates (antifungal and antimicrobial agents 
such as fluoroquinolones and erythromycin, anti-malarial agents, steroids, cardiac 
drugs … ; Dale, 1999; Matheny et al., 2001). Indeed, P-gp has been shown to be a 
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major source of pharmacological drug-drug interactions (Dale, 1999). In addition, 
ivermectin is very persistent in plasma after parenteral or oral administration, 
irrespective of the species (Fink and Porras, 1989, McKellar and Benchaoui, 1996). 
Since ivermectin binds with a high affinity to P-gp compared to other P-gp 
substrates and is a potent modulator of the P-gp function (Pouliot et al., 1997; 
Eneroth et al., 2001), it can be expected that ivermectin alters the disposition of 
concomitantly administered drugs rather than the contrary. 
In conclusion, our study provides further evidence for the existence of an 
intestinal secretion of parent ivermectin from blood into the intestinal lumen, and 
suggests that P-gp, and to a lesser extent MRP2, are involved in the secretion 
process. These findings are of significant clinical relevance, as they contribute to a 
better understanding of the efficacy of ivermectin against gastrointestinal parasites 
in humans and target animal species. 
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Abstract 
 
The transepithelial intestinal elimination of ivermectin was studied using the 
intestinal closed-loop model in the rat. The common bile duct was cannulated, and 
duodenum, jejunum, and ileum were isolated in situ with their intact blood 
supplies. Following administration of 100, 200 or 400 µg/kg b.wt. ivermectin via 
the carotid artery, the elimination of parent ivermectin into the small intestinal 
lumen over 90 min was approximately 5-fold higher than in bile. The major 
amount of secreted ivermectin was recovered in the jejunum, but the duodenum 
showed a higher intestinal elimination capacity than the other intestinal segments 
with respect to the intestinal length. Systemic co-administration of the P-
glycoprotein blocker verapamil significantly reduced the elimination capacity of 
jejunum by 50%, which resulted in a 30% decrease of ivermectin overall 
elimination by the small intestine. In contrast, verapamil did not significantly affect 
ivermectin secretion in duodenum, ileum, or bile in the same animals. Ivermectin 
small intestinal and biliary clearances were estimated to account for 27 and 5.5% of 
the total drug clearance, which was evaluated from a parallel in vivo experiment in 
which rats were given 200 µg/kg b.wt. ivermectin intra-arterially. In conclusion, 
intestinal secretion plays a greater role than biliary secretion in the overall 
elimination of ivermectin in the rat, providing major amounts of active drug to the 
intestinal lumen and to faeces. This is discussed in terms of therapeutic efficacy 
against intestinal parasites in humans and in animals and of ecotoxicity resulting 
from the contamination of livestock dung with parent drug. 
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Introduction 
 
Ivermectin is an anthelmintic of unprecedented efficacy, currently used 
worldwide to treat and control various parasitic diseases in human and veterinary 
medicine. It has become the drug of choice in the treatment of a major public 
disease, human onchocerciasis, and is administered to more than 18 million people 
each year (Burkhart, 2000). Ivermectin is extensively eliminated by the faecal route 
as parent drug and metabolites, regardless of the species and of the route of 
administration with less than 2% excreted in the urine (Campbell, 1985). As the 
biliary concentration of ivermectin is substantially higher than that in plasma 
(Bogan and McKellar, 1988; Lifschizt et al., 2000), it has been assumed that biliary 
secretion was the major pathway of elimination of the parent drug. The study of 
Hennessy et al. (2000), performed in sheep with the structural analogue 
doramectin, supported this hypothesis. However, absolute amounts of biliary 
secreted ivermectin have never been determined in human or animal species. In 
addition, recent findings have shown that ivermectin was a substrate for some 
intestinal efflux transporters, which points towards the possible existence of 
another elimination pathway e.g. the intestinal secretion of drug from blood into 
the intestinal lumen. 
P-glycoprotein (P-gp) is a plasma membrane protein, which is able to pump a 
broad range of structurally and functionally unrelated compounds out of the cell in 
an energy-dependent manner (reviewed by Sharom, 1997). First identified as a 
factor for multidrug resistance in mammalian tumour cells (Juliano and Ling, 
1976), P-gp has been discovered to be physiologically expressed in a number of 
tissues including the liver, the intestines, and the blood-brain barrier (Thiebaut et 
al., 1987; Cordon-Cardo et al., 1989). The strategic distribution of P-gp on the 
biliary canalicular membrane of hepatocytes and on the apical side of enterocytes 
provides a mechanistic support for both the biliary and the intestinal secretion of 
xenobiotics (Hunter and Hirst, 1997; Smit et al., 1998; Van Asperen et al., 1998). 
Ivermectin was shown to be actively excreted in vitro by multidrug resistant 
tumour cells (Pouliot et al., 1997) and by cells transfected by the gene coding for P-
gp in human or in mouse, MDR1 and mdr1a, respectively (Schinkel et al., 1995; 
Smith et al., 2000). In vivo, the kinetic disposition of ivermectin was modified in 
mice lacking their P-gp I function (Schinkel et al., 1994; Lankas et al., 1997; Kwei 
et al., 1999), with a markedly increased accumulation in brain tissue and signs of 
neurotoxicity. In the intestines, P-gps constitute a barrier against the absorption of 
orally-administered ivermectin (Kwei et al., 1999), but their role in ivermectin 
elimination was never documented. 
Chapter 3 
52 
The purpose of the current study was to investigate in vivo the existence, and 
the extent, of a non-biliary intestinal elimination pathway with direct secretion of 
ivermectin from systemic blood through the gut wall. The involvement of P-gp in 
ivermectin elimination was assessed by co-administration of verapamil, a 
prototypic P-gp substrate and inhibitor (Ford and Hait, 1990), which was already 
shown to affect the in vivo disposition of ivermectin in the rat following topical 
application (Alvinerie et al., 1999). 
 
Materials and Methods 
 
Materials 
Ivermectin (IVOMEC INJECTABLE OVIN®) was purchased from Merial 
(Lyon, France). Verapamil hydrochloride was from Sigma-Aldrich (St. Quentin 
Fallavier, France), and [14C]-inulin (62.5 µCi/mL) was obtained from PerkinElmer 
Life Sciences (Boston, MA, USA). All other chemicals used were of the highest 
grade available. 
 
Animals 
Male Wistar rats (Iffa Credo, L’Arbresle, France) weighing 323 ± 30 g were 
used in the experiments. All the investigations were performed in accordance with 
the European Regulations for the use of laboratory animals. 
 
Pilot experiments (open-perfusion model) 
Two rats were prepared as described below for the closed-loop model (Trial 1), 
but the intestinal elimination was investigated from a 20-cm jejunal loop only, 
following systemic administration with 200 or 400 µg/kg b.wt. ivermectin. The 
jejunal segment was isolated 2 cm distal to the ligament of Treizt, and perfused 
continuously with thermostated saline at the constant flow rate of 0.6 mL/min 
determined as optimal by Savina et al. (1981). A catheter was placed at the distal 
end of the segment, allowing serial recuperation of intestinal perfusates into tubes 
at 8-min intervals, up to 184 min. The rats were sacrificed at the end of the 
experiments. The 20-cm segment was excised, opened lengthwise, and the residual 
content was scraped. Acetonitrile was added to the perfusate samples in order to 
achieve an acetonitrile:water 4:5 v/v mixture, and all samples were stored at –20°C 
until analysis. 
 
Trial 1 (intestinal closed-loop model) 
After an overnight fast with free access to water, animals were anaesthetised by 
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i.p. administration of 1.5 g/kg b.wt. urethane and 40 mg/kg b.wt. α-chloralose. Rats 
were tracheotomised for a facilitated respiration under anaesthesia and placed 
under a heating lamp. The left carotid artery was cannulated with a polyethylene 
tube (i.d. 0.58 mm) and perfused using an electric syringe with thermostated 
(37°C) saline at the constant flow rate of 1 mL/h. A midline abdominal incision 
was made, and a polyethylene tube (i.d. 0.3 mm) was inserted into the common bile 
duct, near the hilum of the liver, for bile collection. The segments of the small 
intestine were exposed in situ with their blood supply intact. A polyethylene 
catheter (25 × 0.9 mm, BD Biosciences, Meylan, France) was placed at the 
proximal end of the duodeno-jejunum (starting from the pylorus and ending 30 cm 
above the ileocaecal junction), and the intestinal contents were washed out by 
perfusing thermostated (37°C) saline for 20 min at the constant rate of 0.6 mL/min. 
A small incision was made at the distal end of the duodeno-jejunum to allow 
collection of intestinal contents and effluents. Five minutes before the end of 
intestinal perfusion, the segment was gently ligated at its distal end and filled with 
perfusion liquid. The proximal end of the segment was ligated, and one additional 
ligature was placed 1 cm distal to the ligament of Treitz to separate the duodenum 
from the jejunum. The two segments were carefully returned to the abdominal 
cavity. The ileal segment (30 cm) was prepared following the same procedure. 
Care was taken not to interrupt the normal blood supply of the segments during 
their preparation. The abdominal cavity was then covered with a compress soaked 
with saline to prevent heat loss and evaporation. The perfusion of the carotid artery 
with saline was interrupted and ivermectin was injected rapidly (1min) via the 
catheter at the dose of 100, 200 or 400 µg/kg b.wt. (ivermectin was diluted in 
polyethylene glycol 400 to fit low dose rates). Saline was perfused again during 90 
min.  
In the competition experiments, the i.a. perfusion of saline was stopped 5 min 
prior to ivermectin administration, and verapamil was given at a loading rate of 24 
mg/kg b.wt. per hour during 5 min via the carotid artery. Ivermectin was then 
injected i.a. at the standard dose of 200 µg/kg b.wt., and verapamil was perfused 
again at 4.8 mg/kg b.wt. per hour and during 90 min. 
Bile was collected throughout the experiment. Animals were sacrificed at 90 
min after ivermectin administration. Blood was previously collected by cardiac 
puncture in some treated and non-treated rats. The intestinal segments were 
excised, their length measured, and they were opened lengthwise. The whole 
intestinal content was carefully collected using a cell scraper, and 3 mL of 
acetonitrile was added to the samples. The scraping procedure was very gentle to 
remove the mucous layer with minimal disruption of the intestinal cells. Blood 
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samples were centrifuged, and plasma was collected. Biliary, plasma and intestinal 
samples were stored at –20°C until analysis. Five to six rats were used to test each 
dose level of ivermectin in the non-competition experiments, and seven rats were 
used in the competition experiments. 
Another group of animals (n = 8) was taken for an accurate estimation of the 
area under the plasma concentration-time curve between 0 and 90 min post-
administration. Rats were anaesthetised as described above, but no other surgical 
procedure was performed. Blood was sampled at 2, 5, 15, 30, 60 and 90 min after 
i.a. administration of 200 µg/kg b.wt. ivermectin.  
 
Validation of the study model of intestinal elimination 
To determine the extent of non-specific paracellular transport, three rats were 
prepared as described for the closed-loop model. They were injected with 9 µCi of 
[14C]-inulin via the carotid artery. At 90 min post-administration, the intestinal 
content was collected from duodenum, jejunum, and ileum, and radioactivity was 
measured in a beta scintillation counter (Kontron Beta V, Montigny Le 
Bretonneux, France). 
 
Trial 2: determination of ivermectin total (plasma) clearance 
Forty-two rats were used to evaluate ivermectin total clearance. Rapid 
anaesthesia was achieved by i.p. injection of 87 mg/kg b.wt. xylazine and 13 mg/kg 
b.wt. ketamine. The left carotid artery was cannulated, and ivermectin was injected 
via the catheter at the dose of 200 µg/kg b.wt. The rats began to recover 30 min 
after the beginning of anaesthesia. At 2, 5, 15, 30, 60, 90 min, 4, 8, 24 h, and 2, 3, 
4, 5, 7, 9, 12, 15, 18 days post-administration, two to three rats were taken for 
terminal blood sampling performed by cardiac puncture under anaesthesia 
(xylazine and ketamine, i.p.).  
 
Analytical assay 
Ivermectin was analysed using a high-performance liquid chromatography 
method with automated solid phase extraction and fluorescence detection, as 
previously described by Alvinerie et al. (1987). Minor modifications were made to 
fit analysis of low plasma and bile volumes (extraction of 100 µL of plasma or 
bile). 
The intestinal samples were sonicated twice for 20 min. After 2 min of 
centrifugation at 2000 g, the clean supernatant was transferred into a first tube, and 
the pellet was resuspended in 3 mL of acetonitrile, sonicated for 20 min, and 
centrifuged (2000 g, 2 min). The resulting clean supernatant was removed into a 
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second tube. Deionised water was added to the tubes to achieve an 
acetonitrile/water 4:5 v/v mixture. Solid phase extraction was then performed as 
described by Alvinerie et al. (1987). 
Ivermectin H2B1a (22,23 dihydroavermectin B1a) was designated as analyt. 
The limit of quantification of the high-performance liquid chromatography method 
was 0.05 ng/mL. Accuracy and precision (intra-assay variation) expressed as 
relative standard deviation were less than 8 and 6%, respectively. 
 
Pharmacokinetic and statistical analysis 
The plasma concentrations were fitted using non-linear regression analysis 
(SYSTAT ® 8.0, SPSS Inc., Chicago, IL). The areas under the mean plasma 
concentration-time curve, AUC (0-tlast) (from 0 to the last quantifiable sample) and 
AUC (0-90) (from 0 to 90 min), were calculated using the trapezoidal rule. 
Ivermectin total clearance was obtained by dividing the administered dose (200 
µg/kg) by AUC (0-tlast). Biliary and intestinal clearances were computed as the 
ratio of the total amount of drug (H2B1a) eliminated within 90 min into bile and in 
the small intestinal lumen, respectively, divided by the corresponding plasma AUC 
(0-90) obtained in Trial 1. The mean residence time (MRT), the plasma terminal 
half-life (t1/2λz), and the steady-state volume of distribution (Vss) were calculated 
according to the classical pharmacokinetic equations associated with non-
compartmental analysis (Gibaldi and Perrier, 1982). 
The results were expressed as means ± SD. Analysis of variance was used to 
test the significance of differences between the three intestinal segments and the 
three dose levels (SYSTAT ® 8.0). Post hoc comparisons were performed using the 
Bonferroni test. A t test was done to compare verapamil-treated and non-treated 
rats A p < 0.05 was regarded as significant. 
 
Results 
 
Validation of the study model 
Less than 0.1% of the administered radioactivity was detected in any of the 
intestinal segments of rats receiving labelled inulin, indicating that the integrity of 
intestinal epithelium was preserved under the described experimental conditions. 
 
Pilot experiments (open-perfusion model) 
The perfusion of the 20-cm jejunal segment with saline resulted in low basal 
concentrations of parent ivermectin in most perfusate samples. However, very high 
concentrations of parent ivermectin were observed in intestinal effluents each time 
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some intestinal mucous had leaked accidentally via the distal catheter into the 
sample. These results indicate that ivermectin was largely associated with mucous. 
Following systemic administration of 200 and 400 µg/kg ivermectin, 111 and 163 
ng ivermectin were eliminated unchanged from the 20-cm loop, respectively. 
About 65 and 74% of these amounts were obtained from perfusate samples, and 35 
and 26% by collection of residual mucous in the lumen of the loop. 
 
Trial 1 (closed-loop model) 
At the end of the 90-min experiments, the contents of the closed intestinal loops 
consisted almost exclusively of mucous containing high amounts of ivermectin as 
parent drug. The total amount of ivermectin recovered in the small intestinal lumen 
exceeded systematically (from 3.2 to 8.8 times) that eliminated in bile over the 
same 90-min period, in the same animal (Table 1). The ratio of intestinal-to-biliary 
elimination did not show any significant difference between the tested doses (Table 
1). The cumulative amount of ivermectin excreted into bile and in the small 
Table 1. Total amounts (ng/kg b.wt.) of ivermectin eliminated into bile and in the small 
intestinal lumen over 90 min post-administration in rat, and biliary and intestinal 
clearances.  
  Dose (µg/kg)  
 100 200 400 
Bile (ng/kg) 
Biliary clearance (mL/day/kg) 
170 ±  71 a    389 ±  111 b 
      55.7 
  667 ±  152 c 
Small intestine (ng/kg) 
Intestinal clearance (mL/day/kg) 
862 ±  368 a  1936 ±  204 b 
          277.2 
3526 ±  669 c 
- Duodenum (ng/kg)  146 ±  34 a   338 ±  124 b   511 ±  161 b 
- Jejunum (ng/kg) 578 ±  318 a 1320 ±  134 b 2239 ±  541 b 
- Ileum (ng/kg) 138 ±  32 a    277 ±  62 b   776 ±  172 c 
Ratio small intestine/bile  5.2 ±  1.5 a    5.4 ±  1.8 a    5.5 ±  2.0 a 
Ivermectin was administered intra-arterially at the doses of 100 (n = 6), 200 (n = 5) and 400 µg/kg 
b.wt. ivermectin (n = 5). The data are presented as means ± SD. Comparisons were performed 
between the dose levels for each parameter. Values followed by the same superscript ( a, b or c ) are not 
statistically different (p > 0.05). 
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intestinal lumen within 90 min following i.a. administration of ivermectin 
accounted for approximately 1% of the administered dose, independently of the 
dose level. The bile flow rate was homogenous among the rats and equal to 0.84 ± 
0.13 mL/h. 
Over the dose range tested, the intestinal elimination of ivermectin was greater 
in the jejunum than in the other intestinal segments (Table 1). However, when 
normalised by the length of the segment, ivermectin elimination was statistically 
higher in the duodenum at the doses of 100 and 200 µg/kg and statistically lower in 
the ileum at the dose of 100 µg/kg, in the same animal (Fig. 1). 
Co-administration of the P-gp inhibitor, verapamil, significantly reduced the 
overall small intestinal elimination of ivermectin by 28% (1397 ± 378 versus 1936 
± 204 ng/kg in controls, p < 0.05) but did not statistically affect ivermectin 
secretion into bile (346 ± 129 versus 389 ± 111 ng/kg in controls). The elimination 
capacity of the jejunum was markedly reduced by 50% in the treated rats compared 
with the controls, whereas no statistical difference could be observed with respect 
to the rate of elimination in the duodenum or in the ileum (Fig. 2). Plasma 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Segmental elimination of ivermectin through the gut wall following intra-arterial 
administration to rats at the doses of 100 (n = 6), 200 (n = 5) and 400 µg/kg b.wt. 
ivermectin (n = 5). The data (mean ± SD) correspond to the elimination capacities of the 
intestinal segments, which were obtained by dividing the total amount of parent drug 
eliminated in duodenum, jejunum, or ileum over 90 min by the length of the corresponding 
segment. * (p < 0.05) and ** (p < 0.01) indicate a significant difference between duodenum 
and jejunum in the same animal, whereas ## (p < 0.01) indicates a significant difference 
between jejunum and ileum. 
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concentrations of ivermectin at 90 min post-administration were not significantly 
different between treated rat (82 ± 9.6 ng/mL) and non-treated rats (71 ± 9.6 
ng/mL). No signs of toxicity were detected in any of the seven rats treated with 
verapamil under our experimental conditions. 
The second group of rats taken for an accurate estimation of AUC (0-90) 
showed plasma levels of ivermectin very similar to those obtained in the rats given 
200 µg/kg ivermectin in the closed-loop study. The AUC (0-90) was equal to 168 
ng.h/mL. Small intestinal and biliary clearances in situ were 0.277 and 0.056 
L/day/kg, respectively. 
 
Trial 2 
The plasma data were best fitted with a triexponential concentration-time curve 
(Fig. 3). The values of AUC (0-tlast) and AUC (0-90) were 2233 ng.h/mL and 355 
ng.h/mL, respectively. The MRT, t1/2 λz and Vss were 1.09 days, 2.51 days and 2.34 
L/kg, respectively. Ivermectin total clearance was found to be equal to 2.15 
L/day/kg. Trial 2 was referred to as an in vivo situation, considering that xylazine 
and ketamine produced a short-duration surgical anaesthesia with moderate side 
effects. 
The difference between the AUCs (0-90) in Trial 2 and that in Trial 1 (twice 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Influence of verapamil on the elimination capacities of the intestinal segments in 
rats given 200 µg/kg b.wt. i.a. ivermectin. The data (mean ± SD) correspond to the total 
amounts of parent drug eliminated in each intestinal segment over 90 min post-
administration in treated (n = 7) and non-treated rats (n = 5), divided by the length of the 
segment. ** (p < 0.01). 
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lower) shows that anaesthesia with urethane and α-chloralose, albeit required by 
the model, most likely influenced the plasma disposition of ivermectin. This was 
taken into account for the assessment of ivermectin total (plasma) clearance in the 
rats used in Trial 1. Assuming the homogeneity of the rats used in Trials 1 and 2, 
the total plasma clearance of ivermectin in Trial 1 (in situ) was estimated from that 
obtained in Trial 2 (in vivo) corrected by the ratio of the AUCs (0-90) e.g. 1.02 
L/day/kg. It results that the small intestinal clearance of ivermectin accounted for 
27% of the corrected total (plasma) clearance versus 5.5% for the biliary clearance. 
 
Discussion 
 
At all three different ivermectin dose rates, the amount of parent ivermectin 
eliminated in the small intestinal lumen was 5 times higher than in bile. Since 
conjugates of parent ivermectin have never been detected in bile, this study clearly 
demonstrates that the major route for the elimination of parent ivermectin in the rat 
intestine is not biliary but intestinal secretion. Such a difference between intestinal 
and biliary elimination has been already observed for other drugs such as 
roxithromycin (Arimori et al., 1998), ciprofloxacin (Dautrey et al., 1999) and 
vinblastine (Van Asperen et al., 2000). 
The open-perfusion model is commonly used to study the intestinal secretion of 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Ivermectin plasma concentration-time profile following intra-arterial 
administration of rats (n = 42) with 200 µg/kg ivermectin. Each point corresponds to one 
rat. 
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drugs, as it enables measurement of an overall intestinal elimination by keeping the 
reabsorption phenomenon negligible (Dautrey et al., 1999). The use of this model 
was, however, not desirable in the present study given the extensive binding of 
ivermectin to intestinal mucous. Indeed, the random leakage of mucous in 
perfusate samples observed in pilot experiments impairs a reliable and reproducible 
quantification of the drug intestinal elimination. Consequently, we used the 
alternative closed-loop model, of which the advantage was to extend the 
investigation from 20-cm loops (open-perfusion model) to the totality of the small 
intestine, allowing thereby a more reliable prediction of the in vivo state. The 
resulting drawback was, however, a possible reabsorption into blood of the 
ivermectin secreted in the intestinal lumen and thus the measurement of the net 
intestinal elimination of drug compared with the overall biliary secretion. It is 
therefore possible that the intestine-to-bile elimination ratio might be slightly 
underestimated. 
On the other hand, it cannot be excluded that the gentle scraping procedure for 
collection of intestinal contents resulted in a slight overestimation of ivermectin 
intestinal elimination. This procedure was necessary to ensure collection of the 
totality of the mucous present in the lumen as it is known to be partly bound to the 
glycocalyx layer of enterocytes. However, this technique implies that some 
intestinal mucosa tissue might be scraped as well. In pilot experiments (open-
perfusion model), up to 74% of the drug eliminated by a 20-cm loop was already 
obtained from perfusate samples and not by scraping. Thus, even if the contribution 
of intestinal mucosa tissue to the total collection of ivermectin cannot be excluded, 
this would not affect the conclusions of the study. The experiments were 
terminated 90 min after ivermectin administration, before a deterioration of animal 
condition and depletion of bile salts could have been able to affect the bile flow, 
and thus the extent of ivermectin elimination in bile.  
Compared with the other intestinal segments, the jejunum provided the major 
source of parent ivermectin regardless of the administered dose. However, the 
intestinal elimination capacity (expressed per unit of intestinal length) appeared to 
decrease gradually from proximal-to-distal small intestine, with maximal values in 
the duodenum. Regional differences could possibly be attributed to differences in 
passive diffusion, expression levels of efflux transporters, or in carrier affinity 
(Makhey et al., 1998), but other factors should be considered as well in the 
interpretation of data such as a different proportion of villi in the intestinal 
segments (Olivier et al., 1998). Data were expressed per unit of intestinal length 
and not of intestinal area, since the loop diameter along the segments was too 
variable to be properly assessed. 
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In duodenum and jejunum, increasing the dose from 200 to 400 µg/kg did not 
result in a significantly higher absolute elimination of ivermectin, which is 
consistent with the involvement of an active (saturable) transport mechanism. As 
the P-gp substrate and inhibitor verapamil significantly inhibited the elimination of 
ivermectin into the jejunum by 50%, the involvement of a P-gp carrier-mediated 
process in the jejunum can be assumed. In contrast, neither the i.a. perfusion of 
verapamil nor a i.a. bolus administration of 5 mg/kg verapamil (data not shown) 
could significantly affect ivermectin elimination in bile, duodenum, or ileum in the 
same animals. It is likely that, at the applied low (non-toxic) dosages, verapamil 
did not completely block the P-gp function. However, these results also suggest 
that other efflux mechanisms might play a significant role in the secretion process. 
This would be in agreement with the observations of Kwei et al. (1999) who 
systemically administered 200 µg/kg b.wt. ivermectin to mdr1a-P-gp-deficient 
mice with a non-cannulated gallbladder and reported only a partial 30% reduction 
(from 3.4 to 2.4% of the administered dose) of the cumulative ivermectin excreted 
in bile plus intestinal contents, compared with wild-type mice. Additional in vitro 
or ex vivo studies should clarify the potential role of P-gp and/or other carriers 
without the drawbacks related to the use of P-gp inhibitors in vivo and highlight the 
differences between intestinal segments. 
Finally, qualitative analysis of chromatograms indicated the ability of the 
intestinal epithelium to excrete ivermectin-derived metabolites (data not shown). 
As for the parent drug, this should be further investigated in vitro. 
Biliary and small intestinal clearances of ivermectin were found to account for 
5.5 and 27% of ivermectin total (plasma) clearance, respectively. Intestinal 
clearance was calculated solely from the small intestine, but other regions of the 
digestive tract may participate as well in the elimination process. Ivermectin 
elimination by distal parts of the digestive tract has never been investigated thus 
far, but colon has been reported to display high levels of P-gp expression (Thiebaut 
et al., 1987) and therefore could provide a significant contribution to the absolute 
intestinal elimination of ivermectin as for other xenobiotics (Mayer et al., 1996; 
Ramon et al., 1996; Makhey et al., 1998; Van Asperen et al., 2000). Besides these 
considerations, our findings suggest an important metabolism of ivermectin in the 
rat. The proportion of metabolites in faecal drug residues has never been 
documented in rat following systemic administration, but is known to represent 
approximately 60 and 70% in cattle and swine, respectively (Halley et al., 1989), 
which would be consistent with our results. 
Our study suggests the existence of an intestinal route of elimination of  
ivermectin in human and target animal species. The observations reported in cattle 
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by Bogan and McKellar (1988) support this hypothesis. Following subcutaneous 
administration, ivermectin was found at rather high concentrations in small 
intestinal mucous with no significant difference between mucous distal and 
proximal to the bile duct opening. Furthermore, ileal fluid showed three times 
higher concentrations of ivermectin than in intestinal fluids sampled proximal to 
the bile duct. In contrast, following systemic administration with the structural 
analogue doramectin to sheep, Hennessy et al. (2000) recovered 130% of the 
administered dose in bile. This would imply that bile was the major elimination 
pathway, which is difficult to conciliate with our results apart from interspecies 
differences. 
The characterisation of an intestinal elimination pathway in human and target 
animal species would be of therapeutic significance. Not all parasites feed on 
plasma, and the compartmental distribution of drugs out of the plasma in secondary 
compartments (bile, intestinal secretions) needs to be taken into consideration to 
discuss and optimise the efficacy of antiparasitic drugs. It has been suggested that 
ivermectin could be available to parasites in intestinal mucous (Bogan and 
McKellar, 1988). Consequently, an extensive elimination of ivermectin along the 
digestive tract following systemic absorption or parenteral administration would 
provide high concentrations of drug at the site of action. It is also possible that the 
mucous functions as a reservoir for exchange of drug into intestinal fluid.  
Besides clinical considerations, it is noteworthy that a large part of the 
ivermectin excreted in cattle dung (38% of the dose after systemic administration; 
Laffont et al., 2001) may arise from intestinal secretion. The presence of parent 
(active) ivermectin in faeces can have deleterious effects on non-target organisms 
such as some dung-degrading and dung-breeding insects (Wall and Strong, 1987; 
Sommer et al., 1993). Although the issue of environmental impact of ivermectin 
used in large scale in cattle is still under debate, our study provides new directions 
into the pharmacokinetic behaviour of endectocides to reduce the faecal excretion 
of parent drug. The therapeutically desirable intestinal secretion should be then 
evaluated against the undesirable exposure of the environment with faeces 
containing ivermectin.  
In conclusion, we have provided evidence that the major route for the 
elimination of parent ivermectin in the rat intestine is not biliary but intestinal 
secretion, which enforces the role of the intestines in the elimination of 
xenobiotics. In vitro studies are now underway to clarify the mechanisms involved 
in ivermectin intestinal elimination. A better understanding of these mechanisms is 
of interest for the further development of endectocides to optimise their safety and 
efficacy. 
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Abstract 
 
Peripheral blood lymphocytes (PBL) were used to evaluate the expression of 
functional P-gp in cattle, sheep, goat, horse, pig and rat. Flow cytometric analysis 
of rhodamine-123 (Rh-123) dye efflux and its inhibition by prototypic P-gp 
inhibitors were used to quantify P-gp activity. Human PBL were included in the 
study as a reference. The efflux of Rh-123 could be demonstrated in lymphocytes 
from all species, but considerable interspecies and interindividual variations were 
observed. The average efflux of Rh-123 over 2.5 h at 37°C was 78 ± 18.1% for 
goats, 55 ± 11.2% for cattle, 49 ± 12.0% for sheep, 38 ± 6.8% for pigs, 30 ± 3.9% 
for horses and 17 ±11.7% for rats vs 55 ± 4.0% for men. Verapamil (40 µM), 
cyclosporin A (20 µM) and ivermectin (1 µM) clearly (p < 0.001) inhibited the 
efflux of Rh-123 in PBL of goats, cattle, sheep, pigs and men. These inhibitors had 
an overall significant effect (p<0.05) on Rh-123 efflux in PBL from rats and 
horses, but the inhibition was not obvious in all animals tested. In human PBL, 
similar inhibition of Rh-123 efflux by P-gp modulators and the human-specific P-
gp antibody MRK-16 suggests that this inhibition reflects P-gp activity. Using the 
monoclonal antibody C219, Western-blots confirmed the expression of P-gp in 
PBL from goats, sheep, cattle and pigs but not from rats and horses, and in 
intestinal tissue (jejunum) of all animal species. In conclusion, this study 
demonstrates the expression of functional P-gps in lymphocytes of all animal 
species studied. However, the large interindividual variations in P-gp activity 
suggest that additional wide-scale studies are performed. This PBL-based model 
offers new perspectives to study the P-gp function in the different animal species at 
a population level. 
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Introduction 
 
The drug transporting P-glycoproteins (P-gps) are now recognised as major 
determinants of disposition for numerous pharmacologic agents (Tanigawara, 
2000; Matheny et al., 2001; Borst and Elferink, 2002). P-gp is an efflux trasnporter 
localised in the plasma membrane, which uses ATP to extrude a broad range of 
structurally and functionally unrelated substances from the cell (Borst and Elferink, 
2002). Among the P-gp substrates are antibiotics (erythromycin, fluoroquinolones), 
antiparasitic drugs (ivermectin and probably moxidectin), steroids (cortisol, 
dexamethasone), anti-diarrheal agents (loperamide), immunosuppressive agents 
(cyclosporin A) and anticancer drugs (Vinca alkaloids, epipodophyllotoxines, 
taxanes, anthracyclines) (Matheny et al., 2001; Borst and Eferink, 2002; Lifschitz 
et al., 2002). P-gp was originally identified in mammalian tumour cells as 
overexpressed proteins conferring multidrug resistance (Juliano and Ling, 1976). It 
has been shown to be also expressed in various normal tissues, including the liver, 
the kidneys, the intestines, the blood-brain and blood-testis barriers, and the 
placenta (Thiebaut et al., 1987; Cordon-Cardo et al., 1989). It has become clear that 
P-gp plays an important role in the protection of the body against the potentially 
toxic compounds arising from the environment. P-gp limits the uptake of drugs and 
xenotoxins from the gastrointestinal tract, protects critical organs such as the brain 
and the fœtus against an undesirable drug exposure, and enhances drug elimination 
by biliary, renal or intestinal secretion (Tanigawara, 2000; Matheny et al., 2001; 
Borst and Elferink, 2002). 
P-gp is encoded by the two genes in humans (MDR1 and MDR3) and three 
genes in rodents (mdr1a, mdr1b and mdr2), but only the human MDR1 P-gp and 
the murine mdr1a and mdr1b isoforms appear to be involved in drug transport 
(Borst and Elferink, 2002). Five P-gp genes have been identified in pigs, four of 
which show similarity with the MDR1, mdr1a and mdr1b homologues (Childs and 
Ling, 1996). Recently, the first ruminant P-gp gene was cloned and sequenced 
from sheep (Longley et al., 1999). In cattle, the presence of three P-gp genes is 
expected based on genomic DNA analysis (Childs and Ling, 1996). However, 
although the physiological role of P-gp has been extensively documented in 
humans and laboratory animals, little information is available about the P-gp 
function in other animal species. In pigs and cattle, expression of functional P-gps 
has been shown in freshly isolated brain capillaries or primary cultures of brain 
capillary endothelial cells (Fontaine et al., 1996; Miller et al., 2000; Nobmann et 
al., 2001). In contrast, none or very low P-gp activity was detected in the porcine 
kidney proximal tubule cell line (LLC-PK1) (Schinkel et al., 1995). It is difficult 
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though to appreciate the extent of the P-gp function in vivo from immortalised cell 
lines or primary cells, since protein expression is often modified during cell 
culture, varying from total loss of expression to overexpression. 
The purpose of this study was to measure the P-gp function directly in the 
animals. Peripheral blood lymphocytes have been shown to express functional P-
gps in humans (Drach et al., 1992; Klimecki et al., 1994; Ludescher et al., 1998) 
and are widely used to study and monitor the evolution of multidrug resistance in 
leukaemic patients. Therefore, we isolated peripheral blood lymphocytes from 
various animal species (cattle, sheep, goat, pig, horse and rat) and evaluated the P-
gp function by flow cytometric analysis. The fluorescent dye Rhodamine (Rh-123) 
has been extensively used to measure P-gp activity in human lymphocytes (Beck et 
al., 1996; Canitrot et al., 1996; Huet et al., 1998; Broxterman, 1999; Parasrampuria 
et al., 2001). In the present study, this activity was evaluated upon the extent of Rh-
123 efflux from the cells and the ability of P-gp blockers to reduce dye efflux. 
Verapamil, cyclosporin A and ivermectin were selected as efficient modulators of 
the P-gp function (Ford and Hait, 1990; Pouliot et al., 1997; Eneroth et al., 2001). 
Furthermore, expression of P-gp was examined by Western-blot analysis in 
lymphocytes and intestinal tissue (jejunum) of all animal species studied. 
 
Materials and Methods 
 
Materials 
Rhodamine 123 (Rh-123), verapamil hydrochloride, cyclosporin A, ivermectin 
and propidium iodide were purchased from Sigma Chemical Co. (St. Louis, MO, 
USA). Cell culture media and reagents were from Gibco BRL (Breda, the 
Netherlands). Ficoll Hypaque (Ficoll Paque®) was purchased from Pharmacia 
Biotech (Uppsala, Sweden). Monoclonal P-gp antibodies, MRK-16 and C219, were 
obtained from Kamiya Biomedical Co. (Seattle, WA, USA) and Fujirebio 
Diagnostics, Inc. (Malvern, PA, USA), respectively. Biotinylated goat anti-mouse 
IgG and streptavidin-AP conjugate were from Zymed (CA, USA) and Boehringer 
(Mannheim, Germany), respectively. All other chemicals used were of the highest 
grade available. Stock solutions of Rh-123 (40 mM), verapamil (40 mM), 
cyclosporin A (20 mM) and ivermectin (10 mM) were prepared in dimethyl 
sulfoxide (DMSO) and stored at -20°C until analysis. 
 
Animals 
All the investigations were performed in accordance with the ethical rules for 
animal experimentation. 
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Blood samples were taken from healthy animals belonging to the Veterinary 
Faculty of Utrecht University. A total of 7 to 10 animals per species were used for 
functional studies: 7 pigs (3 boars 120-250 kg; 4 young castrated pigs, 30-40 kg), 7 
cows (350-550 kg), 10 ewes (40-50 kg), 10 female goats (30-35 kg), 7 horses (3 
mares, 500-550 kg; 2 stallions, 450 and 490 kg, 2 castrated males, 540 and 560 kg), 
7 rats (Wistar males, 300-450 g). Four healthy human volunteers (men, 30-40 years 
old) registered as blood donors at the Academic Hospital Utrecht (UMC) were 
included in the studies after obtaining informed consent. In the case of rats, blood 
was collected by terminal cardiac puncture following anaesthesia with a 
pentobarbital solution containing heparin, and intestinal tissue (jejunum) was 
collected for Western-blot analysis. For other species, intestinal tissues were taken 
from animals of various origin at public slaughter houses. 
 
Isolation of peripheral blood mononuclear cells 
Peripheral blood (20-25 mL in all species except rat: 8-10 mL) was obtained 
from each individual and collected into heparinised tubes. Peripheral blood 
mononuclear cells were isolated on a Ficoll density gradient by centrifugation for 
20 min at 2,000 rpm at room temperature (no brake). Interphase cells were 
collected, washed twice, and resuspended in phenol red-free RPMI-1640 medium 
buffered with 20 mmol/L HEPES, pH 7.4, and supplemented with 10% fetal calf 
serum (FCS). Samples were analysed for the P-gp function on the same day within 
2 to 3 hours. Cells were maintained at 37°C in a 5% CO2 humidified atmosphere 
until the beginning of transport studies. 
 
Measurement of Rh-123 efflux 
This functional assay measures the ability of cells to extrude the fluorescent dye 
Rh-123 and determines whether or not this efflux, if any, is blocked by P-gp 
inhibitors. After centrifugation, peripheral blood mononuclear cells (approximately 
5.0 x 106 cells/mL) were stained with 4 µM of Rh-123 for 30 min at 37°C in 
serum-free RPMI-1640 medium (without phenol red). The cells were washed with 
ice-cold phosphate-buffered saline (PBS) and resuspended in ice-cold, dye-free, 
serum-free RPMI 1640 in the presence or absence of P-gp inhibitors to allow Rh-
123 efflux. Final concentrations for the inhibitors were 20 µM for cyclosporin A, 
40 µM for verapamil and 1 µM for ivermectin. These concentrations were selected 
from previous published studies (cyclosporin A and verapamil; Wang et al., 2000; 
Parasrampuria et al., 2001) or following preliminary titration studies (ivermectin, 
data not shown). The final concentration of DMSO in the samples was adjusted at 
0.1%. Cells were incubated for 2.5 h at 37°C, protected from light by aluminium 
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foil, and cell-associated Rh-123 fluorescence was measured by flow cytometry 
(FACScan, Becton Dickinson, Heidelberg, Germany) at time 0 and every 30 min 
thereafter up to 2.5 h. Dead cells were excluded based on propidium iodide uptake. 
Fluorescence channel-1 (530 nm) was used for evaluating Rh-123-associated 
cellular fluorescence, fluorescence channel-3 (610 nm) for propidium iodide signal. 
The samples were gated on forward scatter vs size scatter to allow selection of the 
lymphocyte population and exclude clumps and debris. After gating the propidium 
iodide-negative population of cells, it was possible to measure the intracellular 
fluorescence of Rh-123 only in living lymphocytes. At least 5000 suitable events 
per sample were collected. Data acquisition was performed using the computer 
program CELLQUEST. Cells that had not been exposed to Rh-123 were used as a 
negative control. The percentage of efflux of Rh-123 was calculated as follows: 
 
Efflux (t) (%) = 100 × [mFI0– mFI(t)] / mFI0 Eq. 1 
 
where mFI(t) and mFI0 are the median fluorescence intensity of Rh-123 at time t 
and time 0, respectively. The percentage of Rh-123 efflux in the presence and 
absence of inhibitors was plotted as a function of time between 0 and 2.5 h, and the 
corresponding areas under the curve  (AUC Inhibitor and AUC Control, respectively) 
were calculated. Percentages of inhibition were determined for each individual, 
using the following equation: 
 
Inhibition (%) = 100 × (1 - AUC Inhibitor / AUC Control ) Eq. 2 
 
Human peripheral blood lymphocytes were used as a positive control. Efflux 
studies were performed as described above using the peripheral blood mononuclear 
cells obtained from 4 healthy volunteers. The monoclonal P-gp antibody MRK-16 
was used to evaluate the efficacy of verapamil, cyclosporin A and ivermectin in the 
blockade of P-gp at the applied concentrations. MRK-16 recognises a human-
specific epitope of the extracellular domain of P-gp, and its binding blocks the P-gp 
function. To ensure that the antibody had correctly bound to P-gp, the decrease in 
Rh-123 cellular fluorescence was analysed 30 min after resuspending the stained 
cells in dye-free medium. AUC Inhibitor and AUC Control were thus calculated from t = 
30 min to t = 2.5 h. 
 
Immunoblot analysis of P-gp expression in lymphocytes and intestinal tissues 
Lymphocytes were isolated from blood following lysis of erythrocytes. 
Polynuclear cells and monocytes were excluded from the cell suspension by 
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adhesion to plastics following serial incubation in tissue culture flasks. This 
isolation procedure was preferred above the Ficoll gradient method, albeit more 
appropriate for functional studies, as the latter does allow complete removal of 
erythrocytes. Briefly, 40 mL of ice-cold lysis buffer [155 mM NH4Cl, 10 mM 
NaHCO3, 0.1 mM Na2EDTA (pH 7.4)] were added to 10-15 mL of chilled blood. 
After 10 min of incubation and gentle mixing on ice, samples were centrifuged 
(600 g, 5 min, 4°C). Cells were resuspended in 5 mL of ice-cold lysis buffer and 
were incubated on ice for another 10 min. After adding 45 mL of ice-cold PBS, 
cells were collected by centrifugation (267 g, 5 min, 4°C). After two washing steps 
at 4°C with RPMI 1640 containing 10% FCS (centrifugation at 167 g, 10 min, 
4°C), cells were resuspended in 10 mL of RPMI 1640 containing 10% FCS. Serial 
incubations (1 h) in two tissue culture flasks allowed removal of polynuclear cells 
and monocytes, which had attached to the plastics. The remaining lymphocyte 
suspension was collected, counted, and washed with PBS. After the last 
centrifugation step, the pellet was resuspended in 100-150 µL of RIPA-buffer and 
was stored at –20°C until use. Brush-border-enriched proteins were prepared from 
intestinal tissues accordingly to a previously described method (Pinto et al., 1983). 
The human colon adenocarcinoma cell line Caco-2 was used as a positive control 
for P-gp expression. Caco-2 cells (purchased from the ATCC, passage 90) were 
routinely cultured in supplemented Dulbecco’s modified Eagle's medium and 
maintained at 37°C in a humidified 5% CO2 atmosphere. The cells were grown in 
tissue culture flasks for 19 days, replacing medium three times per week, after 
which they were scraped in PBS, washed, and lysed in RIPA buffer. Samples were 
stored at –20°C until use. 
Protein concentrations were determined using the Pierce BCA protein assay 
reagent (Pierce, Rockford, IL, USA), using bovine serum albumin (BSA) as a 
standard. Forty µg of protein of each sample were loaded in each lane and 
electrophoresed on SDS-polyacrylamide gels (4% stacking and 8% running gel) in 
a Mini-Protean III Cell (Biorad, Veenendaal, The Netherlands), as described by 
Laemmli (1970). Four µg of proteins from intact Caco-2 cells or brush-border-
enriched preparations of Caco-2 cells were also loaded. Electroblotting was 
performed onto a polyvinylidene difluoride membrane according to the method of 
Towbin et al. (1979). The transfer membrane was then washed and incubated 
overnight at 4°C with the P-gp monoclonal antibody C219 used in a dilution of 
1:200 in TBS (Tris-buffered saline) containing 0.3% (v/v) Tween 20 and 1% (w/v) 
BSA to prevent aspecific binding of the antibody. Biotinylated goat anti-mouse 
IgG and streptavidin-AP conjugate were used for detection of the primary 
antibody. 
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Statistical analysis 
All results are presented as means ± SD. Statistical analysis was carried out by 
using a one-way ANOVA to compare the efflux of Rh-123 (without inhibitor) 
between species, and a two-way ANOVA (treatment, individual) to assess the 
effect of treatment by P-gp inhibitors in a given species. Multiple comparisons 
were performed using the Bonferroni test. A p < 0.05 was regarded as significant. 
 
Results 
 
Functional studies with Rh-123 
The results of Rh-123 efflux studies in the different species are summarised in 
Fig. 1 (Fig. 2A for men) and Table 1. Lymphocytes of all species effluxed the 
fluorescent dye Rh-123 over 2.5 h, however wide interspecies variations could be 
observed. It is noteworthy that in all species, the efflux of Rh-123 was particularly 
important over the first 30 min of incubation. This is probably due to a high passive 
diffusion of the dye resulting from a high concentration gradient between 
intracellular and extracellular compartments. 
The species could be classified into three groups depending on a low, medium 
and high Rh-123 efflux. The highest decrease in Rh-123 intracellular levels was 
obtained in goat lymphocytes (78 ± 18.1 % after 2.5 h), with a complete efflux of 
the dye in three of the ten animals (93-97%). A rather high but significantly lower 
efflux of Rh-123 was observed in lymphocytes from horses, pigs, sheep, cattle and 
men (30 ± 3.9 %, 38 ± 6.8%, 49 ± 12.0%, 55 ± 11.2% and 55 ± 4.0% after 2.5 h, 
respectively). In contrast, lymphocytes from rats showed a poor efflux of Rh-123 
of 17 ± 11.7% after 2.5 h. This efflux was significantly lower than for other animal 
species except horse. However, wide interindividual variations could be observed 
among rats: in 4 rats, lymphocytes effluxed 16 - 39% of the dye, while in the 3 
other rats, lymphocytes retained almost completely Rh-123 (4 - 10% of efflux).  
Figure 1 (next page). Time-dependent efflux of Rh-123 by peripheral blood lymphocytes
of a) rats (n = 7), b) horses (n = 7), c) pigs (n = 7), d) sheep (n = 10), e) cattle (n = 7), and
f) goats (n = 10). After staining with 4 µM Rh-123 at 37°C for 30 min, freshly isolated
lymphocytes were resuspended in dye-free medium in the absence ( ) or presence of the
P-gp inhibitors verapamil (40 µM; )), cyclosporin A (20 µM, h) and ivermectin (1 µM,
"). Efflux of Rh-123 was measured over 2.5 h of incubation at 37°C. Data are presented as
means ± SD.  
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 To determine whether P-gp was responsible for the efflux of Rh-123, stained 
lymphocytes were incubated in the presence of the P-gp modulators verapamil 
(40µM), cyclosporin (20 µM) and ivermectin (1 µM). P-gp modulators had an 
overall significant effect on Rh-123 efflux in all species (albeit at the limit of 
significance in rats). A clear inhibition (p < 0.001) of dye efflux was observed in 
lymphocytes of goats (approximately 65%), cattle (40%), sheep (36%), pigs (32%) 
and men (53%) (Figs. 1 and 2A; Table 1). The inhibition of Rh-123 efflux was also 
statistically significant in lymphocytes of rats and horses (p < 0.05), but was 
obvious in only 4 of the 7 horses (2 males and 2 mares) and 3 of the 7 rats. On the 
basis of these considerations, we concluded to only low levels of P-gp activity in 
lymphocytes of rats and horses. 
Verapamil (40 µM), cyclosporin A (20 µM) and ivermectin (1 µM) inhibited 
Rh-123 efflux to a similar extent. Indeed, no statistical difference in inhibition 
could be observed between the different modulators, irrespective of the species. 
One exception, however, was found in rats for cyclosporin A, which resulted in a 
higher dye efflux than for control lymphocytes. As the use of propidium iodide 
Table 1. Efflux of the fluorescent dye Rh-123 by peripheral blood lymphocytes of goats 
(n=10), cattle (n=7), sheep (n=10), pigs (n=7), horses (n=7) and rats (n=7). Men (n=4) 
were included in the study as a reference. 
Species Efflux of Rh-123  Range  Inhibition (%) 
 after 2.5 h (%) (%) Verapamil Cyclosporin A Ivermectin 
Goat   78 ± 18.1 46 – 97   66 ± 11.8 64 ± 9.7  66 ± 9.7 
Man 55 ± 4.0 50 – 58 52 ± 9.7 52 ± 7.7  54 ± 6.9 
Cattle   55 ± 11.2 35 – 68   39 ± 10.2   42 ± 12.3   38 ± 10.3 
Sheep   49 ± 12.0 33 – 72   31 ± 12.2   39 ± 11.4   38 ± 10.6 
Pig 38 ± 6.8 31 – 48   32 ± 14.8   29 ± 16.8   34 ± 15.2 
Horse 30 ± 3.9 22 – 34   23 ± 13.7   19 ± 12.4   23 ± 14.4 
Rat 17 ±11.7  4 – 39   50 ± 14.8 —   41 ± 31.3 
After staining with 4 µM Rh-123 at 37°C, freshly isolated lymphocytes were resuspended in dye-free 
medium in the absence or presence of the P-gp inhibitors verapamil (40 µM), cyclosporin A (20 µM) 
and ivermectin (1 µM) to allow dye efflux. Efflux of Rh-123 was measured over 2.5 h of incubation 
at 37°C. Data are presented as means ± SD. 
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supports the integrity of the plasma membrane, no convincing explanation of this 
leakage has been found and the corresponding data were not included in the 
analysis. 
The relevance of the inhibition of Rh-123 efflux by the three P-gp modulators 
was examined in human lymphocytes, by using the human-specific monoclonal 
antibody MRK-16, which blocks the P-gp function. To ensure that the antibody had 
correctly bound to P-gp, the analysis of Rh-123 efflux was performed not 
immediately after resuspending stained cells in dye-free medium but after 30 min 
of incubation. The resulting profiles of inhibition are presented in Fig. 2B. They 
show no significant difference in the decrease of Rh-123 intracellular fluorescence 
between samples treated with MRK-16, verapamil, cyclosporin A and ivermectin. 
Wide interindividual variations were generally observed within a given species 
(see the range of Rh-123 efflux in Table 1). These were particularly obvious in 
goats, cattle, sheep, pigs and rats, in which the efflux of Rh-123 could vary by a 
factor 2 among individuals (a factor 10 in rats). In pigs, a striking and significant 
difference in P-gp activity was observed between young castrated animals (30-35 
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Figure 2. Efflux of Rh-123 by human peripheral blood lymphocytes (4 healthy volunteers).
A) Rh-123 efflux in the absence ( ) or presence of the P-gp inhibitors verapamil (40 µM;
)), cyclosporin A (20 µM, h) and ivermectin (1 µM, ") after staining with 4 µM Rh-
123.  B) Comparison of the inhibition of Rh-123 efflux by the human-specific monoclonal
antibody against P-gp MRK-16 (f), verapamil (40 µM; )), cyclosporin A (20 µM, h)
and ivermectin (1 µM, ") in human lymphocytes. Data are presented as means ± SD. 
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kg) and older boars (200-300 kg) under our experimental conditions (Fig. 3). The 
boars (n=3) showed a higher efflux of Rh-123 (45 ± 5.0% vs 34 ± 2.1% for the 
young castrated pigs; p < 0.05), which was also more sensitive to P-gp inhibitors 
(46% vs 23% of inhibition, respectively; p < 0.05). 
The histograms obtained by flow cytometric analysis for a representative animal 
of each species are presented in Fig. 4. At t = 0, lymphocytes that have 
incorporated Rh-123 appear as a single sharp peak. After incubation at 37°C for 2.5 
h in the absence of inhibitors (control samples), these cells appear as a much 
broader peak, indicating an heterogeneous distribution of Rh-123 fluorescence in 
the cell population. These results suggest a differential efflux of Rh-123 in subsets 
of lymphocytes due to a different P-gp activity.  
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Figure 3. Comparison of Rh-123 efflux by lymphocytes derived from 4 young castrated 
pigs (A) and 3 older boars (B). After staining with 4 µM Rh-123 at 37°C, freshly isolated 
lymphocytes were resuspended in dye-free medium in the absence () or presence of the P-
gp inhibitors verapamil (40 µM; )), cyclosporin A (20 µM, h) and ivermectin (1 µM, 
"). Efflux of Rh-123 was measured over 2.5 h of incubation at 37°C. Data are presented as 
means ± SD. 
Figure 4 (next page). Representative sample histograms obtained after flow cytometric 
analysis of Rh-123 retention in lymphocytes of a) goats, b) men, c) cattle, d) sheep, e) pigs, 
f) horses and g) rats. X axis: cellular-associated fluorescence intensity of Rh-123 
(logarithmic scale). Y axis: counted events (arithmetic scale).  
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At t = 0, lymphocytes that had incorporated 
Rh-123 appeared as a single sharp peak 
(normal-width line). After incubation at 
37°C for 2.5 h in the absence of inhibitors 
(control samples), these cells appeared as a 
much broader peak (grey filled area) in 
goats, men, cattle, sheep and pigs. The 
lymphocytes which retained Rh-123 had 
high fluorescence intensity, and those 
which effluxed Rh-123 had lower 
fluorescence intensity. In the presence of 
inhibitors, the peak of Rh-123 stayed 
relatively sharp (tick line).
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Figure 5. Western-blot analysis of P-gp expression in peripheral blood lymphocytes from 
goats using the monoclonal antibody C219. Four individual animals are represented. 
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Figure 6. Western-blot analysis of P-gp expression in small intestinal tissue (jejunum) from 
A) horses, B) pigs, C) goats, D) sheep, E) rats, and F) cattle, using the monoclonal 
antibody C219. Four individual animals are represented for each species. 
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P-gp expression by Western-blot analysis 
The expression of P-gp in lymphocytes and intestinal tissue (jejunum) was 
examined using the C219 human monoclonal antibody to P-gp. Western-blot 
analysis clearly demonstrated the expression of P-gp in goat lymphocytes (Fig. 5). 
P-gp expression could also be detected in lymphocytes from sheep, cattle and pigs, 
but the 170-kDa band obtained was weaker than for goats (data not shown). In 
contrast, no P-gp expression could be detected in lymphocytes from horses and rats 
(data not shown). In intestinal tissues of goats, pigs, sheep and horses, C219 
interacted with a band of protein of approximately 170 kDa molecular weight (Fig. 
6). In intestinal tissues of rats and cattle, however, C219 interacted with a band of 
protein of 90-110 kDa molecular weight (Fig. 6). No aspecific binding was found.  
 
Discussion 
 
The purpose of the study was to assess the expression of functional P-gps in 
freshly isolated peripheral blood lymphocytes from cattle, sheep, goats, horses, 
pigs and rats. The mitochondria-binding fluorescent dye Rh-123 was shown to be a 
reliable marker of the P-gp function in human lymphocytes, on the basis of both 
the efflux of Rh-123 and its inhibition by P-gp modulators (Beck et al., 1996; 
Broxterman, 1999). According to these criteria, three groups of species with high, 
medium or low P-gp activity could be identified. Goat lymphocytes clearly showed 
higher P-gp activity than other species, with an average efflux of Rh-123 of 78% 
after 2.5 h of incubation at 37°C. Under the same experimental conditions, 
lymphocytes from pigs, sheep, cattle and men displayed a lower but marked efflux 
of Rh-123 of 38-55%. In all these species, P-gp activity was confirmed by clear 
inhibition of Rh-123 efflux by the P-gp modulators verapamil, cyclosporin A, and 
ivermectin from 32% to 65%. A less obvious but still significant P-gp activity 
could be detected in lymphocytes from horses and rats. Approximately 30% of the 
intracellular Rh-123 was effluxed by horse lymphocytes after 2.5 h of incubation at 
37°C vs 17.7% for rat lymphocytes. However, although P-gp modulators had an 
overall significant effect in reducing dye efflux in these species, the inhibition of 
Rh-123 efflux was observed only in 4 of the 7 horses and 3 of the 7 rats. It must be 
stressed that the low activity of P-gp in rat and horse lymphocytes was detected 
because AUCs from t = 0 to t = 2.5 h were measured. By comparison, Schluesener 
et al. (1992) did not find any significant efflux of Rh-123 in rat lymphocytes but 
used a single time point for the measurement of dye efflux. 
Measurement of Rh-123 efflux was preferred to dye accumulation studies, 
which are more convenient but theoretically less sensitive (Canitrot et al., 1996; 
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Huet et al., 1998). Even though, our functional assay may not be sensitive enough 
to detect very low levels of P-gp activity, which may be a problem in rats. Rh-123 
has been shown to be one of the most specific and sensitive dyes for evaluation of 
P-gp function (Broxterman, 1999). However, it was unable to allow detection of P-
gp activity in some tumour cell lines expressing low P-gp levels (Canitrot et al., 
1996). Another factor limiting the sensitivity of the method may be a 
heterogeneous efflux of Rh-123 by the overall population of lymphocytes. This 
was observed on sample histograms from men, goats, cattle, sheep and pigs 
obtained after incubation of stained lymphocytes in dye-free medium without 
inhibitors. Previous reports have indicated a differential expression of P-gp in 
subsets of human lymphocytes (Drach et al., 1992; Klimecki et al., 1994; 
Ludescher et al., 1998). These results suggest that this is also probably the case in 
the studied animal species. 
Verapamil and cyclosporin A are widely used as P-gp inhibitors in transport 
studies. However, the resulting inhibition of R-123 efflux may not reflect the 
overall P-gp activity. In the present study, no statistical difference in inhibition was 
observed between verapamil, cyclosporin A and ivermectin at the applied 
concentrations. Furthermore, in human lymphocytes, the monoclonal P-gp 
antibody MRK-16 blocked Rh-123 efflux to a similar extent than the three P-gp 
modulators, suggesting that this inhibition was representative for the P-gp function. 
To ensure that the antibody had correctly bound to P-gp, the comparison in the 
decrease of Rh-123 cellular fluorescence was done 30 min after resuspending the 
stained lymphocytes in dye-free medium. Calculation of AUCs from t = 30 min to t 
= 2.5 h gave a percentage of inhibition of approximately 78% for ivermectin, 
cyclosporin A and verapamil in human lymphocytes. This percentage of inhibition 
is higher than that obtained by calculation of AUCs from t = 0 to t = 2.5 h (53%). 
One explanation for this may be that the applied inhibitors did not immediately 
block the P-gp pumps at t = 0. It is also possible that the actual contribution of P-gp 
in dye efflux was initially lower due to a higher passive diffusion of Rh-123 and/or 
the saturation of P-gp at the initially high intracellular Rh-123 concentrations. The 
analysis of Rh-123 efflux from t = 30 min to t = 2.5 h gave higher percentages of 
inhibition in all animal species (82% inhibition in goats, 52% in cattle, 51% in 
sheep, 48% in pigs and 33% in horses) but did not change the conclusions of the 
comparative study. 
In all cases, neither the human specific antibody MRK-16 nor the P-gp 
modulators were able to block Rh-123 efflux completely. The efflux of Rh-123 is 
the result of both active transport mechanisms and passive diffusion, but the 
involvement of transporters other than P-gp cannot be excluded. Rh-123 has been 
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suggested to be a relatively specific substrate for P-gp but not MRP (multidrug 
resistance-associated proteins) in multidrug resistant tumour cells (Feller et al., 
1995) and human lymphocytes (Parasrampuria et al., 2001). This remains to be 
documented in lymphocytes for the present animal species. 
P-gp expression in lymphocytes and small intestinal tissue (jejunum) was 
assessed using the human monoclonal antibody C219. This antibody recognises a 
highly conserved amino acid sequence (Georges et al., 1990) found in all P-gp 
isoforms characterised to date, and has been successively used for detection of P-
gp expression in tissues or cell lines derived from rat, cattle and pig (Schinkel et 
al., 1994; Fontaine et al., 1996; Nobmann et al., 2001). However, possible 
differences in C219 affinity for P-gp across animal species hamper any quantitative 
interspecies comparison, which explains the interest of functional studies for 
quantitative investigations. Furthermore, as the specificity of C219 for P-gp is 
certainly lower in animal species than in man, aspecific binding may be a problem. 
For this reason, Western-blot analysis appeared as the most appropriate technique 
for detection of P-gp expression (expected molecular weight of approximately 170 
kDa). Finally, although an amplified detection system was used for detection of the 
primary antibody, it is noteworthy that a lack of detection by the C219 antibody 
does not exclude P-gp expression, as this may be due to a very low binding affinity 
of the antibody for the protein. In the present study, the results of Western-blot 
analysis correlate well with those of the functional studies. P-gp was clearly 
expressed in peripheral blood lymphocytes from goats and could be detected in 
lymphocytes from cattle, pigs and sheep at the level of the positive control (Caco-2 
cells, 170 kDa). In contrast, P-gp could not be detected in lymphocytes from rats 
and horses, which is consistent with the low levels of P-gp activity observed. 
Western-blot analysis of jejunal tissue revealed a large band of about 170 kDa for 
goats, sheep, pigs and horses, and of 90-110 kDa for rats and cattle. In cattle and 
rats, the 90-110 kDa band of protein corresponds most likely to P-gp, considering 
the intensity of the signal and the absence of aspecific binding. Furthermore, it is 
known that P-gp is expressed in rat jejunum (Brady et al., 2002). A degradation of 
P-gps into 90-kDa proteins has been already reported in the literature (Doi et al., 
2001), and it is likely that the P-gps of rats and cattle are more sensitive to 
degradation than P-gps of other species.  
Even if only low levels of P-gp activity were detected in rat and horse 
lymphocytes, the present study suggests the expression of functional P-gps in all 
animal species studied. High interindividual variations in P-gp activity were 
observed in rats, goats, sheep, cattle and pigs, similar to those that have been 
reported in human lymphocytes (Schluesener et al., 1992). Young castrated pigs 
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showed a significantly lower Rh-123 efflux and inhibition than older boars, 
suggesting that P-gp activity could vary with the age or hormonal status of animals. 
This is consistent with previous reports in the literature, indicating an upregulated 
P-gp function in lymphocytes with age in mice (Witkowski and Miller, 1993) and 
humans (Gupta, 1995), and suggesting a higher P-gp activity in lymphocytes from 
men than women (Steiner et al., 1998). Further investigations at a large scale are 
required to confirm this trend. 
In addition to functional studies, P-gp expression was found in intestinal tissue 
(jejunum) of all animal species. Taken together, the present results suggest that P-
gps equivalent to those identified in humans and rodents exist in cattle, goats, 
sheep, pigs and horses. P-gp has been shown to play a major role in the disposition 
(distribution, elimination) of many important veterinary drugs such as ivermectin 
(Schinkel et al., 1994; Laffont et al., 2002), a worldwide used antiparasitic drug in 
livestock, and fluoroquinolones (Yamaguchi et al., 2002). Interspecies differences 
in the pharmacokinetics of these drugs could, therefore, be partly explained by 
interspecies differences in P-gp activity, in addition to possible differences in 
metabolism. Whether the proposed classification of the species with respect to P-gp 
applies to tissues other than lymphocytes remains to be documented. However, it is 
striking that the highest P-gp activity was found in lymphocytes from goats, known 
to eliminate ivermectin much more rapidly than other farm animal species (Scott et 
al., 1990). 
High levels of P-gp activity were observed in lymphocytes from goats, cattle, 
sheep and generally pigs. Consequently, lymphocytes offer the possibility to study 
transport of veterinary drugs and drug-drug interactions in the target animal 
species. Although the relevance of the lymphocyte-based model needs to be further 
documented, it is certainly more predictive that in vitro conventional models, 
which cannot take into account interspecies differences. Furthermore, it has been 
reported that the expression of P-gp could vary following drug exposure (Matheny 
et al., 2001) or under inflammatory conditions (Hartmann et al., 2001). Thus, the 
lymphocyte-based model could also be used to evaluate the influence of various 
physiological or pathological factors on the P-gp function, and monitor the effects 
of drugs (particularly long-acting drugs such as ivermectin) on P-gp. Since 
lymphocytes can be easily isolated from a single blood sampling, this model is 
suitable for a population approach. 
In conclusion, our study shows the existence of a physiological P-gp function in 
peripheral blood lymphocytes from goats, sheep, cattle, pigs and horses, that has 
yet not been reported. However, in contrast to the other species, only low levels of 
P-gp activity were detected in horse lymphocytes. The lymphocyte-based model 
Comparative evaluation of P-gp activity in lymphocytes of cattle, sheep, goats, pigs, horses and rats 
85 
offers new perspectives to study and monitor the P-gp function and expression in 
cattle, goats, sheep and pigs. P-gp expression was also shown in intestinal tissues 
of all animal species studied.  
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Abstract 
 
Pour-on formulations of endectocides are extensively used to treat and control 
systemic parasitic diseases in cattle, worldwide. The purpose of the present study 
was to investigate the influence of the natural licking behaviour of cattle on the 
plasma and faecal disposition of topically-administered ivermectin. Twelve 
Holstein cattle were given one single i.v. (200 µg/kg) and topical (500 µg/kg) 
administration of ivermectin at a 5-month interval. For the pour-on administration, 
the animals were allocated into two groups (n = 6): one control group (lickers) and 
one group where licking was prevented (non-lickers). Ivermectin plasma (total) 
clearance (270 ± 57.4 mL/kg/day) was very homogeneous among the 12 cattle. In 
contrast, major differences between lickers and non-lickers were observed 
following pour-on administration. Prevention of licking resulted in an extended 
terminal plasma half-life (363 ± 16.2 vs 154 ± 7.4 h in lickers) and in a lower and 
less variable systemic availability of ivermectin (19 ± 4.9 vs 33 ± 18.5% in lickers). 
More importantly, nearly 70% of the pour-on dose was recovered as parent drug in 
the faeces of lickers vs only 6.6% in non-lickers. Altogether, these results are 
consistent with an oral rather than percutaneous absorption of topical ivermectin in 
control animals, the non-systemically available fraction of ingested ivermectin 
providing a major contribution (80%) to the drug faecal output. The consequences 
of licking on the disposition of pour-on ivermectin are discussed in terms of 
environment, given the known ecotoxicity of this drug, and of cross-contamination. 
Animals licking themselves and each other could result in unexpected residues in 
edible tissues of untreated animals and in possible subtherapeutic drug 
concentrations, a factor in drug resistance. According to the Precautionary 
Principle, these considerations elicit concern over the use of topical drug 
formulations in cattle. 
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Introduction 
 
In both livestock and companion animals, many different antiparasitic drugs, 
including pyrethroid compounds, organophosphates and later, endectocides (such 
as ivermectin, doramectin, eprinomectin and moxidectin) are administered 
topically to treat different parasitic conditions. Pour-on formulations of 
endectocides limit the risk of injury to user and animal and are particularly 
convenient for farmers who can apply the product easily themselves (Hennessy, 
1997). For these reasons, pour-on have largely displaced therapeutically equivalent 
injectable formulations in farming practice and are routinely used to treat millions 
of cattle per year, worldwide. 
Ivermectin and structurally related drugs are extensively excreted as metabolites 
and parent drug in the faeces of treated animals, regardless of administration route 
(Campbell, 1985; Chiu et al., 1990). Unchanged (active) compound in the faeces 
may be toxic to non-target organisms such as dung-breeding insects and the fauna 
involved in the degradation of livestock dung on the pasture (Wall and Strong, 
1987). The issue of environmental impact of endectocides used in large scale has 
been debated for almost 20 years (Fincher, 1992, 1996; Sommer et al., 1993), and 
there is still little sign of consensus since different studies have shown conflicting 
results with varying degrees of ecotoxicity (Strong and Wall, 1994). Contradictory 
data can be partly explained by the observation that different routes of 
administration (s.c., topical, oral) lead to different ivermectin excretion profiles 
(Herd et al., 1996). Interestingly, higher faecal concentrations of ivermectin have 
been reported following pour-on application than following s.c. injection (Herd et 
al., 1996), which is unexpected considering the lower plasma concentrations. 
Indeed, if it is assumed that the plasma concentration of ivermectin is the only 
driving force for ivermectin excretion into faeces, lower faecal concentrations of 
parent drug should be expected after the pour-on administration. To explain this 
apparent inconsistency, we decided to explore the influence of the natural 
grooming behaviour of domestic cattle on the disposition of ivermectin pour-on 
formulation. This grooming behaviour consists predominantly of self-licking or 
licking another animal (so called allo-licking). It serves an important physiological 
function in skin and hair hygiene, can be stimulated by the presence of 
ectoparasites and is also a factor in the establishment and cohesion of herd social 
structure (Simonsen, 1979; Sato et al., 1991, 1993; Krohn, 1994). The present 
experiment was designed to test the hypothesis that a relevant fraction of the 
ivermectin topically-administered to cattle was actually ingested by licking. 
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Materials and Methods 
 
Experimental design 
 Six pairs of monozygotic twin Holstein cattle (567 ± 24 kg body weight, 3 
years old), obtained by micro-manipulation (Ozil et al., 1982) and maintained 
under identical conditions, were given a single i.v. administration of injectable 
ivermectin (Ivomec® injectable, Merial; 200 µg/kg). After a 5-month washout 
period, each animal was given one single administration of topical ivermectin 
(Ivomec® pour-on bovin, Merial) at the recommended dose of 500 µg/kg. For the 
pour-on administration, each pair of twins was separated into two groups of six 
animals. One group (the lickers) was kept in individual tie-stalls, each animal being 
tethered with a loose chain so that it could lick itself and its immediate neighbours. 
In the other group (the non-lickers), each animal was isolated from the others by a 
screen and was fitted with a wooden neck collar to prevent self-licking. The collar 
was removed 44 days after administration. Blood was collected regularly for 44 
days and 31 days following pour-on and i.v. administration, respectively. An 
additional blood sample was obtained in the 12 cattle on day 56 following pour-on 
application (12 days after removal of collars). Once collected, the blood samples 
were chilled on wet ice and promptly centrifuged. The plasma was removed from 
the tubes, and stored at − 20°C until analysis. Total faeces were collected over 24 h 
on days 4, 7 and 14 after the i.v. administration. Following the pour-on 
administration, faeces were collected for 6 h (from 09:00 to 15:00 h) on days 1, 2, 
3, 4, 7, 14, 18, 22 and 28 after application. Wet faeces were weighed, 
homogenized, and a 50-g aliquot was collected and stored at − 20°C until analysis. 
 
Analytical method 
Ivermectin (22,23-dihydroavermectin B1a) concentrations in plasma and faeces 
were measured using a high-performance liquid chromatography (HPLC) 
technique (Alvinerie et al., 1987). The lower limit of quantification for ivermectin 
was 0.05 ng/mL for the plasma and 0.5 ng/g for the wet faecal samples. Accuracy 
and precision (intra-assay variation) expressed as relative standard deviation were 
less than 8 and 6%, respectively. 
 
Pharmacokinetic analysis 
Data were analysed using a non-compartmental approach. The areas under the 
plasma concentration-time curve AUC (0-tlast) (from 0 to the last sample e.g. 31 
days (i.v.) or 44 days (pour-on)) were computed using the trapezoidal rule. 
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Ivermectin total (plasma) clearance was calculated by dividing the administered 
dose by the AUC (0-tlast) obtained for the i.v. route (Eq. 1): 
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=  Eq.1 
 
The systemic availability for topical ivermectin was calculated using the ratio of 
the AUC (0-tlast) obtained after topical ( onpourtlastAUC
−
−0 ) and i.v. administration 
( ..0
vi
tlastAUC − ), corrected by the ratio of the administered doses (Eq. 2): 
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The faecal excretion rate of ivermectin at each time point (t) was obtained by 
dividing the total amount of parent drug eliminated in faeces within the collection 
interval ( faeces, τQ ) by the time of collectionτ  (6 or 24 h):  
 
τ
faeces, τQte retion ratfaecal exc =)(  Eq. 3 
 
where faeces, τQ  was the product of the weight of wet faeces and the faecal 
concentration of ivermectin (µg/g wet faeces) over the collection period. The total 
amount of parent drug eliminated in faeces within 28 days post-topical 
administration was estimated by integration of the faecal excretion rate profile in 
function of time between 0 and 28 days using the trapezoidal rule.  
 
Faecal clearances were calculated at each time point (t) following the equation 
given below: 
 
plasma, τ
faecal C
e (t)retion ratfaecal exctCl =)(   Eq. 4 
where plasma, τC  was the corresponding plasma concentration over τ . 
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Statistics 
The arithmetic means and standard deviations (SD) of the different parameters 
were calculated. For terminal plasma half-life, the harmonic means and SD were 
computed using the Jackknife technique (Lam et al., 1985). Comparison between 
lickers and non-lickers was carried out using paired t-test for terminal half-lives, 
AUC (0-tlast), total (plasma) clearance and Cmax, and a using non-parametric paired 
test (Wilcoxon) for Tmax and F% (SYSTAT ® 8.0, SPSS Inc., Chicago, IL). A p < 
0.05 was considered as significant. 
 
Results 
 
Plasma disposition 
Ivermectin plasma concentration-time profiles obtained in cattle following i.v. 
and pour-on administrations are presented in Figs. 1 and 2, respectively. Table 1 
gives the mean values of ivermectin pharmacokinetic parameters for both i.v. and 
pour-on administrations in the licker and non-licker groups. Ivermectin total 
(plasma) clearance following i.v. administration was found to be homogeneous 
among the 12 cattle, and equal to 270 ± 57.4 mL/kg/day (n = 12). The terminal 
plasma half-life was similar between pour-on and i.v. administrations in lickers, but 
was much longer after pour-on (363 ± 16.2 h) than following i.v. administration 
Figure 1. Ivermectin mean plasma concentration-time profile over 31 days in the 6 pairs
of monozygotic twin cattle simultaneously administered with 200 µg/kg ivermectin i.v.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Each point represents the mean ± SD obtained in the 12 animals. 
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(144 ± 3.0 h) in the non-licker group, indicating a flip-flop phenomenon in non-
licking cattle. The systemic availability for topical ivermectin was higher and more 
variable in lickers than in non-lickers (33 ± 18.5 % vs 19 ± 4.9 %). 
At the end of the 44-day trial, the collars were removed from the six non-licking 
cattle, and measurement of ivermectin plasma concentrations 12 days later 
indicated an obvious rebound in three of the six animals. In these three animals, the 
plasma concentrations on day 56 were increased by a factor of 39, 56 and 135% 
compared to the plasma concentrations measured on day 44, which could not be 
attributed to the variability of the analytical method. 
 
Faecal disposition 
Comparison of ivermectin excretion profiles in faeces (Fig. 3) showed a major 
difference between lickers and non-lickers. On day 4 post-administration, for 
example, the faecal elimination rate of ivermectin in the licker group was  33-times 
Table 1. Pharmacokinetic parameters (mean ± SD) of ivermectin following intravenous 
and topical administration of ivermectin (200 and 500 µg/kg, respectively) to six licking 
and six non-licking monozygotic twin cattle. 
Parameter Lickers (n = 6) Non-lickers (n = 6) 
 i.v. pour-on i.v. pour-on 
t1/2 (h)  137  ±  2.7  154  ±  7.4  144  ±  3.0   363  ±  16.2 **, # 
AUC (ng.h/mL) 18429  ±  3652 14283  ±  6424 18749  ±  3036 9146  ±  3078 * 
Cl (mL/kg/day)    274  ±  68.8     264  ±  47.4  
F (%)         33  ±  18.5    19  ±  4.9 * 
Cmax (ng/mL)       39  ±  20.9       16  ±  6.4 *** 
Tmax (day)     147  ±  43.6       191  ±  15.2 
* (p < 0.05), ** (p < 0.01), *** (p < 0.001) indicate a significant difference between the licker and 
non-licker groups for this parameter.  
# The plasma terminal half-life (t1/2) differed significantly between i.v. and pour-on administrations 
(p < 0.01).  
A paired t-test was used for plasma terminal half-lives, AUC, Cl, and Cmax, whereas a non-
parametric paired test (Wilcoxon) was used for F(%) and Tmax. 
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higher than in the non-licker group (825 ± 227.5 vs 25 ± 10.0 µg/h) and 10-times 
higher than after the i.v. administration (83 ± 10.4 µg/h). The estimated amount of 
ivermectin eliminated in the faeces over 28 days was 346 ± 60.5 µg/kg body 
weight (69% of the administered dose; Fig. 3B) in the lickers vs 33 ± 11.7 µg/kg 
body weight in non-lickers (6.6% of the dose; Fig. 3B).  
  
 A) 
 
 
 
 
 
 
 
 
 
 
B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Comparative ivermectin plasma concentration-time profiles in six licking 
(filled symbol) and six paired non-licking (open symbol) monozygotic twin cattle over a 
56-day period, following a single 500 µg/kg topical administration with ivermectin pour-
on formulation. Each point represents the mean ± SD obtained in the six animals of each 
group. A) Arithmetic scale shows a higher and more variable ivermectin bioavailability in 
lickers than in non-lickers. B) Semi-logarithmic scale shows a different slope for the 
plasma terminal phase in lickers and non-lickers. 
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Figure 3. Comparative excretion profiles of unchanged ivermectin in the faeces of six
licking (filled symbol) and six paired non-licking (open symbol) monozygotic twin cattle 
over 28 days, following a single 500 µg/kg administration of pour-on ivermectin. A) Faecal 
elimination rates (mean ± SD) of ivermectin as parent drug. B) Cumulative amounts of 
ivermectin eliminated in faeces expressed as percentages of the administered dose (mean ±
SD). 
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 In non-lickers (Fig. 4A), individual faecal clearances of ivermectin were similar 
after pour-on (89 ± 24.5 mL/kg/day) and i.v. administrations (102 ± 23.5 
mL/kg/day). In contrast, in the licker group (Fig. 4B), the individual apparent 
faecal clearances of ivermectin following pour-on administration (ranging from 
203 ± 170.6 to 1671 ± 724.1 mL/kg/day) were much higher than the faecal 
clearance obtained for the i.v. route (106 ± 33.5 mL/kg/day) throughout the 28 days 
of investigation.  
The values of ivermectin faecal clearance obtained in the 12 cattle on day 4, 7 
and 14 after i.v. administration were very homogeneous (104 ± 28.6 mL/kg/day, n 
= 12), representing 38% (CI 95% : [36%;40.5%]) of the plasma (total) clearance 
(270 ± 57.4 mL/kg/day, n = 12). 
 
Discussion 
 
Our results indicated that i.v. faecal clearance accounted for 38% of total 
(plasma) clearance following i.v. administration, which implies that 38% of the i.v. 
dose was actually excreted as parent drug in the faeces. This is consistent with the 
Figure 4. Ivermectin faecal clearance on days 4, 7 and 14 post-administration, following an
i.v. injection of ivermectin at 200 µg/kg (filled column) and a pour-on application of
ivermectin at 500 µg/kg (open column).  A) mean ± SD in the non-licker group. B) mean ±
SD in the licker group. The figures show that ivermectin faecal clearance was similar after
i.v. and pour-on administrations in non-lickers, but much higher after pour-on than
following i.v. administration in lickers due to the large ingestion of ivermectin by licking. 
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study performed in cattle and with radiolabelled drug by Halley et al. (1989), who 
showed that 39-45% of the faecal output consisted of parent drug and 59% of 
metabolites after subcutaneous administration. 
After the pour-on administration, a marked difference was observed between 
licker and non-licker groups for both plasma and faecal disposition of ivermectin. 
In the non-licker group, faecal clearance of ivermectin following pour-on 
application was similar to faecal clearance found after i.v. administration, which is 
consistent with the assumption that the plasma concentration was the only driving 
force controlling ivermectin faecal elimination in non-lickers. The percentage of 
the administered dose eliminated in faeces from systemic blood can be 
theoretically assessed as the product of the faecal-to-total clearance ratio (0.38) and 
the fraction systemically available. In non-lickers, this theoretical percentage was 
7% (0.38×0.19), which is very close to the value estimated by integration of the 
excretion rate profile against time (6.6%). In lickers, we would expect 13% of the 
dose (0.38×0.33) to be removed as parent drug from blood in faeces. In contrast, 
we observed that nearly 70% of the pour-on dose (500 µg/kg) was eliminated 
unchanged in the dung. In addition, pour-on faecal clearance in lickers was much 
higher than the faecal clearance obtained for the i.v. route throughout the 28 days 
of investigation, and could exceed up to nine times the i.v. plasma (total) clearance 
in the same animals, which is theoretically impossible. Altogether, these findings 
demonstrate that over this time period, a large fraction of the ivermectin eliminated 
in the faeces of licking animals (nearly 57% of the dose e.g. 80% of the faecal 
output) could not be of plasma origin. It is concluded that an important amount of 
topically administered drug was actually ingested by licking and transited directly 
through the digestive tract into faeces.  
The systemic availability for topical ivermectin was highly variable in lickers 
(coefficient of variation of 56%), which is in line with previous studies (Gayrard et 
al., 1999). The prevention of licking resulted in a lower and less variable systemic 
availability (coefficient of variation of 26% in non-lickers) and in an extended 
elimination half-life (363 h in non-lickers vs 154 h in lickers). The terminal plasma 
half-life in the non-licker group was also much longer than after the i.v. 
administration (144 h). This indicates that ivermectin absorption through the skin 
was a very slow process limiting the drug plasma elimination. In contrast, the 
terminal plasma half-life of ivermectin in the licker group was very similar to that 
observed after the i.v. administration. These results conclusively demonstrate that 
the rate and extent of ivermectin absorption differed between licking and non-
licking animals, which is consistent with a difference in absorption mechanism. 
Considering that a large amount of drug transited through the digestive tract, it is 
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strongly suggested that a large fraction of topical ivermectin gained access to 
systemic circulation by the oral route, rather than percutaneous absorption, as a 
consequence of the licking behaviour. We found a relatively high systemic 
availability in the licker group (33%). By comparison with the s.c. route, the 
systemic availability for the oral route was estimated to be 12.5% for the sustained 
release bolus (Alvinerie et al., 1998) and 26% for the intra-ruminal bolus (Chiu et 
al., 1990). This suggests that perlingual absorption of ivermectin cannot be ruled 
out in licking cattle. 
The obvious rebound in plasma concentration observed in three of the six 
animals (non-licking group) 12 days after removal of the collar suggests that some 
ivermectin was still present on the skin of the animals and available for licking. 
This implies that ivermectin did not undergo complete degradation over 44 days, 
which is surprising given the alleged photolability of the drug.  
The present findings are consistent with the observations reported by others but 
not previously understood (Sommer et al., 1992; Herd et al., 1993, 1996). Our 
results provide clear evidence that the natural grooming behaviour of cattle has a 
major influence on the plasma disposition of topical ivermectin. Self- and allo-
grooming are governed by various social, nutritional, physiological, pathological, 
environmental and managerial factors (Sato et al., 1991, 1993), which makes the 
systemic availability of topical ivermectin more variable and unpredictable. More 
importantly, allo-grooming might result in cross-contamination of animals, giving 
rise to unexpected drug residues in edible tissues of untreated cattle, and 
undesirable subtherapeutic concentrations in both treated and untreated cattle, 
which can contribute to the development of drug resistance. Finally, our study 
demonstrates that the prevention of licking can lead to 10-times lower amounts of 
parent drug in faeces, under our experimental conditions. This suggests that the 
licking behaviour of cattle should be taken into consideration in the environmental 
risk assessment of endectocides. It must also be stressed that the poor and erratic 
bioavailability of pour-on formulations has led to increased dose rates for 
ivermectin, doramectin and moxidectin by a factor of 2.5 compared with the s.c. 
formulation. However, with approximately 70% of the dose recovered in the faeces 
of licking cattle, increasing the dose contributes to a higher and unnecessary 
environmental burden of parent drug. In contrast, the therapeutically equivalent s.c. 
formulation would provide a lower faecal output of ivermectin. Indeed, the 
maximum faecal excretion of parent drug following s.c. administration (200 µg/kg) 
can be estimated using our i.v. faecal clearance to be about 78 µg/kg vs 346 ± 60.5 
µg/kg in lickers given topical ivermectin. Altogether, these considerations elicit 
concern over the topical route for endectocide administration in cattle, and it is 
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strongly suggested that the use of safe and efficacious injectable preparations be 
encouraged. 
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Abstract 
 
Animal behaviour is generally not recognised as a major determinant of drug 
disposition in animals. In the present study, pharmacokinetic modeling was applied 
to quantify the contribution of physiological cattle behaviour (licking) on the 
plasma and faecal disposition of topical ivermectin, a worldwide-used antiparasitic 
drug largely administered to cattle as a percutaneous formulation (pour-on). Six 
pairs of monozygotic twin cattle were given successively a single i.v. and two 
pour-on administrations of ivermectin at a 3-5-month interval. For the second pour-
on administration, the twins were separated into two groups: a control group 
(lickers) and a group where self- and allo-licking were prevented. Ivermectin data 
obtained after i.v. and the second pour-on administrations in licking and non-
licking twins were fitted simultaneously to a set of differential equations describing 
a seven-compartment model. Licking conferred a high intra- and inter-individual 
variability of systemic exposure after topical administration. We show that 58-87% 
of the pour-on dose was ingested, while only 10% of the dose was absorbed 
percutaneously. It results that 50-77% of the drug systemic absorption was 
achieved by the oral route. Approximately 72% of the ingested ivermectin transited 
directly into faeces, increasing by 5-fold the environmental burden of parent drug. 
This is of ecological interest, given the potential of ivermectin to adversely affect 
dung-degrading insects. We conclude that topical administration does not 
guarantee a controlled drug delivery in cattle. More importantly, simulations 
revealed that non-treated cattle could get easily contaminated by allo-licking, 
raising the public health problem of unexpected drug residues in edible tissues. 
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Introduction 
 
Licking is an important part of the natural grooming behaviour of animals in 
many species. In cattle, it serves an important physiological function in skin and 
hair hygiene, and plays a major role in the establishment and maintenance of the 
herd social structure (Simonsen, 1979; Sato et al., 1991, 1993; Krohn, 1994). 
However, despite the increasing use of percutaneous drug formulations in both 
companion and food-producing animals (see Magnusson et al., 2001), the influence 
of licking on the disposition of topical drugs has never been documented. Over the 
last twenty years, the percutaneous route has received considerable interest in 
veterinary medicine for local and/or systemic delivery of drugs (Hennessy, 1997; 
Magnusson et al., 2001; Riviere and Papich, 2001). This application technique is 
particularly convenient for the owner who can easily apply the treatment himself 
with minimal risk of injury and minimal animal distress (Hennessy, 1997; Rothen-
Weinhold et al., 2000). Furthermore, topical administration avoids the problems of 
hepatic first pass metabolism and of drug degradation in the gastrointestinal tract 
following oral administration, and therefore may be a good alternative to the oral 
route to achieve systemic therapeutic effects (Hennessy, 1997; Magnusson et al., 
2001). 
Ivermectin is a worldwide-used antiparasitic drug, which is routinely 
administered to millions of cattle per year for systemic effects. As for other 
endectocides (doramectin, moxidectin, eprinomectin), the topical "pour-on" 
formulation of ivermectin has largely displaced the conventional injectable 
formulation in farming practice. In a recent study (Laffont et al., 2001), we showed 
that the disposition of pour-on ivermectin in cattle was markedly modified with 
restriction of animal licking. Prevention of licking resulted in a significantly lower 
absolute bioavailability of ivermectin, in a two-times longer plasma elimination 
half-life, and overall in a ten-times lower elimination of the parent drug in faeces 
(Laffont et al., 2001). Altogether, these results suggested that under normal licking 
conditions, a large amount of the topical drug reached the systemic circulation by 
oral rather than percutaneous absorption. The raw data of this study on ivermectin 
in non-licking and control cattle are used in the present paper for the purpose of 
pharmacokinetic modeling. The aim was to quantify the actual contribution of 
licking to the systemic availability of pour-on ivermectin and to the excretion of 
the parent drug in faeces. The extent of ivermectin faecal excretion is indeed of 
special concern, given the potential negative environmental impact caused by the 
effect of the parent drug against some beneficial dung-breeding and dung-
degrading insects (for review, see McKellar, 1997). We also present original data 
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on another pour-on administration of ivermectin performed in the same animals, in 
order to assess the intra-individual variability of exposure of the treated cattle. 
This paper addresses the general problem of controlled drug delivery by topical 
application in animals, and discusses the consequences of animal social licking in 
terms of public health and food safety.  
 
Materials and Methods 
 
Study design and animals 
The material and methods have been extensively described in the original paper 
(Laffont et al., 2001), except for information related to the first pour-on 
administration (PO1). Briefly, six pairs of monozygotic twin Holstein cattle (467 ± 
19 kg b.wt., 3 years old) obtained by micromanipulation (Ozil et al., 1982) were 
used in the experiments. Each cattle received a single i.v. administration of 
injectable ivermectin (IVOMEC® injectable, Merial, Lyon, France; 200 µg/kg 
b.wt.) and two topical administrations of ivermectin (IVOMEC® pour-on, Merial, 
Lyon, France) at the standard dose of 500 µg/kg b.wt. All administrations were 
performed at a 3- to 5-month interval. For the second pour-on administration 
(PO2), the twins were separated into two groups of six animals. In the control 
group (the lickers), animals were kept in individual tie-stalls, each cattle being 
tethered with a loose chain so it could lick itself and its immediate neighbours. In 
the other group (the non-lickers), each animal was isolated from the others by a 
screen and was fitted with a wooden neck collar to prevent self-licking. Blood was 
collected regularly at 17 times up to 28 days after application of PO1, at 22 times 
up to 44 days after application of PO2, and at 20 times up to 31 days following i.v. 
administration. Total faeces were collected over 24 hours on days 4 and 14 after 
application of PO1. Following application of PO2, total faeces were collected for a 
period of 6 h (from 09:00 to 15:00 h) on days 1, 2, 3, 4, 7, 14, 18, 22 and 28 post-
administration.  
 
Analytical method 
Concentrations of ivermectin (22,23-dihydroavermectin B1a) in plasma and in 
wet faeces were measured using a high-performance liquid chromatography 
(HPLC) technique (Alvinerie et al., 1987). The lower limit of quantification for 
ivermectin was 0.05 ng/mL for the plasma and 0.5 ng per g of wet faeces for the 
faecal samples. The limit of detection for ivermectin in plasma was 0.01 ng/mL. 
Accuracy and precision (intra-assay variation) expressed as relative standard 
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deviation were less than 8 and 6%, respectively. 
 
Pharmacokinetic analysis 
 
Non-compartmental approach. Individual areas under the plasma 
concentration-time curve, AUC(0-infinite), were computed using the trapezoidal 
rule. The extrapolated area (from the last sample to infinity) was calculated by 
dividing the last plasma concentration measured by the slope of the terminal phase 
(estimated in a semi-logarithmic scale). 
Ivermectin (total) plasma clearance (CLtot) was calculated as the ratio of the 
administered dose (200 µg/kg) divided by the AUC (0-infinite) obtained for the i.v. 
route : 
 
CLtot = Dose i.v. / AUC i.v. Eq. 1 
 
The systemic availability for topical ivermectin (Ftot ) was calculated using the ratio 
of the AUCs (0-infinite) obtained after topical (AUC pour-on) and i.v. administrations 
(AUC i.v.) corrected by the ratio of the administered doses : 
 
Ftot (%) = (AUC pour-on /AUC i.v) × (Dose i.v. / Dose pour-on) × 100 Eq. 2 
 
Cumulative amounts of parent ivermectin eliminated in faeces were calculated by 
integration of the faecal excretion rate profile as a function of time, using the 
trapezoidal rule. The faecal excretion rates were obtained as the total amount of 
parent drug eliminated in faeces within the collection interval (i.e., the product of 
the faecal concentration of ivermectin and the weight of wet faeces), divided by the 
time of collection. 
 
Data modeling. Twin cattle were considered as the same animal taken under 
normal and restricted licking conditions. Each pair of twins was fitted separately. 
The pharmacokinetic model presented in Fig. 1 was selected among other different 
models to fit simultaneously the plasma and faecal ivermectin data obtained in the 
licking and non-licking twins after pour-on administration (PO2) and the i.v. 
plasma ivermectin data of the two twin cattle. The model was assumed dose-
independent, but was not time-independent since the rate constant of ingestion of 
topical ivermectin (Ka) was described as a biexponential function of time. It was 
defined by the following equations : 
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Figure 1. Disposition model for ivermectin after i.v. and topical (pour-on) administration in 
one pair of licking and non-licking monozygotic twin cattle. Kij is the first-order rate 
constant of transfer from compartment i to compartment j. K10 is the first-order rate 
constant of elimination from compartment 1. The rate constant Ka traduces the ingestion of 
topical ivermectin by licking and is modelised as a biexponential function of time. The i.v. 
dose (200 µg/kg) is introduced in compartment 1 (plasma), while the pour-on dose (500 
µg/kg) is introduced in compartment 5 (at the surface of the skin). The subscripts " L " and 
" nL " refer to the "licking" (control) or "non-licking" twin, respectively. "GIT 1", 
gastrointestinal compartment 1. "GIT 2", gastrointestinal compartment 2. " PT ", peripheral 
tissues. 
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Cp  = X1 ./ V1 Eq. 3 
 
dX1 /dt = K21 × X2  +  K31 × X3  +  K51 × X5  +  K61 × X6 Eq. 4 
 – (K10 + K12 + K13) × X1  
 
dX2 /dt = K12 × X1  –  K21 × X2 Eq. 5 
 
dX3 /dt = K13 × X1  –  (K31 + K34) × X3 Eq. 6 
 
dX4 /dt = K34 × X3  +  K64 × X6 Eq. 7 
 
dX5 /dt = – (K51 + Ka(t) + K57) × X5 Eq. 8 
 
dX6 /dt = Ka (t) × X5 – (K61+ K64) × X6 Eq. 9 
 
dX7 /dt = K57 × X5   Eq. 10 
 
where Cp is the concentration of ivermectin in plasma (compartment 1, volume 
V1), Xi is the amount of ivermectin in compartment i, Kij is the first-order rate 
constant of transfer from compartment i to compartment j, and K10 is the first-
order rate constant of elimination from compartment 1.  
For the disposition of topical ivermectin in non-lickers, Ka (the constant of transfer 
from compartment 5 to compartment 6) was set to zero. For the disposition of 
topical ivermectin in control animals (the lickers), Ka was empirically described as 
a function of time (Eq. 11), increasing up to a maximum and then decreasing (see 
discussion).  
 
Ka (t) = A × [ exp ( – B × t)  –  exp ( – C × t) ]   Eq. 11 
 
where the parameters A, B and C are expressed in h-1. 
 
The i.v. dose (200 µg/kg) was introduced into the plasma compartment, while the 
pour-on dose (500 µg/kg) was introduced into compartment 5 representing the skin 
surface. K12, K21, K13, K31 are the distribution rate constants between the plasma 
and the peripheral compartments 2 and 3. The rate constant K10 relates to the 
elimination of ivermectin from plasma by metabolism, while the rate constant K34 
traduces the removal of parent ivermectin from the gastrointestinal tract (GIT 2; 
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compartment 3) into faeces (compartment 4). K51 is the rate constant for the 
systemic absorption of topical ivermectin via the skin. It was assumed that K51 did 
not differ between lickers and non-lickers (see discussion). The rate constant K57nL 
accounts for the fraction of topical ivermectin which was not systemically available 
by the percutaneous route in the non-licking cattle (e.g. left at the skin surface, 
photo-degraded, or metabolised by the enzymes of the skin). In control animals 
(the lickers), the topical drug could be absorbed through the skin (K51) or ingested 
by licking (Ka). One fraction of the ingested ivermectin was then absorbed in 
plasma (K61), while the remaining fraction transited unchanged into faeces (K64). 
The model assumes that the local disposition of ivermectin is not the same at all 
sites of the digestive tract (see discussion). The rates of drug absorption and 
elimination were indeed different in the gastrointestinal compartments 3 and 6 
(GIT 1 and GIT 2, respectively). In  lickers, the rate constant K57L refers to the 
fraction of topical ivermectin which was neither ingested nor systemically-
available by the percutaneous route. First pass metabolism of ivermectin by the 
oral route was considered negligible, given the low value of the drug total 
clearance (overall coefficient of extraction < 1% in cattle). Tlag-L is the delay to oral 
absorption, and Tlag-nL is the delay to percutaneous absorption. 
 
The differential equations were solved numerically using the SCIENTIST 
program (MicroMath Scientific Software, Inc., Version 2.01). The goodness of fit 
was assessed by examination of the lines of best fit and of residual patterns, taking 
into account a modified Akaike information criterion. The data points were 
weighed by the inverse of the squared observed values (1/Y2) for ivermectin 
plasma concentrations, and by the inverse of the observed values (1/Y) for the 
amounts of ivermectin excreted in faeces. The fitting was performed stepwise: 1) 
the i.v. plasma concentrations of ivermectin obtained in the two twins were fitted 
simultaneously to equations 3-6, 2) the i.v. plasma data of the twins and the pour-
on (plasma and faecal) data of the non-licker were fitted simultaneously using 
equations 3-10 (the estimates yielded by the first fitting were used as initial values 
for the parameters), and 3) the pour-on (plasma and faecal) data of the licking and 
non-licking twins and the i.v. plasma data of the two cattle were fitted 
simultaneously using the equations 3-11. The estimates yielded by the second 
fitting were taken as initial values for the parameters. 
 
Pharmacokinetic parameters were calculated from the final estimates of the model 
parameters. Ivermectin total (plasma) clearance, CL tot IVM, was calculated for each 
pair of twins according to the following equation (for demonstration, see 
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Nakashima and Benet, 1988):  
 
CL tot IVM = V1 × [ K10  +  K34  × K13 / (K31+K34) ]   Eq. 12 
 
The relative importance of the oral and percutaneous routes in the removal of 
ivermectin from the skin was assessed for each licking cattle by simulation of X1, 
X6 and X7 using equations 4 and 8-10 with K10, K12, K13, K61, K64 equal to 
zero. Simulations were performed over a period of 6000 h, until no ivermectin was 
left in compartment 5. The fraction of topical ivermectin absorbed though the skin, 
ingested (f ingested), and remaining (left on the skin or degraded) were calculated as 
the final amount of ivermectin obtained by simulation in compartment 1, 6 and 7, 
respectively, divided by the applied dose of pour-on (500 µg/kg). 
The absolute oral bioavailability of ivermectin (Foral) was estimated by modeling : 
 
Foral (%) = [ K61 / (K61 + K64 )] × 100   Eq. 13 
 
The percentage of topical ivermectin systemically-available by the oral route was 
obtained as f ingested × Foral (%). 
 
Simulation of the ingestion of topical ivermectin with increased rates of 
percutaneous absorption 
The influence of the rate of percutaneous absorption on the extent of drug 
ingestion was examined. Cumulative amounts of ivermectin ingested and absorbed 
through the skin after topical application were simulated for various magnitudes of 
percutaneous absorption rates. Simulations were performed using the estimated 
parameters obtained in each pair of twins (see Table 2). Equations 4 and 8-10 were 
used for the simulations with K10, K12, K13, K61, K64 equal to zero. 
 
Simulation of the exposure of non-treated animals following cross-contamination 
by allo-licking 
The possibility of the cross-contamination of non-treated cattle by licking of 
those topically-treated was examined. Simulations were carried out to evaluate the 
minimal amount of ivermectin that had to be licked to achieve non-negligible 
plasma exposure of untreated cattle. Residues of ivermectin in milk were given as 
an indicator of the contamination of food. The simulations were performed for each 
pair of twins using the final estimated parameters (listed in Table 2). For simulation 
of a single oral uptake, the dose was introduced into compartment 6. In the case of 
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the ingestion of topical ivermectin by multiple oral uptake (modelised by Ka), the 
dose was introduced into compartment 5 with K51 and K57L equal to zero, and 
equations 3-9 and 11 were used for the simulations. Residues of ivermectin in milk 
were predicted from the corresponding plasma concentrations of ivermectin, given 
a milk/plasma concentration ratio of 0.766 (Toutain et al., 1988).  
 
Statistical analysis 
Statistical analysis was performed using the SYSTAT® 8.0 (SPSS Inc., Chicago, 
IL) software. ANOVA was used to compare the within-pair and between-pair 
variability of plasma exposure (AUC) and of ivermectin total clearance after i.v. 
administration in the 6 pairs of twins. ANOVA was also applied to compare the 
intra- and inter-individual variability of plasma exposure (AUC) in the licker group 
after pour-on administration. A p < 0.05 was considered as significant. The results 
were expressed as means ± SD. 
 
Results 
 
Intravenous administration of ivermectin 
The plasma concentration profiles of ivermectin obtained in the twelve cattle 
were very homogenous (Fig. 2A). It must be noted that for all pairs of twins, the 
plasma concentration-time curves of the two twins were exactly superposed (see 
Fig. 3 for a representative pair of twins). Furthermore, the variability in plasma 
AUC was significantly lower between the twins (coefficient of variation (CV) of 
5%) than that between the different pairs of twins (CV of 25%) (p < 0.01). Similar 
results were obtained for ivermectin total clearance, with a lower within-pair than 
between-pair variability (p < 0.01). Altogether, these results consolidate the choice 
of using monozygotic twins for the purpose of modeling. 
The plasma data were well fitted by the model, as it is shown for a 
representative pair of twin cattle in Fig 3. The individual total clearances of 
ivermectin calculated by non-compartmental analysis were consistent with those 
estimated by modeling (Table 1; see the original article for other pharmacokinetic 
parameters: Laffont et al., 2001). 
 
Pour-on administration of ivermectin 
The plasma concentration-time profiles of  ivermectin obtained after application 
of PO2 are presented in Figure 2B. By comparison with the i.v. route, the systemic 
exposure of animals was highly variable, depending on their ability to lick or not.  
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Figure 2. Ivermectin plasma concentration-time curves in 6 pairs of monozygotic twin
cattle after i.v. administration (Fig. 2A) and topical (pour-on) administration (Fig. 2B). The
twins were separated in two groups of 6 animals: the licker group (filled symbols) and the
non-licker group (open symbols). For the pour-on administration, self- and allo-licking
were prevented in the cattle of the non-licker group. 
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Figure 3A shows different slopes for the plasma terminal phase between i.v. and 
pour-on administrations in non-lickers. This “flip-flop” phenomenon (extensively 
described in the original article: Laffont et al., 2001) does not occur under normal 
licking conditions and shows that, in contrast to oral absorption, the percutaneous 
absorption of ivermectin is a very slow process limiting the drug plasma 
elimination. Cumulative amounts of parent ivermectin excreted in faeces under 
normal or restricted liking conditions are presented in Fig. 4A. They show major 
differences in the faecal excretion of the parent drug between licking and non-
licking animals (see also Table 1).  
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! Figure 4. Faecal excretion of parent ivermectin (IVM) following topical application of 6
pairs of monozygotic twin cattle (PO2). Twins were separated into two groups of 6
animals: the non-licker group (open circles), in which self-and allo-licking were prevented,
and the licker group (filled circles, control group). A) Cumulative amounts of ivermectin
excreted in faeces. B) Ivermectin faecal excretion rates. Open triangles and open squares
refer to a previous pour-on administration (PO1) in the same animals (licker and non-licker
groups, respectively), with this time no restriction of licking in any of the two groups. 
 
"Figure 3. Experimental (symbols) and simulated (line) ivermectin data after i.v. and
topical (pour-on) administration in a representative pair of monozygotic twin cattle. Circle
symbols, plasma concentrations of ivermectin after i.v. administration. Triangle symbols,
cumulative amounts of parent ivermectin excreted in faeces after topical administration.
Square symbols, plasma concentrations of ivermectin after topical administration. Licking
was prevented in one of the two twins (open symbols; non-licking cattle), the other twin
serving as a control (filled symbols; licking cattle). A) semi-logarithmic scale. B) arithmetic
scale. 
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 For the cattle of the non-licker group, it was possible to compare the disposition 
of pour-on ivermectin in the same animal under normal (PO1) and restricted (PO2) 
licking conditions. As shown in Fig. 4B, the faecal excretion rates observed in 
these cattle after application of PO1 match those found in their twins (licker group) 
following administration of PO1 and PO2. The overall bioavailability of pour-on 
ivermectin was not significantly increased with licking (24 ± 6.4 % in PO1 vs 22 ± 
6.6 % in PO2), but more importantly no flip-flop phenomenon was observed.  
Taken under normal licking conditions, all cattle showed a high variability of 
plasma exposure. After application of PO1, the difference in ivermectin 
bioavailability within the same pair of twins could be as high as 70%. In the licker 
group, the plasma AUC of ivermectin in a same animal was multiplied by a factor 
of 0.6 to 2.3 from one pour-on application to the other. The intra-individual 
variability (CV of 41%) was not significantly lower than the inter-individual 
variability (CV of 55%). 
The plasma and faecal data obtained for ivermectin after pour-on administration 
were well fitted by the model for all pairs of twins (Table 1; see Fig. 3 for a 
representative pair of twins). In one pair of twins however, the predicted faecal 
data underestimated by 35% the observed amounts of parent drug recovered in the 
faeces of the licker, which will be further discussed. The estimated parameters of 
the overall disposition model presented in Fig. 1 are listed in Table 2. It is 
noteworthy that the parameters showing the highest coefficients of variation were 
those associated with the ingestion of the topical drug by licking (A, B, C, K61, 
K64, K57, Tlag-L). Following topical administration, pharmacokinetic modeling 
gave a mean absolute bioavailability of ivermectin of 32 ± 13.8% in lickers and of 
23 ± 7.5% in non-lickers (see Table 3), which is very close to the values obtained 
by non-compartmental analysis (33 ± 18.6% and 22 ± 6.6%, respectively).  
The model indicates that 58-87% of the topically-applied ivermectin was 
actually ingested by licking (Table 3), and that 50-77% of the drug systemic 
absorption was achieved by the oral route (corresponding to 22% of the applied 
dose; Table 3) vs 23-50% by the percutaneous route (10% of the applied dose; 
Table 3). Oral absolute bioavailability of ivermectin was estimated by modeling 
(Eq. 8), and tended to be higher than for the percutaneous route (28 ± 13.2% vs 22 
± 6.6%, respectively). Together with the large ingestion of drug, this explains the 
higher overall bioavailability of pour-on ivermectin in lickers (Ftot of 32 ± 13.8%), 
compared to non-licking cattle (Ftot of 23 ± 7.5%) (Table 3). 
  
Table 1. Ivermectin total clearance (CL total) in cattle, and evaluation of the contribution of licking to the faecal excretion of parent 
ivermectin after topical application to cattle. 
 CL total (mL/day/kg)   % dose eliminated unchanged in the faeces of lickers 
Pair number non-comp. 
 
comp.  non-comp. 
(0-28 days) 
comp.  
(0-28 days) 
comp. 
(0-infinite) 
By the oral 
route 
Non-lickers        
1 230.8 227.9  6.5 6.7 9.0 
 
2 286.0 322.9  3.3 4.3 6.4 
 
3 332.7 325.1  5.7 5.3 7.1 
 
4 283.6 296.3  6.9 4.6 6.5 
 
5 236.7 258.2  10.6 10.0 15.5 
 
6 225.6 233.0  6.8 7.7 10.2 
 
mean ± SD 266 ± 42.2 277 ± 43.6  6.6 ± 2.3 6.4 ± 2.2 9.1 ± 3.5  
Lickers        
1 211.1 227.9  74.2 74.8 80.5 59.4 
2 322.1 322.9  76.0 75.4 77.5 70.4 
3 328.3 325.1  55.0 54.2 56.5 48.2 
4 355.5 296.3  83.2 54.0 55.7 44.0 
5 214.4 258.2  74.1 73.4 74.8 61.3 
6 210.2 233.0  53.6 56.8 57.6 43.9 
mean ± SD 274 ± 68.5 277 ± 43.6  69 ± 12.1 65 ± 10.7 67 ± 11.6 55 ± 10.8 
Compartmental (comp.) and non-compartmental (non-comp.) analysis were performed in the 6 pairs of monozygotic twin cattle. 
  
Table 2. Estimated parameters of the seven-compartment model (Fig. 1) selected to describe the i.v and topical disposition of ivermectin 
in cattle. 
 pair number   
Parameters 1 2 3 4 5 6 mean %CV 
V1 (L/kg) 0.078 0.084 0.080 0.093 0.074 0.058 0.078 15 
K10 (h-1) 0.054 0.096 0.101 0.105 0.077 0.094 0.088 22 
K12 (h-1) 0.288 0.293 0.439 0.271 0.283 0.358 0.322 20 
K21 (h-1) 0.016 0.016 0.019 0.020 0.017 0.021 0.018 13 
K64 (h-1) 0.345 0.057 0.038 1.929 0.145 0.021 0.423 177 
K61 (h-1) 0.140 0.008 0.008 1.868 0.044 0.011 0.347 216 
K57 L (h
-1) 0.00011 0.00058 0.00181 0.00000 0.00071 0.00223 0.00091 101 
K57 nL (h
-1) 0.00269 0.00192 0.00245 0.00176 0.00143 0.00216 0.00207 22 
K13 (h-1) 1.760 3.872 3.693 2.096 1.673 3.242 2.723 37 
K31 (h-1) 0.642 0.883 0.918 0.484 0.491 0.889 0.718 28 
K34 (h-1) 0.026 0.015 0.018 0.006 0.021 0.021 0.018 37 
TLAG L (h) 37.1 14.3 27.4 20.0 0.0 5.4 17.4 79 
TLAG nL  (h) 6.8 5.4 5.0 2.0 7.1 5.7 5.3 35 
A (h-1) 0.0186 0.0480 0.0042 0.0093 0.0108 0.0114 0.0170 93 
B (h-1) 0.00325 0.00215 0.00096 0.00179 0.00158 0.00241 0.00202 39 
C (h-1) 0.00731 0.00308 0.04622 0.02854 0.01658 0.02418 0.02098 75 
K51 (h-1) 0.00052 0.00037 0.00052 0.00079 0.00070 0.00065 0.00059 25 
The plasma (i.v., pour-on) and faecal (pour-on) ivermectin data of six pairs of monozygotic twin cattle were used for the compartmental analysis. Twins 
were separated as "lickers" and "non-lickers": licking was prevented in one twin, the other twin serving as a control. Each pair of twins was fitted 
separately. "L", Lickers; "nL", Non-lickers. 
  
Table 3. Absolute bioavailability (F total) of pour-on ivermectin in cattle, and evaluation of the extent of ingestion, oral absorption, and 
percutaneous absorption of ivermectin after topical application. 
 F total (%)   % of the dose  
Pair number non-comp. 
analysis 
comp. 
analysis 
 ingested absorbed 
orally 
absorbed 
through the skin 
left 
Non-lickers        
1 17.4 16.2  
  16.2 83.8 
2 15.6 16.2  
  16.2 83.8 
3 16.9 17.5  
  17.5 82.5 
4 30.1 31.0  
  31.0 69.0 
5 29.9 32.8  
  32.8 67.2 
6 24.2 23.2  
  23.2 76.8 
mean ± SD 22 ± 6.6 23 ± 7.5    23 ± 7.5 77 ± 7.5 
Lickers        
1 35.6 37.8  83.4 24.0 13.8 2.6 
2 18.2 18.0  80.5 10.1 7.9 11.7 
3 21.4 20.4  58.4 10.2 10.2 31.4 
4 68.4 56.0  86.6 42.6 13.4 0.0 
5 22.9 28.4  80.1 18.7 9.7 10.3 
6 29.6 31.1  67.8 23.9 7.3 25.0 
mean ± SD 33 ± 18.6 32 ± 13.8  76 ± 10.8 22 ± 12.0 10 ± 2.7 13 ± 12.4 
Compartmental (comp.) and non-compartmental (non-comp.) analysis were performed in the 6 pairs of monozygotic twin cattle. 
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Approximately 72% of the ingested ivermectin was not absorbed and transited 
directly into faeces, providing a major contribution (82%) to the excretion of parent 
drug in the dung (72 = (0.55 / 0.76) × 100; 82 = (0.55 / 0.67) × 100; see Tables 1 
and 3). 
Individual time profiles of the ingestion rate constant, Ka, were generated by 
modeling and are presented in Fig. 5A. Peak values of Ka were reached between 3 
and 16 days after pour-on application. In general, high Ka peak values were 
associated with a rapid decrease of Ka, whereas lower Ka peak values were 
associated with a slower decrease of Ka. Half of the ingestion was achieved 
between 3 and 7 days post-administration, and 90% of the ingestion was achieved 
between 9 and 17 days post-administration. The differences observed among cattle 
are consistent with the large variability expected from the licking behaviour of 
animals.  
 
Simulations of ivermectin ingestion profiles with increased rates of percutaneous 
absorption 
Ingestion profiles were simulated for different magnitudes of percutaneous 
absorption rates, using the final estimated parameters obtained for each pair of 
twins. The results of the simulations are presented in Fig 5B for a representative 
pair of twin cattle. They indicate that the rate constant of percutaneous absorption, 
K51, must be increased by a factor 6 - 10 to obtain less ivermectin ingested by 
licking than absorbed through the skin, and by at least a factor 50 to reduce the 
ingestion of ivermectin by one order of magnitude (down to 8 ± 2.3% of the dose). 
A 8-fold higher rate constant of percutaneous absorption resulted in a higher 
bioavailability of topical drug via the skin (48 ± 6.4% instead of 10 ± 2.7%), and in 
lower amounts of ivermectin remaining as a cutaneous depot or degraded (8 ± 
7.4% of the dose instead of 13 ± 12.4%). 
 
Simulation of the contamination of non-treated animals with ivermectin by allo-
licking 
In the case of multiple oral uptake (modelised by Ka), plasma concentrations of 
1 ng/mL were achieved following total ingestion of 2 - 3.7% of the pour-on dose in 
4 of the 6 pairs of twins, and of 10-11% in the two other pairs. This resulted in 
detectable (> 0.01 ng/mL) and persistent (> 44 days) concentrations of ivermectin 
in milk, with maximal values of 0.8 ng/mL. Only 0.02 - 0.11% of the dose had to 
be ingested in total to recover detectable concentrations of ivermectin in plasma 
(0.01 ng/mL). In the case of single oral uptake, plasma concentrations of 1 ng/mL 
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(0.8 ng/mL in milk) were achieved following total ingestion of 0.3 - 2.5% of the 
pour-on dose in the 6 pairs of twins. Total ingestion of 0.003 - 0.025% of the pour-
on dose was sufficient to recover detectable concentrations of ivermectin in 
plasma. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Ingestion of ivermectin following topical application to cattle along the dorsal
midline. A) The rate constant of ingestion, Ka, obtained by modeling is plotted as a
function of time, for each of the 6 licking cattle. B) Simulations of the percutaneous
absorption (normal-width line) and ingestion (thick line) of topical ivermectin with
increased rates of percutaneous absorption in one representative licking cattle. Solid line,
control values. Short-dashed line, percutaneous rate multiplied by 8. Medium-dashed
line, percutaneous rate multiplied by 50. 
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Discussion 
 
In contrast to what could be expected for a "percutaneous" formulation, the 
present study shows that the main route for the systemic absorption of topical 
ivermectin is not percutaneous but oral, as a result of cattle licking behaviour. This 
is the first time such an interaction between the individual/social behaviour of 
animals and the pharmacokinetics of parenterally-administered drugs is reported. 
The selected pharmacokinetic model adequately describes the experimental 
plasma and faecal data observed after i.v. and pour-on administrations of 
ivermectin in licking and non-licking cattle. The predicted values for the absolute 
bioavailability of pour-on ivermectin (Ftot) and for the drug total clearance (CLtot) 
are very close to those obtained by non-compartmental analysis. It was assumed 
that the rate constant of percutaneous absorption, K51, did not differ between 
lickers and non-lickers. This is supported by a non-significant difference in the 
estimates of K51L and K51nL when considered as separate parameters in the model, 
which suggests that the absence of licking for 44 days did not impair the process of 
ivermectin absorption through the skin. 
It is worthwhile to mention that the pour-on data obtained in lickers were totally 
misfitted by a model containing a single gastrointestinal compartment pooling 
compartments GIT 1 and GIT 2. Selection of a model with two separate 
gastrointestinal compartments suggests that the local disposition of ivermectin is 
not the same at all sites of the gastrointestinal tract in terms of (re-)absorption and 
elimination. This is in line with the experimental finding of a different ivermectin 
bioavailability in the rumen and in the abomasum in sheep (Prichard et al., 1985). 
The low bioavailability of ivermectin after intraruminal administration (75% lower 
than after intra-abomasal administration) was first attributed to an extensive 
degradation or metabolisation of drug in the rumen (Prichard et al., 1985). This 
explanation is however difficult to conciliate with our results, since the unabsorbed 
fraction of ingested ivermectin was fully recovered in the faeces of lickers. 
Moreover, several studies argue for the stability of ivermectin in rumen fluids in 
cattle and in sheep (Bogan and McKellar, 1988; Andrew and Halley, 1996), and 
show that there is rather an extensive adsorption of ivermectin to the digesta 
particulates of the rumen (Ali and Hennessy, 1996). Our model stipulates that the 
fraction of drug which is not absorbed in compartment GIT 1 will not be absorbed 
in compartment GIT 2. A possible interpretation is that ivermectin remains 
adsorbed to the particulate phase of the digesta during intestinal transit, and thus is 
not available anymore for absorption in intestinal fluids. Such a situation has 
already been described for other compounds such as phenylbutazone (Bogan et al., 
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1984; Lees et al., 1988), and is consistent with the high organic-carbon binding 
constant of ivermectin (Koc = 12600-15700; Halley et al., 1989) and its high 
hydrophobicity (Pouliot et al., 1997). Ivermectin oral bioavailability was estimated 
from the model to 28 ± 13.2%, which is in line with the bioavailability found by 
Chiu et al. (1990) in cattle for an intraruminal bolus of ivermectin relative to the 
subcutaneous route (26%). However, the contribution of a buccal absorption of 
drug cannot be excluded. 
Pharmacokinetic modeling showed that approximately 76% of the pour-on dose 
was ingested by licking. As indicated by preliminary deconvolution studies, the 
rate constant of ingestion, Ka, could be modelised as a biexponential function of 
time, with an increase up to a maximum followed by a gradual decrease. 
Ivermectin is a highly lipid soluble drug (Fisher and Mrozik, 1989), which 
markedly accumulates in the ear wax of pigs (Scott and McKellar, 1992). It is thus 
possible that ivermectin spreads over the skin of cattle by diffusion within the skin 
lipid layer, as shown for the antiparasitic agents cypermethrin (Jenkinson et al., 
1986), flumethrin (Stendel et al., 1992) and parathion (Brimer et al., 1994) in 
sheep, cattle or pigs. The first increase of Ka would then be explained by a higher 
licking efficiency, due to a progressive increase in skin surface exposure. 
Conversely, the decrease of Ka would correspond to a reduction in licking 
efficiency, consistent with the decrease of ivermectin concentrations on the skin. 
This decrease would be more or less rapid depending on individual licking activity. 
Kinetic modeling shows an ingestion of topical ivermectin up to 19 days post-
administration, suggesting that ivermectin was available at the skin surface for a 
long period of time. This is in agreement with previously published results, 
indicating that ivermectin was still present on the skin of non-licking cattle 44 days 
post-administration (Laffont et al., 2001). It is though possible that ivermectin 
partitions into the various layers of the skin as for other lipid-soluble compounds 
(chlorpyrifos, Griffin et al., 2000), and is released over a prolonged period at the 
skin surface. Distribution of the drug in the skin after systemic absorption cannot 
be excluded, given the high concentrations of ivermectin found in the epidermis 
and dermis of cattle after subcutaneous administration (Lifschitz et al., 2000). 
The model indicates that 50-77% of ivermectin absorption in plasma was 
achieved by the oral route, compared to 23-50% by the percutaneous route. This 
infers that the systemic exposure of animals most likely depends on their ability to 
lick themselves (self-licking) or each other (allo-licking). This would explain the 
erratic bioavailability of pour-on ivermectin observed in the licker group 
(coefficient of variation of 55% in lickers vs 29% in non-lickers after application of 
PO2) and in previous studies (Gayrard et al., 1999), as well as the large intra-
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individual and within-pair variability of plasma exposure (up to 230% and 70%, 
respectively) which could not be of genetic origin. More generally, the extent of 
licking depends on various social, nutritional, physiological, pathological, 
environmental and managerial factors (Sato et al., 1991, 1993), which makes the 
delivery of drug even more unpredictable. An increased licking activity has been 
reported in parasitised cattle (Sato et al., 1991), which could be in favour of a 
higher plasma exposure of the animals and a better efficacy of the pour-on 
treatment. On the other hand, potential systemic underexposure could result in 
subtherapeutic plasma concentrations, which may promote the development of 
drug resistance (Geerts and Gryseels, 2000). At last, the results question the 
relevance of performing in vivo bioequivalence assays for evaluation of topical 
drug formulations in licking animals. 
For simplicity reasons, allo-licking was not taken into account in the model. 
However, although the cattle of the licking group were housed in individual boxes, 
contacts by allo-licking were observed during the experiments between the 
immediate neighbours. In one pair of twins, the pour-on dose (500 µg/kg) applied 
on the back of the licker did not provide a sufficient amount of ivermectin to 
explain the high faecal data (no ivermectin was left on the skin). This suggests a 
supplementary source of topical drug consistent with allo-licking. 
Under field conditions, allo-licking may result in the contamination of the non-
treated cattle in contact with those topically treated. Our simulations (multiple oral 
uptake) showed a significant (detectable) plasma exposure of non-treated animals 
which would lick small amounts of ivermectin from the skin of one or several 
treated cattle (0.02-0.11% of the pour-on dose in total). It is noteworthy that a 
continuous licking corresponding to 2-11% of the pour-on dose in total would 
result in detectable concentrations in the milk of non-treated cattle for more than 44 
days, with maximal plasma concentrations of 1 ng/mL. These amounts depend 
obviously on the individual licking activity (traduced by the Ka function), but are 
all very low compared to the 76% of the dose actually ingested by the treated cattle 
under the same conditions. Altogether, these results suggest an easy contamination 
of non-treated cattle by social contact with treated animals and elicit concern over 
possible insecticide residues in their milk and edible tissues. 
The skin provides an excellent barrier against the environment and foreign 
substances, and many drugs used in human and veterinary medicine exhibit a low 
rate and extent of dermal absorption (Barry, 2001; Magnusson et al., 2001; Riviere 
and Papich, 2001). In the present study however, we show that a low rate of 
absorption through the skin may not ensure a controlled and optimised delivery of 
drug to the systemic or local circulation. In control cattle, licking reduced by a 
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factor two the total amount of ivermectin delivered to the plasma via the skin (from 
20% of the dose in non-lickers to 10% in lickers) and led to an unpredictable 
absorption of topical drug by the oral route. As indicated by the simulations, the 
rate constant of percutaneous absorption K51 would need to be increased by a 
factor of at least 50 to warrant a good percutaneous absorption of drug, 
independently of animal licking behaviour or other external events (evaporation, 
accidental removal of the drug …).  
In conclusion, we demonstrate that the social/individual licking behaviour of 
animals can markedly interfere with the disposition of topical drugs and can 
contribute to a higher excretion of active compound into the environment. We also 
suggest that allo-licking can result in drug exposure of non-treated animals. This 
route of contamination has to be considered as a general risk for topically-applied 
drug formulations in food-producing animals. 
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General discussion 
 
Avermectins and milbemycins are potent antiparasitic drugs, which are widely 
used in veterinary medicine to treat and control various parasitic conditions. They 
present a unique spectrum of activity against both ecto- and endoparasites, which 
resulted into the embracing name of "endectocides". Ivermectin was the first 
endectocide to be introduced onto the international health market in 1981 and is 
still the most widely used across animal species, worldwide. It is also currently 
used in human medicine and has become the drug of choice for the treatment of  
onchocerciasis. 
Ivermectin is extensively eliminated in faeces, irrespective of the species and 
administration route, with less than 2% excreted in the urine (Campbell, 1985). A 
large amount of ivermectin is eliminated unchanged from blood (40% of a i.v. dose 
in cattle; chapter 5), but the routes by which parent ivermectin reaches the 
digestive tract are still not fully understood. As for other endectocides (Hennessy et 
al., 2000), it is currently believed that biliary secretion is the main elimination 
pathway of the parent drug (Chiu et al., 1990). However, the possibility of an 
intestinal secretion of ivermectin by the gut wall has been raised. In a previous 
study in sheep and cattle, Bogan and McKellar (1988) found indeed three-times 
higher concentrations of ivermectin in duodenal and ileal fluids than in fluids 
sampled proximal to the bile duct opening. Ivermectin was present at even higher 
concentrations in intestinal mucous, with no significant difference between 
proximal and distal small intestine. 
The existence of an intestinal secretion of parent ivermectin was demonstrated 
in the first part of the thesis, using two validated in vitro and in situ models. The 
mechanisms involved in the secretion process are discussed, with special emphasis 
on the drug transporting P-glycoprotein. A better understanding of these routes and 
mechanisms of elimination is of clinical interest, since they influence the 
persistence of ivermectin in plasma and determine the exposure of gastrointestinal 
parasites after systemic absorption or parenteral administration.  
Ivermectin elimination from blood, however, cannot always explain the rate and 
extent of ivermectin excretion into faeces after parenteral administration. Topical 
application results indeed in higher faecal concentrations of ivermectin than for the 
subcutaneous route, which is inconsistent with the lower plasma concentrations 
(Herd et al., 1996). No explanation for this apparent discrepancy has been 
provided. Our hypothesis was that topically-treated cattle could ingest ivermectin 
by licking. This hypothesis was examined in the second part of the thesis and 
proved to be relevant. 
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Intestinal elimination of ivermectin and implication of P-glycoprotein in the 
secretion process 
 
The possibility of an intestinal secretion of ivermectin was examined in vitro 
using the human colon adenocarcinoma cell line Caco-2 (chapter 2). Caco-2 cells 
form confluent monolayers of well-differentiated cells, which display many 
morphological and functional characteristics of the human enterocyte (reviewed by 
Boulenc, 1997). Among other intestinal transporters, they express P-glycoprotein 
(P-gp) and the multidrug resistance-associated protein 2 (MRP2) (Hosoya et al., 
1996; Boulenc, 1997; Hunter and Hirst, 1997; Hirohashi et al., 2000; Walgren et 
al., 2000). P-gp and MRP2 are two drug efflux transporters localised in the apical 
(luminal) membrane, which have been shown to mediate the intestinal secretion of 
several compounds (Hunter and Hirst, 1997; Van Asperen et al., 1998; König et al., 
1999; Gotoh et al., 2000; Suzuki and Sugiyama, 2000; Walgren et al., 2000; Borst 
and Elferink; 2002). The Caco-2 cell line is now a well-established in vitro model 
of the intestinal epithelium and is widely used to characterise the intestinal 
behaviour of drugs (absorption, secretion). We showed that ivermectin was 
preferentially transported from the basolateral side (representing systemic blood) to 
the apical side (representing the intestinal lumen) of Caco-2 cell monolayers 
(chapter 2). The secretory flux was 2- to 10-times higher than that in the opposite 
direction, depending on the concentration of ivermectin in the donor compartment. 
This study provides therefore evidence for a transepithelial secretion of parent 
ivermectin from blood into the intestinal lumen. 
The in vivo relevance of this secretory transport was confirmed by our in situ 
studies in the rat using the intestinal closed-loop model (chapter 3). This model 
allows direct quantification of both biliary and intestinal secretions of parenterally-
administered drugs, by cannulation of the common bile duct and in situ isolation of 
intestinal loops with their intact blood supplies. This study demonstrated the 
existence of an intestinal secretion of parent ivermectin by the small intestine, 
which was 5-fold higher than that into bile at all tested dose rates (100-200-400 
µg/kg i.a.). The secreted ivermectin was extensively associated with intestinal 
mucous, in agreement with the observations of Bogan and McKellar (1988) in 
sheep and cattle (previously described). Ivermectin small intestinal clearance 
accounted for 27% of the drug total clearance, whereas the biliary clearance of 
ivermectin represented only 5.5% of the drug total clearance. Since no glucuronide 
conjugates of ivermectin have ever been identified in vivo, the ivermectin secreted 
into bile was the only contribution of biliary secretion to the total amount of parent 
drug in the intestinal lumen. It results that the major route for the elimination of 
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parent ivermectin in the rat is not biliary but intestinal secretion, in contrast to 
previous beliefs. Besides, it is noteworthy that the intestinal clearance of 
ivermectin was calculated solely from the small intestine, but that other regions of 
the digestive tract may participate as well to the elimination process. The colon, for 
instance, displays high levels of P-gp expression (Thiebaut et al., 1987). Therefore, 
it could contribute significantly to the intestinal elimination of ivermectin, as has 
been shown for other xenobiotics (Mayer et al., 1996; Ramon et al., 1996; Makhey 
et al., 1998; Van Asperen et al., 2000). 
The mechanisms involved in the overall intestinal elimination of ivermectin in 
the rat are not clear. Partial inhibition (50%) of the jejunal secretion of parent 
ivermectin by the P-gp inhibitor verapamil suggests that P-gp plays a role in the 
secretion process (chapter 3). However, verapamil did not significantly affect the 
secretion of ivermectin by the duodenum and ileum in the same animals (chapter 
3). This seems quite unexpected considering the continuous and increased 
expression of P-gp from proximal to distal small intestine (Brady et al., 2002). On 
the other hand, it has been suggested that there are not single but multiple intestinal 
P-gps, with different substrate affinities depending on their location along the 
gastrointestinal tract (Saitoh and Aungst, 1995; Makhey et al., 1998). Although the 
use of verapamil in vivo is not exclusive enough in demonstrating a P-gp-mediated 
process, these results point towards the involvement of other transport mechanisms. 
Examination of the mechanisms of secretion in vitro (chapter 2) confirmed the 
implication of P-gp in the intestinal secretion of ivermectin, which was 
significantly inhibited by the P-gp modulators verapamil, testosterone, and 
cyclosporin A. The secretory flux was also partially inhibited by the MRP-selective 
inhibitor MK571, suggesting that MRP2 could be involved as well in the secretion 
process. It is noteworthy that the potent P-gp modulator cyclosporin A, which 
totally abolished the net secretion of ivermectin across Caco-2 cell monolayers, has 
been shown to also inhibit MRP2 at high concentrations (König et al., 1999). The 
involvement of MRP2 remains to be confirmed in vitro using MRP2-transfected 
vesicles as well as in vivo. In vivo, MRP2 is highly expressed in the proximal small 
intestine, with a gradual decrease in expression from jejunum to distal ileum 
(Mottino et al., 2000), and could therefore significantly contribute to the overall 
intestinal elimination of the drug. Finally, a high passive diffusion of ivermectin 
and/or the involvement of other efflux transporters cannot be excluded. 
In both studies, intestinal P-gps were identified as an important mechanism of 
intestinal secretion (chapters 2  and 3). This is in line with previous reports 
showing that ivermectin is a substrate of P-gp and that P-gp is implicated in the 
disposition of this drug in mice and rats (Schinkel et al., 1994, 1995; Didier and 
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Loor, 1995; Lankas et al., 1997; Pouliot et al., 1997; Alvinerie et al., 1999; Kwei et 
al., 1999; Smith et al., 2000). In vivo, P-gp is not only expressed in the intestines 
but in various other tissues, including the biliary canalicular membrane of 
hepatocytes, the apical membrane of renal proximal tubule cells, the lumenal 
membrane of capillary endothelial cells at the blood-brain and blood-testis barriers, 
and the apical membrane of placental trophoblasts (Thiebault et al., 1987; Cordon-
Cardo et al., 1989). This transporter was shown to protect the brain and the foetus 
against the toxic effects of ivermectin (or abamectin) by limiting the entry of the 
drug in these organs (Schinkel et al., 1994; Didier and Loor, 1995; Lankas et al., 
1997, 1998; Kwei et al., 1999). However, the involvement of P-gp in ivermectin 
elimination had never been clearly investigated. P-gp-deficient mice with no 
cannulated gallbladder showed a 30% lower secretion of [3H]-ivermectin in bile 
plus intestinal contents than wild-type mice after i.v. administration (Kwei et al., 
1999), suggesting that P-gp was somehow involved in the elimination process. 
A 3-fold increase in ivermectin plasma concentrations was observed in P-gp-
deficient mice compared to wild-type mice after oral administration (Schinkel et 
al., 1994; Lankas et al., 1997; Kwei et al., 1999). Thus, it has been suggested that 
P-gp could limit the absorption of orally-administered ivermectin by pumping the 
drug back into the intestinal lumen (Schinkel et al., 1994; Lankas et al., 1997; Kwei 
et al., 1999). This hypothesis is consistent with our studies in Caco-2 cells, which 
showed a directional and active transport of ivermectin in the secretory direction 
(chapter 2). On the other hand, it is noteworthy that ivermectin is relatively well 
absorbed in mice following oral administration (over 60% of the dose; Kwei et al., 
1999), suggesting that this increase in plasma concentrations could be due to a 
reduced elimination of ivermectin as well. As for other P-gp substrates, a good 
intestinal absorption of ivermectin could be explained by the saturation of P-gps at 
the local drug concentrations, high rates of passive diffusion, or the existence of 
gastrointestinal sites with a lower expression of P-gp where drugs are easily 
absorbed (Makhey et al., 1998; Van Asperen et al., 1998; Aungst, 1999; 
Doppenschmit et al., 1999). In contrast to mice, a low oral bioavailability of 
ivermectin has been reported in cattle, sheep, pig and horse (for review, see 
McKellar and Benchaoui, 1996). However, the existence of a relevant first pass-
effect (metabolic and transport processes) in these species is doubtful. Indeed, the 
total clearance of ivermectin is low in most species (rat, cattle, and sheep; chapters 
3 and 5; Prichard et al., 1985), corresponding to a body extraction ratio below 1%. 
Even considering the possibility of a synergistic action of intestinal cytochrome 
P450 3A and P-gp in reducing even more systemic availability (Wacher et al., 
1995; Benet and Cummins, 2001), it is unlikely that such a low extraction ratio 
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(metabolic and transport processes) has an impact on the overall oral 
bioavailability of the drug. Other factors are probably more relevant in explaining 
the poor bioavailability of ivermectin by the oral route in these species. In sheep, 
the bioavailability of ivermectin given intraruminally was shown to be 75% lower 
that that after intra-abomasal administration (Prichard et al., 1985). Given the 
stability of ivermectin in ruminal fluids (Bogan and McKellar, 1988, Andrew and 
Halley, 1996), this has been attributed to an extensive binding of ivermectin to 
particulate phase of rumen digesta (>95% in cattle and sheep; Steel, 1993; Ali and 
Hennessy, 1996). We even suggest that once ivermectin is bound to digesta 
particulates in the rumen, it is not available anymore for further absorption in the 
gastrointestinal tract (chapter 6). 
There has been so far no direct demonstration of a P-gp-mediated process for 
ivermectin secretion into bile. In vitro studies using primary cultures of hepatocytes 
suggested that hepatic P-gps could mediate the efflux of the structural analogue 
moxidectin (Dupuy et al., 2001). Our own studies (chapter 3) in anaesthetised rats 
showed no significant reduction of the biliary secretion of ivermectin following 
systemic co-administration of the P-gp modulator verapamil. However, it is 
possible that a reduced secretion of drug had been masked by a metabolic 
interaction between ivermectin and verapamil (inhibition of P450 3A isoenzymes), 
resulting in a compensatory increase in the secretion of parent ivermectin. A recent 
study using a MDR3-transfected cell line showed that the MDR3 gene product 
could also transport ivermectin, albeit to a lesser extent than P-gp (Smith et al., 
2000). MDR3 is a close homologue of the MDR1 gene encoding P-gp (for review, 
see Borst and Elferink, 2002), which is expressed in the canalicular membrane of 
hepatocytes. The MDR3 P-gp has been shown to play a major role in hepatobiliary 
function by transporting phosphatidylcholine into bile (Smit et al., 1993). Its 
possible role in drug transport has just been raised (Smith et al., 2000). 
Active secretion of ivermectin by renal P-gps was demonstrated in vitro using 
kidney proximal tubules of killifish (Fricker et al., 1999). These results are, 
however, quite inconsistent with the poor excretion of ivermectin in the urine 
observed in vivo (< 2% in all species; Campbell, 1985), suggesting that there is 
either a very low renal secretion process or a major reabsorption of the secreted 
ivermectin into blood. This study shows that the importance of secretory transport 
in vivo can be sometimes over-emphasised from in vitro data. 
Altogether, chapters 2 and 3 support the existence in vivo of an intestinal 
elimination of parent ivermectin through the gut wall. They provide further 
evidence of the role of the intestines in the elimination of drugs (Hunter and Hirst, 
1997; Van Asperen et al., 1998; Matheny et al., 2001) and offer new directions into 
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the pharmacokinetics of endectocides to understand their clinical efficacy against 
gastrointestinal parasites. Indeed, many parasites do not feed on plasma, and an 
important secretion of active drug along the digestive tract could be of major 
clinical significance. The characterisation of a P-gp-mediated process offers also 
the possibility to modulate the elimination of biologically-active ivermectin in the 
gut and in faeces. 
 
Existence of functional P-gps in the target animal species 
 
Our previous results are of relevance in rat (chapter 3) and probably in humans 
(chapter 2) but the question arises whether or not they could be extrapolated to 
other animal species such as cattle, sheep, goat, pig and horse, which are the target 
species for ivermectin use in veterinary medicine. 
In both previous studies (chapters 2 and 3), P-gp was identified as an important 
mechanism of ivermectin intestinal secretion. In this respect, an indication for the 
existence of functional P-gps in the target animal species would be of major 
interest. Five P-gp genes have been identified in pig, four of which show similarity 
with the Class I P-gp isoforms(s) in man (MDR1) and rodents (mdr1a, mdr1b) 
(Childs and Ling, 1996). Recently, the first ruminant P-gp gene has been cloned 
and sequenced from sheep (Longley et al., 1999). In cattle, the presence of three P-
gp genes is expected based on genomic DNA analysis (Southern blotting) (Childs 
and Ling, 1996). It is noteworthy that Murray Grey cattle are particularly sensitive 
to ivermectin, suggesting that like Collie dogs and CF-1 mice, this breed of cattle 
may be naturally deficient with P-gp (Seaman et al., 1987). 
However, little information is available on the P-gp function in these animal 
species, in contrast to humans and laboratory animals, in which the P-gp function 
has been extensively documented (Matheny et al., 2001; Borst and Elferink, 2002). 
Expression of functional P-gps has been shown in freshly isolated brain capillaries 
or primary brain capillary endothelial cells from pig and cattle (Rose et al., 1998; 
Miller et al., 2000; Nobmann et al., 2001). In contrast, no or very low P-gp activity 
was detected in the porcine kidney proximal tubule cell line (LLC-PK1) (Schinkel 
et al., 1995). It is difficult though to appreciate the extent of the P-gp function in 
vivo from immortalised cell lines or primary cells, as protein expression is often 
modified during cell culture, varying from total loss of expression to 
overexpression. 
An alternative to the conventional in vitro models could be the use of freshly 
isolated peripheral blood lymphocytes. These have been shown to express 
functional P-gps in humans (Drach et al., 1992; Klimecki et al., 1994; Ludescher et 
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al., 1998) and are widely used for evaluation and monitoring of multidrug 
resistance in leukaemia patients (Beck et al., 1996). Peripheral blood lymphocytes 
were therefore isolated from cattle, sheep, goats, pigs, horses, rats, and men (taken 
as a reference) for evaluation of the P-gp function (chapter 4). Lymphocytes were 
stained with the fluorescent dye Rhodamine 123 (Rh-123), a prototypic P-gp 
substrate, after which they were resuspended in dye-free medium in the absence or 
presence of P-gp modulators (verapamil, cyclosporin A, ivermectin) to allow dye 
efflux. The ability of the cells to extrude Rh-123 was evaluated indirectly, by 
measuring intracellular dye retention using flow cytometric analysis. 
Rh-123 has been shown to be a reliable marker of P-gp activity in human 
lymphocytes, on the basis of both dye efflux and its inhibition by P-gp modulators 
(Beck et al., 1996; Huet et al., 1998; Broxterman, 1999). According to these 
criteria, three groups of species were identified (chapter 4). Goat lymphocytes 
showed a significantly higher P-gp activity than lymphocytes of other species, 
under the same experimental conditions. A relatively high but lower P-gp activity 
was observed in lymphocytes from cattle, sheep, pigs and men. In contrast, only 
low levels of P-gp activity could be detected in lymphocytes from rats and horses. 
These interspecies differences suggest that the capacity and/or affinity of P-gp may 
differ from one species to another. This is consistent with the study of Schinkel et 
al. (1995), who showed that certain drugs (morphine) could be transported to a 
different extent by the human MDR1 P-gp and the murine Mdr1 P-gp in 
transfected cell lines. In addition to interspecies differences, large interindividual 
variations in P-gp activity were observed (chapter 4). Our data in pigs even 
suggested that the P-gp function could be influenced by various physiological 
factors such as the age and the sex, as has been reported in humans using the same 
lymphocyte-based model (Gupta, 1995; Steiner et al., 1998). Finally, P-gp 
expression was confirmed in small intestine tissue (jejunum) of goats, cattle, sheep, 
pigs and horses (chapter 4). 
Altogether, our findings suggest that P-gps equivalent to those identified in 
humans and rodents exist in cattle, sheep, goats, pigs and even horses, providing 
thereby the mechanistic support for an intestinal secretion of ivermectin. The large 
interspecies differences in P-gp activity suggest, however, that the actual 
contribution of this secretion mechanism may differ from one species to another. 
The high P-gp activity observed in goat lymphocytes is particularly striking, since 
goats are known to eliminate ivermectin much more rapidly than any other farm 
animal species (Scott and McKellar, 1990; McKellar and Benchaoui, 1996). 
Differences in metabolic capacities have to be considered as well. 
It is noteworthy that ivermectin inhibited significantly the efflux of Rh-123 in 
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lymphocytes of all species to a similar extent as verapamil and cyclosporin A. This 
infers that P-gps of goats, cattle, sheep, pigs and horses could interact with 
ivermectin, and it can be expected that they transport ivermectin as well. This 
would be consistent with a previous in vivo study in ivermectin-treated sheep, 
showing a transient increase in ivermectin plasma concentrations following i.v. 
administration of verapamil (data not shown). Furthermore, in moxidectin-treated 
cattle, the clearance of the structural analogue moxidectin was significantly 
decreased (33%) by co-administration of loperamide (Lifschitz et al., 2002), 
another P-gp substrate (Schinkel et al., 1996).  
High levels of P-gp activity were observed in lymphocytes from goats, cattle, 
sheep and generally pigs (chapter 4). Consequently, lymphocytes offer the 
possibility to study transport of veterinary drugs in the target animal species as well 
as drug-drug interactions. Although the relevance of the lymphocyte-based model 
needs to be further documented, it is certainly more predictive than other 
conventional in vitro models consisting of immortalised or primary cell lines. 
Finally, it has been shown in humans that P-gp expression could vary among 
individuals, depending on natural polymorphisms, exposure to P-gp substrates or 
inducers, and physiological and pathological (inflammatory) factors (Hartmann et 
al., 2001; Matheny et al., 2001; Borst and Elferink, 2002). Thus, the lymphocyte-
based model could also be used to document the effect of these factors on the P-gp 
function. Since lymphocytes can be easily isolated from a single blood sampling, 
this model is suitable for a population approach. 
 
Influence of animal behaviour on the plasma and faecal disposition of topical 
ivermectin 
 
The elimination of parent ivermectin from the bloodstream may not always 
explain the rate and extent of ivermectin excretion into faeces following parenteral 
administration. It has been shown that topical (pour-on) administration of 
ivermectin to cattle results in lower ivermectin plasma concentrations but in higher 
ivermectin faecal concentrations than subcutaneous administration (Herd et al., 
1996). We confirmed this discrepancy by measuring the faecal clearance of 
ivermectin after topical and i.v. administrations to cattle. Ivermectin faecal 
clearance was indeed 2 to 16-times higher after topical application than following 
i.v. administration (chapter 5), which clearly indicated that the plasma 
concentration was not the only driving force for the elimination of parent 
ivermectin in faeces. Our hypothesis was that cattle could ingest a part of the 
topical drug by licking, and that a fraction of the ingested ivermectin could transit 
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directly into faeces. This hypothesis proved to be relevant, since we found that 58-
87% of the dose applied over the back of cattle was actually ingested by licking 
(chapters 5 and 6). In contrast, only 10% of the pour-on dose (500 µg/kg) was 
absorbed through the skin (chapters 5 and 6). Approximately 72% of the ingested 
ivermectin transited directly into faeces (mean oral bioavailability of 28%), which 
accounted for approximately 80% of the total faecal output (chapter 6). 
Licking is an important part of the natural grooming behaviour of cattle. It 
serves an important physiological function in skin and hair hygiene, and plays a 
major role in the formation and maintenance of social bounds (Simonsen, 1979; 
Sato et al., 1991, 1993; Krohn, 1994). However, a possible influence of cattle 
licking behaviour on the disposition of topical drugs had never been documented. 
Topical drugs are generally applied over the backline of animals, in a region where 
they cannot theoretically scratch, snatch or lick. This recommendation was made 
without considering the particular ability of cattle to turn and stretch to lick, as has 
been observed during our experiments. Furthermore, topical drugs can spread over 
the skin from the site of application to a larger surface and thus be exposed to 
licking. This has been shown for many antiparasitic agents in sheep, cattle, or pig 
(cypermethrin, flumethrin, parathion; Jenkinson et al., 1986; Stendel et al., 1992; 
Brimer et al., 1994) and is also probably the case of ivermectin (chapter 6). 
When licking was prevented, the absorption of ivermectin into the systemic 
circulation was very slow, resulting in a much longer plasma elimination half life 
than following i.v. administration (so-called flip-flop effect) (chapters 5 and 6). 
This shows that topical ivermectin is in fact very slowly absorbed through the skin 
of cattle. In normal licking cattle, half to two-third of the topical ivermectin 
entering the systemic circulation resulted from oral absorption (chapter 6). There 
was therefore a major contribution of the oral route, which explains that the 
absorption of ivermectin in plasma was rapid (as for an oral dosing; Steel, 1993) 
and that the plasma elimination half life was similar to that obtained after i.v. 
administration (no flip-flop effect) (chapters 5 and 6). Taken together, our results 
suggest that the plasma exposure of topically-treated animals depends mainly on 
their ability to lick themselves (self-licking) or each other (allo-licking). When 
animals were successively given two pour-on administrations of ivermectin (500 
µg/kg) at a washout interval, the plasma exposure of a same cattle could vary from 
60% to 240% from one pour-on application to the other (chapter 6). Intra-
individual variability of drug exposure was not significantly lower than inter-
individual variability, which is a very uncommon feature in pharmacology 
(chapter 6). Furthermore, it is noteworthy that the extent of licking is influenced 
by various physiological, nutritional, managerial and pathological factors including 
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parasitism of animals (Sato et al., 1991; 1993). Thus, it can be expected that under 
field conditions, the exposure of animals is even more variable and unpredictable. 
The possibility of underexposure of animals has to be considered in the case of 
high allo-licking and/or low self-licking activity. Underexposure of animals is of 
special concern, since subtherapeutic concentrations may promote the development 
of drug resistance (Smith et al., 1999; Geerts and Gryseels 2000). 
Finally, allo-licking was observed during our experiments (chapters 5 and 6), 
which raises the possibility of a transfer of ivermectin from treated to non-treated 
cattle. Our simulations indicated that a continuous licking accounting for only 2 % 
of the pour-on dose in total could be sufficient to obtain non-negligible systemic 
exposure of non-treated cattle (maximum plasma concentration of 1 ng/mL), along 
with a significant and persistent elimination of ivermectin in milk (chapter 6). 
These results elicit concerns over the possible occurrence of violative residues of 
ivermectin in milk and edible tissues of untreated cattle that would have been in 
contact with those topically-treated. 
In conclusion, it appears that the relevance of cattle licking behaviour has been 
largely underestimated. Possible consequences in terms of public health suggest 
that animal licking behaviour should be more carefully addressed in the future in 
food-producing animals. One solution to reduce the relevance of licking on the 
disposition of topical ivermectin in cattle would be to increase the rate of drug 
absorption through the skin. Simulations indicated that the rate of percutaneous 
absorption should be increased by a factor 8 to have as much ivermectin absorbed 
trough the skin as ingested, and by at least a factor 50 to reduce the extent of drug 
ingestion below 10% of the dose (chapter 6). It must be stressed, however, that a 
reliable and safe alternative to the pour-on formulation exists, which is the 
subcutaneous formulation.  
 
Summarising conclusions and perspectives 
 
It was the aim of the presented investigations to contribute to the understanding 
of the diverse factors involved in the pharmacokinetics of ivermectin, a very potent 
antiparasitic drug widely used in both human and veterinary medicine. 
Convincing evidence for an intestinal secretion of ivermectin from blood into 
the intestinal lumen was provided by experiments in vitro (Caco-2 cells) and in situ 
(rat intestinal loops). In the rat, intestinal secretion was even more important than 
biliary secretion in the overall elimination of the parent drug. These findings may 
initiate a re-appraisal of the disposition of ivermectin, particularly its distribution in 
the digestive tract, and thus allow a better understanding of its clinical efficacy 
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against gastrointestinal parasites. 
The above mentioned investigations also pointed towards the prominent role of 
P-gp in the intestinal secretion process, although other transport mechanisms 
(MRP2) may be involved. 
The relevance of these findings for veterinary target species was demonstrated 
by examining the P-gp function in cattle, sheep, goats, pigs and horses using a 
lymphocyte-based ex vivo model. P-gp activity was found in peripheral blood 
lymphocytes of all animal species studied, albeit at different levels. In addition, P-
gp expression was shown in the intestines for all species. These results strongly 
suggest the presence of P-gp proteins in cattle, sheep, goats, horses, and pigs, 
equivalent to those identified in humans and rodents. They provide therefore a 
mechanistic support for the intestinal secretion of ivermectin and other P-gp 
substrates. Since wide interspecies variations in P-gp activity were observed, it can 
be expected that the contribution of this secretion mechanism may differ from one 
species to the other. 
Finally, we identified that external, behavioural factors such as animal licking 
does obviously contribute to the disposition of ivermectin in cattle following 
topical application. Under our experimental conditions, 58-87% of the dose (500 
µg/kg) applied topically over the back of cattle was actually ingested by licking, 
while only 10% of the dose was absorbed through the skin. Thus, the systemic 
exposure of topically-treated animals depends most likely on their ability to lick 
themselves or each other. Furthermore, social contacts with other cattle (allo-
licking) may result in the cross-contamination of non-treated cattle present in the 
same herd. 
 
In conclusion, our results provide evidence for 
- the intestinal secretion of ivermectin from blood into the intestinal 
lumen (in vitro and in vivo data). 
- the involvement of P-gp in the intestinal secretion process, as shown in 
the Caco-2 cell model and further supported by our findings in the rat. 
- the existence of functional P-gps in the target animal species (cattle, 
sheep, goat, pig and horse) using a lymphocyte-based model, together 
with the expression of P-gp in their intestinal tissues. 
- the contribution of cattle licking behaviour to the plasma and faecal 
disposition of topical ivermectin, resulting in a higher faecal excretion 
of the parent drug. 
 
These results may stimulate further investigations towards the contribution of 
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intestinal secretion to the overall elimination of endectocides in target animal 
species. The examination of the role of P-gp and P-gp-like transporters (MRP2) in 
the relative disposition of different endectocides may be useful to understand 
differences in their pharmacokinetics and support the development of new 
pharmaceutical formulations tailored towards individual compounds and target 
animal species. 
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Korte nederlandse samenvatting van de onderzoeken. 
 
Het doel van het hier beschreven onderzoek was een bijdrage te leveren aan het 
begrip van de diverse factoren betrokken in de farmacokinetiek van ivermectine, 
een potent anti-parasitair medicijn dat veel gebruikt wordt in zowel de humane 
geneeskunde als de diergeneeskunde. Het onderzoek omvat twee verschillende 
onderdelen: in vivo en in vitro onderzoek.  
Middels in vitro (humane Caco-2 cellen) en in situ (darmsegmenten van ratten) 
experimenten kon worden aangetoond dat er intestinale uitscheiding van 
ivermectine vanuit het bloed naar het darm-lumen plaats vindt. In de rat was zelfs 
de uitscheiding van systemisch toegediend ivermectine via de darm belangrijker 
dan via de gal. Deze bevindingen geven aanleiding tot een heroverweging van de 
kinetiek van ivermectine, met name de verdeling in de digestie tractus, en daarmee 
tot een beter begrip van de klinische effectiviteit van ivermectine tegen maag-darm 
parasieten. 
Bovendien duiden de resultaten van de onderzoeken op een prominente rol van 
het transport eiwit Pg-p in de intestinale secretie, hoewel ook andere transporters, 
zoals MRP2, betrokken kunnen zijn. 
Het belang van de bevindingen met de humane Caco-2 cellen voor de 
doeldieren is aangetoond door de functie van P-gp in rundvee, schapen, geiten, 
varkens en paarden te onderzoeken met behulp van een ex vivo model van 
lymfocyten uit het perifere bloed. Activiteit van P-gp is gevonden in de lymfocyten 
van alle genoemde species, echter met verschil in grootte. Daarnaast is de 
aanwezigheid (expressie) van P-gp aangetoond in de darmen van deze diersoorten. 
Onze resultaten suggereren de aanwezigheid van P-gp eiwitten in rundvee, 
schapen, geiten, varkens en paarden gelijk aan die in mensen en knaagdieren. Ze 
voorzien daarmee in een mechanisme dat de intestinale secretie van ivermectine en 
andere P-gp substraten kan verklaren. Aangezien er duidelijke variaties in P-gp 
aktiviteit tussen de diersoorten zijn waargenomen, kan het verwacht worden dat de 
bijdrage van dit mechanisme verschilt van de ene diersoort tot de andere. 
In het tweede deel van het proefschrift hebben we laten zien dat externe 
gedragsfactoren zoals likken eveneens bijdragen aan de lotgevallen van 
ivermectine in rundvee na topicale toediening op de huid. Onder onze 
experimentele omstandigheden werd 58-87% van de dosis (500 µg/kg LG) 
toegediend op de rug van koeien eigenlijk oraal opgenomen door likken, terwijl 
maar 10% van de dosis door de huid werd opgenomen. Dit houdt in dat de 
systemische beschikbaarheid van topicaal behandelde dieren zeer waarschijnlijk 
afhankelijk is van de mogelijkheid om zichzelf en/of elkaar te likken. De sociale 
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contacten met andere koeien (allo-licking) resulteren in een besmetting van niet-
behandelde koeien in hetzelfde koppel. 
 
Ter conclusie, onze resultaten voeren bewijs aan voor: 
- Intestinale secretie van ivermectine vanuit het systemische bloed 
naar het darm lumen (in vitro en in vivo data). 
- De betrokkenheid van P-gp in het intestinale secretie proces, zoals 
aangetoond in het Caco-2 cel model en ondersteund door de bevindingen 
in het ratten model (darmsegmenten in situ). 
- Het bestaan van functioneel P-gp in de doel-diersoorten (rundvee, 
schapen, geiten, varkens en paarden), door het gebruik van het lymfocyten 
model samen met de expressie van P-gp in het darm weefsel. 
- De bijdrage van het likgedrag van koeien aan de bloedplasma en 
mest spiegels na topicale toediening van ivermectine op de huid. 
 
Deze resultaten geven aanleiding tot verder onderzoek naar de bijdrage van 
intestinale secretie in de totale eliminatie van endecticiden (Avermectinen) in de 
doeldieren. Onderzoek naar de rol van P-gp en andere transport eiwitten, zoals 
MRP2, met betrekking tot de lotgevallen van verschillende endectosiden in het 
lichaam, kan het begrip van de verschillen in hun farmacokinetiek verduidelijken 
en de ontwikkeling van nieuwe farmaceutische formuleringen, die op maat 
gemaakt zijn om een optimaal effect in een bepaalde diersoort te bewerkstelligen, 
ondersteunen. 
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